,variant,EvidenceLevel,ClinicalSignificance,Disease,TherapyRegimen
0,P124S,D,Resistance,Melanoma,Selumetinib
1,Q56P,D,Resistance,Melanoma,Selumetinib
2,Q61,B,Resistance,Melanoma,Vemurafenib
3,D842V,B,Resistance,Gastrointestinal Stromal Tumor,Imatinib
4,D842V,B,Resistance,Gastrointestinal Stromal Tumor,Imatinib
5,S214C,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Sorafenib
6,R882,B,Sensitivity/Response,Acute Myeloid Leukemia,Idarubicin
7,V617F,B,Sensitivity/Response,Polycythemia Vera,
8,V617F,D,Sensitivity/Response,Polycythemia Vera,Fedratinib
9,G13D,C,Sensitivity/Response,Melanoma,Tanespimycin
10,Q61L,C,Sensitivity/Response,Melanoma,Temozolomide
11,Q61R,C,Sensitivity/Response,Melanoma,Temozolomide
12,F1174L,D,Resistance,Inflammatory Myofibroblastic Tumor,Crizotinib
13,F1174L,D,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
14,L576P,D,Resistance,Melanoma,Nilotinib+Imatinib+Sorafenib
15,G12/G13,B,Resistance,Lung Non-small Cell Carcinoma,Gefitinib+Erlotinib
16,Q61,B,Resistance,Colorectal Cancer,Cetuximab+Chemotherapy
17,F1174L,D,Sensitivity/Response,Neuroblastoma,Alectinib
18,F1174L,D,Sensitivity/Response,Neuroblastoma,Crizotinib
19,R1275Q,D,Sensitivity/Response,Neuroblastoma,TAE684
20,S214C,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Sorafenib
21,S214C,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Trametinib
22,L576P,D,Sensitivity/Response,Melanoma,Dasatinib
23,D842I,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Crenolanib
24,D842V,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Crenolanib
25,D842Y,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Crenolanib
26,I843DEL,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Crenolanib
27,D842_I843delinsVM,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Crenolanib
28,R1275Q,D,Resistance,Neuroblastoma,TAE684
29,Exon 11 Mutation,B,Sensitivity/Response,Melanoma,Imatinib
30,V600E and V600M,C,Sensitivity/Response,Melanoma,Dabrafenib
31,C634W,D,Resistance,Thyroid Gland Medullary Carcinoma,Motesanib
32,M918T,D,Resistance,Thyroid Gland Medullary Carcinoma,Motesanib
33,M918T,D,Sensitivity/Response,Thyroid Gland Medullary Carcinoma,JAK2 Inhibitor AZD1480
34,V600,B,Resistance,Colorectal Cancer,Panitumumab
35,V600E,D,Sensitivity/Response,Colorectal Cancer,Panitumumab+Sorafenib
36,V600E,D,Resistance,Melanoma,Vemurafenib
37,V600E,C,Resistance,Lung Non-small Cell Carcinoma,Dabrafenib
38,V600E and Amplification,E,Resistance,Colorectal Cancer,Selumetinib
39,V600,B,Sensitivity/Response,Melanoma,Dabrafenib+Trametinib
40,V600D,B,Sensitivity/Response,Melanoma,Dabrafenib
41,V600E,B,Sensitivity/Response,Melanoma,Trametinib+Dabrafenib
42,V600E,D,Sensitivity/Response,Colorectal Cancer,Pictilisib Bismesylate+PLX4720
43,V600E,D,Sensitivity/Response,Colorectal Cancer,PLX4720+Nutlin-3
44,V600E,D,Sensitivity/Response,Colorectal Cancer,Bevacizumab+Capecitabine+Vemurafenib
45,V600E,D,Sensitivity/Response,Colorectal Cancer,Vemurafenib
46,F1174L,D,Resistance,Neuroblastoma,Crizotinib
47,V600E,B,Resistance,Colorectal Cancer,Cetuximab
48,ITD,B,Resistance,Acute Myeloid Leukemia,Tretinoin
49,ITD,D,Resistance,Acute Myeloid Leukemia,Daunorubicin
50,ITD,D,Resistance,Acute Myeloid Leukemia,SU5614
51,G12/G13,B,Resistance,Colorectal Cancer,Chemotherapy+Cetuximab
52,G12/G13,D,Resistance,Colorectal Cancer,Cetuximab
53,G12V,D,Resistance,Colorectal Cancer,Cetuximab
54,EXON 12 MUTATION,B,Resistance,Acute Myeloid Leukemia,Tretinoin
55,Exon 21 Mutation,B,Resistance,Colorectal Cancer,Chemotherapy+Cetuximab
56,EXON 7 MUTATION,B,Resistance,Acute Myeloid Leukemia,Daunorubicin+Cytarabine
57,EML4-ALK L1196M,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Alectinib
58,F1174L,D,Sensitivity/Response,Neuroblastoma,TAE684
59,R1275Q,D,Sensitivity/Response,Neuroblastoma,Crizotinib
60,FGFR3-BAIAP2L1,D,Sensitivity/Response,Bladder Carcinoma,PD173074
61,G13D,D,Sensitivity/Response,Colorectal Cancer,Cetuximab
62,EXON 12 MUTATION,B,Sensitivity/Response,Acute Myeloid Leukemia,Tretinoin
63,EXON 12 MUTATION,B,Sensitivity/Response,Acute Myeloid Leukemia,Daunorubicin
64,EXON 12 MUTATION,B,Sensitivity/Response,Acute Myeloid Leukemia,Valproic Acid
65,EXON 12 MUTATION,D,Sensitivity/Response,Acute Myeloid Leukemia,Tretinoin+NSC348884
66,EXON 12 MUTATION,E,Sensitivity/Response,Acute Myeloid Leukemia,Anti-CD33+Anti-CD123
67,EXON 12 MUTATION,E,Sensitivity/Response,Acute Myeloid Leukemia,Anti-CD33
68,W288FS,D,Sensitivity/Response,Acute Myeloid Leukemia,NSC348884
69,W288FS,E,Sensitivity/Response,Acute Myeloid Leukemia,Daunorubicin+Cytarabine+Etoposide
70,FRAMESHIFT TRUNCATION,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Sirolimus
71,Loss-of-function,B,Sensitivity/Response,Bladder Carcinoma,Everolimus
72,Loss-of-function,B,Sensitivity/Response,Ovarian Cancer,Olaparib
73,Loss-of-function,B,Sensitivity/Response,Ovarian Cancer,Olaparib
74,L858R,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib+Erlotinib
75,BCR-ABL,D,Resistance,Acute Myeloid Leukemia,Imatinib
76,BCR-ABL E255K,D,Resistance,Chronic Myeloid Leukemia,Imatinib
77,BCR-ABL T315I,B,Resistance,Chronic Myeloid Leukemia,Imatinib
78,BCR-ABL T315I,D,Resistance,Chronic Myeloid Leukemia,Imatinib
79,EML4-ALK C1156Y,C,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
80,EML4-ALK L1196M,C,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
81,T790M,A,Resistance,Lung Non-small Cell Carcinoma,Erlotinib
82,T790M,B,Resistance,Lung Non-small Cell Carcinoma,Gefitinib
83,T790M,B,Resistance,Lung Non-small Cell Carcinoma,Dacomitinib
84,L755S,D,Resistance,Breast Cancer,Lapatinib
85,L536Q,D,Resistance,Breast Cancer,Hormone Therapy
86,D538G,D,Resistance,Breast Cancer,Hormone Therapy
87,Y537C,D,Resistance,Breast Cancer,Hormone Therapy
88,Y537N,D,Resistance,Breast Cancer,Hormone Therapy
89,Y537S,D,Resistance,Breast Cancer,Hormone Therapy
90,TKD MUTATION,B,Resistance,Acute Myeloid Leukemia,Sorafenib
91,TKD MUTATION,B,Resistance,Acute Myeloid Leukemia,Sorafenib
92,V654A,D,Resistance,Gastrointestinal Stromal Tumor,Imatinib
93,Exon 2 Mutation,B,Resistance,Colorectal Cancer,Cetuximab
94,G12A,B,Resistance,Lung Adenocarcinoma,Gefitinib+Erlotinib
95,E542K,B,Resistance,Colorectal Cancer,Cetuximab+Panitumumab
96,BCR-ABL,A,Sensitivity/Response,Acute Myeloid Leukemia,Imatinib
97,BCR-ABL,A,Sensitivity/Response,Chronic Myeloid Leukemia,Imatinib
98,BCR-ABL,A,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib+Nilotinib
99,EML4-ALK,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Crizotinib
100,LOSS,D,Sensitivity/Response,T-cell Lymphoblastic Leukemia/lymphoma,Palbociclib
101,EXPRESSION,D,Sensitivity/Response,Estrogen-receptor Positive Breast Cancer,Alpelisib
102,G253C,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Dasatinib
103,G505S,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Dasatinib
104,G774V,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Dasatinib
105,I638F,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Dasatinib
106,L239R,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Dasatinib
107,L63V,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Dasatinib
108,S768R,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib+Dasatinib
109,Exon 19 Deletion,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
110,G719S,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
111,L858R,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib+Gefitinib
112,L858R,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
113,T790M,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Pemetrexed+Erlotinib
114,T790M,E,Sensitivity/Response,Lung Non-small Cell Carcinoma,Staurosporine
115,D769H,D,Sensitivity/Response,Breast Cancer,Lapatinib+Neratinib
116,D769Y,D,Sensitivity/Response,Breast Cancer,Neratinib
117,L755_T759del,D,Sensitivity/Response,Breast Cancer,Neratinib
118,G309A,D,Sensitivity/Response,Breast Cancer,Neratinib
119,L755S,D,Sensitivity/Response,Breast Cancer,Neratinib
120,L755W,D,Sensitivity/Response,Breast Cancer,Neratinib
121,P780INS,D,Sensitivity/Response,Breast Cancer,Neratinib
122,R678Q,D,Sensitivity/Response,Breast Cancer,Neratinib+Lapatinib
123,R896C,D,Sensitivity/Response,Breast Cancer,Neratinib
124,V777L,D,Sensitivity/Response,Breast Cancer,Neratinib
125,V842I,D,Sensitivity/Response,Breast Cancer,Neratinib
126,L536Q,D,Sensitivity/Response,Breast Cancer,Fulvestrant+Tamoxifen
127,D538G,D,Sensitivity/Response,Breast Cancer,Fulvestrant+Tamoxifen
128,Y537C,D,Sensitivity/Response,Breast Cancer,Tamoxifen+Fulvestrant
129,Y537N,D,Sensitivity/Response,Breast Cancer,Tamoxifen+Fulvestrant
130,Y537S,D,Sensitivity/Response,Breast Cancer,Fulvestrant+Tamoxifen
131,FGFR2-MGEA5,C,Sensitivity/Response,Cholangiocarcinoma,Ponatinib
132,FGFR2-TACC3,C,Sensitivity/Response,Cholangiocarcinoma,Ponatinib+Pazopanib
133,ITD,B,Sensitivity/Response,Acute Myeloid Leukemia,Lestaurtinib
134,ITD,B,Sensitivity/Response,Acute Myeloid Leukemia,Sorafenib
135,ITD,D,Sensitivity/Response,Acute Myeloid Leukemia,Tyrphostin AG 1296
136,EXPRESSION,D,Sensitivity/Response,Lung Adenocarcinoma,Fasudil+Bortezomib
137,Internal Duplication,C,Sensitivity/Response,Malignant Anus Melanoma,Imatinib
138,L576P,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Dasatinib+Imatinib+Nilotinib
139,V654A,B,Sensitivity/Response,Gastrointestinal Stromal Tumor,Sunitinib
140,G12D,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Dactolisib+Selumetinib
141,G13D,B,Sensitivity/Response,Colorectal Cancer,Cetuximab
142,Promoter Methylation,A,Sensitivity/Response,Glioblastoma,Temozolomide
143,Promoter Methylation,B,Sensitivity/Response,Glioblastoma,Carmustine
144,Promoter Methylation,E,Sensitivity/Response,Glioblastoma,O6-Benzylguanine
145,E542K,D,Sensitivity/Response,Breast Cancer,PI3K-alpha Inhibitor MEN1611
146,E542K,D,Sensitivity/Response,Breast Cancer,Sirolimus
147,H1047R,D,Sensitivity/Response,Breast Cancer,PI3K-alpha Inhibitor MEN1611
148,PML-RARA,B,Sensitivity/Response,Acute Promyelocytic Leukemia,Tretinoin
149,R233*,D,Sensitivity/Response,Breast Cancer,MTOR Inhibitor
150,R175H,D,Sensitivity/Response,Breast Cancer,Doxorubicin
151,FRAMESHIFT TRUNCATION,B,Sensitivity/Response,Invasive Bladder Transitional Cell Carcinoma,Everolimus
152,BCR-ABL,A,Sensitivity/Response,Chronic Myeloid Leukemia,Imatinib
153,EXPRESSION,B,Sensitivity/Response,Estrogen-receptor Positive Breast Cancer,Palbociclib
154,E545K,C,Resistance,Colorectal Cancer,Panitumumab+Cetuximab
155,H1047R,C,Resistance,Colorectal Cancer,Panitumumab+Cetuximab
156,R249,B,Sensitivity/Response,Breast Cancer,Doxorubicin
157,MEF2D-CSF1R,D,Sensitivity/Response,Acute Lymphoblastic Leukemia,GW-2580+Imatinib
158,Mutation,B,Resistance,Acute Myeloid Leukemia,Cytarabine
159,Exon 19 Deletion,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib+Erlotinib
160,Overexpression,D,Sensitivity/Response,Prostate Cancer,Docetaxel+Cabazitaxel+Linsitinib
161,C481S,B,Resistance,Chronic Lymphocytic Leukemia,Ibrutinib
162,Q79K,D,Resistance,Melanoma,Vemurafenib
163,EML4-ALK and Amplification,D,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
164,ALK Fusion G1202R,D,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
165,EML4-ALK L1196M,D,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
166,EML4-ALK S1206Y,D,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
167,EML4-ALK T1151INST,C,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
168,MUTATION,D,Sensitivity/Response,Colon Carcinoma,JW55
169,MUTATION,D,Sensitivity/Response,Colorectal Cancer,G007-LK
170,F877L,D,Resistance,Prostate Cancer,Apalutamide+Enzalutamide
171,W742,D,Resistance,Prostate Carcinoma,Bicalutamide
172,Mutation,D,Sensitivity/Response,Glioblastoma,Temozolomide
173,Mutation,D,Sensitivity/Response,Melanoma,Temozolomide
174,Underexpression,D,Sensitivity/Response,Cancer,NU7441+KU-0060648
175,Mutation,D,Sensitivity/Response,Hematologic Cancer,Olaparib
176,AMPLIFICATION,E,Sensitivity/Response,Esophagus Adenocarcinoma,Alisertib+Cisplatin
177,Overexpression,D,Resistance,Cervical Adenocarcinoma,Paclitaxel
178,V560DEL,C,Sensitivity/Response,Thymic Carcinoma,Imatinib
179,Loss,B,Resistance,Colorectal Cancer,Cetuximab
180,Loss,D,Sensitivity/Response,Prostate Cancer,Temsirolimus
181,Amplification,B,Sensitivity/Response,Her2-receptor Positive Breast Cancer,Trastuzumab
182,Amplification,B,Sensitivity/Response,Her2-receptor Positive Breast Cancer,Trastuzumab
183,G12/G13,B,Resistance,Pancreatic Adenocarcinoma,Trametinib+Gemcitabine
184,LOSS-OF-FUNCTION,D,Sensitivity/Response,Ovarian Serous Carcinoma,Olaparib
185,R367Q,D,Resistance,T-cell Acute Lymphoblastic Leukemia,Mercaptopurine+Thioguanine
186,K359Q,D,Resistance,T-cell Acute Lymphoblastic Leukemia,Mercaptopurine+Thioguanine
187,D407A,D,Resistance,T-cell Acute Lymphoblastic Leukemia,Mercaptopurine+Thioguanine
188,BCR-ABL F317L,B,Resistance,Chronic Myeloid Leukemia,Dasatinib
189,BCR-ABL F317L,D,Sensitivity/Response,Chronic Myeloid Leukemia,Ponatinib
190,BCR-ABL F317L,B,Sensitivity/Response,Chronic Myeloid Leukemia,Ponatinib
191,T790M,D,Resistance,Lung Cancer,Gefitinib+Multikinase Inhibitor AEE788
192,Loss,B,Resistance,Bladder Carcinoma,Everolimus
193,Loss,B,Resistance,Breast Cancer,Trastuzumab
194,T790M,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Rociletinib
195,S2289*,C,Sensitivity/Response,Prostate Cancer,Olaparib
196,N2875H,C,Sensitivity/Response,Prostate Cancer,Olaparib
197,Y177fs,C,Resistance,Peritoneal Mesothelioma,Carboplatin+Cisplatin
198,Loss-of-function,B,Sensitivity/Response,Prostate Cancer,Olaparib
199,D842V,D,Resistance,Gastrointestinal Stromal Tumor,Imatinib
200,V561A,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Imatinib
201,Exon 11 Mutation,B,Sensitivity/Response,Gastrointestinal Stromal Tumor,Imatinib
202,R194W,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gemcitabine+Vinorelbine+Docetaxel
203,DELETION,D,Sensitivity/Response,Ovarian Carcinoma,Carboplatin+Cisplatin+Paclitaxel
204,AMPLIFICATION,D,Resistance,Colon Cancer,Cisplatin
205,Exon 4 Deletion,D,Resistance,Epithelial Ovarian Cancer,Cisplatin
206,3' UTR MUTATION,B,Resistance,Ovarian Cancer,Paclitaxel+Carboplatin
207,RS61764370,B,Resistance,Epithelial Ovarian Cancer,Paclitaxel+Carboplatin
208,A222V,B,Sensitivity/Response,Stomach Cancer,Fluorouracil
209,I105V,B,Sensitivity/Response,Colorectal Cancer,FOLFOX Regimen
210,Q399R,B,Sensitivity/Response,Cervical Cancer,Cisplatin+Carboplatin
211,S893T,B,Sensitivity/Response,Ovarian Cancer,Paclitaxel
212,I1145I,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Carboplatin+Cisplatin
213,K751Q,B,Resistance,Osteosarcoma,Cisplatin
214,K751Q,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Paclitaxel+Carboplatin
215,5' TANDEM REPEAT,B,Resistance,Colorectal Cancer,Irinotecan+Fluorouracil
216,EXON 12-22 DELETION,D,Resistance,Ovarian Cancer,Doxorubicin
217,Amplification,D,Sensitivity/Response,Lung Squamous Cell Carcinoma,PD173074
218,Expression,D,Sensitivity/Response,Lung Cancer,Ponatinib
219,Amplification,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,PD173074
220,REARRANGEMENT,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Crizotinib
221,Amplification,C,Sensitivity/Response,Gastric Adenocarcinoma,Onartuzumab
222,Overexpression,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
223,p16 Expression,B,Resistance,Head And Neck Squamous Cell Carcinoma,Panitumumab
224,KIF5B-RET,C,Sensitivity/Response,Lung Adenocarcinoma,Vandetanib
225,G13D,C,Resistance,Colorectal Cancer,Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
226,MUTATION,D,Sensitivity/Response,Cancer,MTOR Kinase Inhibitor AZD8055+Everolimus+Mirdametinib+Binimetinib+Selumetinib
227,Expression,B,Sensitivity/Response,Melanoma,Nivolumab+Pembrolizumab
228,MUTATION,C,Sensitivity/Response,Bladder Carcinoma,Everolimus+Pazopanib
229,EXPRESSION,B,Sensitivity/Response,Breast Cancer,Trastuzumab
230,E17K,D,Sensitivity/Response,Melanoma,Uprosertib
231,Loss,D,Sensitivity/Response,Melanoma,Uprosertib
232,E17K,C,Sensitivity/Response,Breast Cancer,Capivasertib
233,E545K,D,Sensitivity/Response,Breast Cancer,Pictilisib+Akt Inhibitor MK2206
234,Loss,D,Sensitivity/Response,Breast Cancer,PI3Kbeta Inhibitor AZD8186
235,H1968Y,D,Sensitivity/Response,Melanoma,Capivasertib+PI3K/BET Inhibitor LY294002
236,Loss,B,Sensitivity/Response,Cancer,Buparlisib+Carboplatin+Paclitaxel
237,K159fs,C,Sensitivity/Response,Breast Cancer,Temsirolimus
238,Loss,D,Resistance,Breast Cancer,Alpelisib
239,S492R,C,Resistance,Colorectal Cancer,Cetuximab
240,MUTATION,B,Resistance,Colorectal Cancer,Cetuximab+Panitumumab
241,MUTATION,B,Resistance,Colorectal Cancer,Panitumumab+Cetuximab
242,UNDEREXPRESSION,D,Resistance,Head And Neck Squamous Cell Carcinoma,Cetuximab
243,H1968Y,D,Sensitivity/Response,Melanoma,Capivasertib
244,P2213S,D,Sensitivity/Response,Melanoma,Capivasertib+PI3K/BET Inhibitor LY294002
245,AGK-BRAF,C,Sensitivity/Response,Melanoma,Sorafenib
246,AGK-BRAF,D,Resistance,Melanoma,Vemurafenib
247,PAPSS1-BRAF,D,Resistance,Melanoma,Vemurafenib
248,PAPSS1-BRAF,D,Sensitivity/Response,Melanoma,Trametinib
249,TRIM24-BRAF,D,Sensitivity/Response,Melanoma,Trametinib
250,L597R,C,Sensitivity/Response,Melanoma,Vemurafenib
251,Overexpression,B,Resistance,Colorectal Cancer,Cetuximab
252,OVEREXPRESSION,B,Sensitivity/Response,Colorectal Cancer,Cetuximab
253,R132C,D,Sensitivity/Response,Acute Myeloid Leukemia,GSK321
254,Amplification,D,Resistance,Lung Non-small Cell Carcinoma,Gefitinib
255,OVEREXPRESSION,D,Resistance,Breast Cancer,Paclitaxel
256,Amplification,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Crizotinib
257,EXON 14 SKIPPING MUTATION,D,Sensitivity/Response,Cancer,Crizotinib
258,Overexpression,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
259,D842V,B,Resistance,Gastrointestinal Stromal Tumor,Imatinib
260,P471L,C,Sensitivity/Response,Merkel Cell Carcinoma,Idelalisib
261,Overexpression,D,Sensitivity/Response,Breast Cancer,Vandetanib
262,MUTATION,D,Sensitivity/Response,Lung Adenocarcinoma,Pictilisib+Selumetinib
263,Expression,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Nivolumab+Pembrolizumab
264,Amplification,D,Sensitivity/Response,Neuroblastoma,FACT Complex-targeting Curaxin CBL0137
265,D473H,C,Resistance,Medulloblastoma,Vismodegib
266,Mutation,B,Resistance,Basal Cell Carcinoma,Vismodegib
267,Mutation,D,Sensitivity/Response,Basal Cell Carcinoma,PSI+Arsenic Trioxide
268,MUTATION,B,Sensitivity/Response,Medulloblastoma,Sonidegib
269,LOH,B,Sensitivity/Response,Medulloblastoma,Vismodegib
270,UNDEREXPRESSION,D,Sensitivity/Response,Prostate Cancer,SB202190
271,OVEREXPRESSION,D,Resistance,Ovarian Cancer,Paclitaxel
272,p16 Expression,B,Sensitivity/Response,Head And Neck Squamous Cell Carcinoma,Panitumumab
273,D473H,D,Resistance,Basal Cell Carcinoma,Vismodegib
274,Amplification,C,Sensitivity/Response,Epithelial Ovarian Cancer,Pictilisib
275,V600E,C,Sensitivity/Response,Melanoma,Pictilisib
276,Amplification,D,Sensitivity/Response,Breast Cancer,AKTi-1/2
277,Amplification,B,Sensitivity/Response,Her2-receptor Positive Breast Cancer,Neratinib
278,T790M,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Rociletinib
279,EML4-ALK L1152R,C,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
280,EML4-ALK G1269A,C,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
281,EML4-ALK G1269A,C,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
282,EML4-ALK and Amplification,C,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
283,EML4-ALK and Amplification,C,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
284,AUTOCRINE ACTIVATION,D,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
285,AUTOCRINE ACTIVATION,B,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
286,MUTATION,D,Sensitivity/Response,Melanoma,Lapatinib
287,Mutation,D,Sensitivity/Response,Colorectal Cancer,Cabozantinib
288,VIII,B,Sensitivity/Response,Glioblastoma,Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
289,VIII,C,Sensitivity/Response,Glioblastoma,Afatinib
290,Expression,B,Sensitivity/Response,Glioblastoma,Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
291,Expression,D,Sensitivity/Response,Glioblastoma,Dacomitinib
292,Expression,D,Sensitivity/Response,Head And Neck Squamous Cell Carcinoma,Lapatinib
293,Expression,D,Resistance,Colorectal Cancer,Cetuximab
294,Expression,D,Sensitivity/Response,Ovarian Cancer,Seribantumab
295,Expression,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gemcitabine+Paclitaxel+Cisplatin+Carboplatin
296,Expression,D,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
297,Expression,B,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
298,G724S,D,Sensitivity/Response,Colorectal Cancer,Cetuximab
299,G719S,D,Sensitivity/Response,Colorectal Cancer,Cetuximab
300,Expression,B,Sensitivity/Response,Colorectal Cancer,Cetuximab
301,EXPRESSION,B,Sensitivity/Response,Colorectal Cancer,Cetuximab
302,EXPRESSION,B,Sensitivity/Response,Colorectal Cancer,
303,E322K,C,Sensitivity/Response,Head And Neck Squamous Cell Carcinoma,Erlotinib
304,AMPLIFICATION,D,Resistance,Lung Non-small Cell Carcinoma,WZ4002
305,A146V,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Abemaciclib
306,G12V,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Palbociclib
307,Mutation,B,Sensitivity/Response,Papillary Renal Cell Carcinoma,Foretinib
308,EXON 14 SKIPPING MUTATION,C,Sensitivity/Response,Lung Adenocarcinoma,Crizotinib
309,Expression,D,Sensitivity/Response,Head And Neck Squamous Cell Carcinoma,Infigratinib
310,Expression,D,Sensitivity/Response,Gastric Adenocarcinoma,Infigratinib
311,Expression,D,Sensitivity/Response,Bladder Carcinoma,PD173074+Dovitinib
312,Expression,D,Sensitivity/Response,Bladder Carcinoma,
313,Overexpression,D,Sensitivity/Response,Bladder Carcinoma,Tyrosine Kinase Inhibitor SU5402+PD173074+Dovitinib
314,EXPRESSION,D,Resistance,Cancer,Olaparib
315,MUTATION,D,Sensitivity/Response,Head And Neck Carcinoma,JSI-124
316,EXPRESSION,B,Sensitivity/Response,Prostate Cancer,Docetaxel
317,AMPLIFICATION,D,Sensitivity/Response,Colorectal Cancer,NOTCH1 Antibody (PF-06293622)
318,Expression,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Patritumab
319,RS3910384,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Platinum Compound+Gemcitabine
320,RS11623866,B,Resistance,Ovarian Cancer,Lonafarnib
321,PROMOTER HYPERMETHYLATION,D,Sensitivity/Response,Head And Neck Squamous Cell Carcinoma,Stattic+JSI-124
322,Decreased Peri-therapeutic Expression,B,Sensitivity/Response,Colorectal Cancer,Fluorouracil+Irinotecan+Levoleucovorin+Bevacizumab
323,EXPRESSION,D,Sensitivity/Response,Ovarian Cancer,Decitabine
324,Mutation,D,Sensitivity/Response,Ovarian Cancer,Decitabine
325,EXPRESSION,B,Sensitivity/Response,Lung Cancer,Paclitaxel
326,RS16906252,B,Sensitivity/Response,Glioblastoma,Temozolomide
327,EXPRESSION,B,Sensitivity/Response,Breast Cancer,Aminoglutethimide+Tamoxifen
328,NUCLEAR EXPRESSION,B,Resistance,Colorectal Cancer,Oxaliplatin+Fluorouracil+Irinotecan+Levoleucovorin
329,CD44s Expression,D,Sensitivity/Response,Cancer,RG7356
330,EXPRESSION,D,Resistance,Head And Neck Squamous Cell Carcinoma,Cetuximab
331,EXPRESSION,B,Resistance,Malignant Pleural Mesothelioma,Pemetrexed+Cisplatin
332,EXPRESSION,B,Resistance,Renal Cell Carcinoma,Sunitinib+Sorafenib
333,Overexpression,D,Sensitivity/Response,Ewing Sarcoma Of Bone,Conatumumab
334,Overexpression,B,Resistance,Lung Non-small Cell Carcinoma,Pemetrexed
335,OVEREXPRESSION,D,Resistance,Lung Non-small Cell Carcinoma,Gefitinib
336,Amplification,C,Sensitivity/Response,Lung Adenocarcinoma,Crizotinib
337,UNDEREXPRESSION,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Vinorelbine+Cisplatin
338,EML4-ALK C1156Y,C,Resistance,Lung Non-small Cell Carcinoma,Crizotinib+Ceritinib+Luminespib
339,EML4-ALK C1156Y,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Lorlatinib
340,EML4::ALK C1156Y-L1198F,C,Resistance,Lung Non-small Cell Carcinoma,Lorlatinib
341,EML4::ALK C1156Y-L1198F,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Crizotinib
342,Loss-of-function,C,Sensitivity/Response,Prostate Cancer,Olaparib
343,Expression,B,Resistance,Head And Neck Squamous Cell Carcinoma,Cetuximab+Docetaxel
344,Expression,B,Resistance,Head And Neck Squamous Cell Carcinoma,
345,VIII,B,Resistance,Head And Neck Squamous Cell Carcinoma,Docetaxel+Cetuximab
346,Mutation,B,Sensitivity/Response,Gastric Adenocarcinoma,Chemotherapy
347,Mutation,D,Sensitivity/Response,Breast Cancer,Doxorubicin
348,EXPRESSION,B,Resistance,Colorectal Cancer,Fluorouracil
349,EXPRESSION,B,Resistance,Colorectal Cancer,Fluorouracil
350,Amplification,B,Sensitivity/Response,Colorectal Cancer,Cetuximab+Panitumumab
351,EXPRESSION,B,Resistance,Endometrial Carcinoma,Paclitaxel
352,Overexpression,B,Resistance,Estrogen-receptor Positive Breast Cancer,Tamoxifen
353,AMPLIFICATION,B,Resistance,Breast Cancer,Tamoxifen
354,OVEREXPRESSION,D,Sensitivity/Response,Breast Cancer,Dactolisib
355,CYTOPLASMIC MISLOCALIZATION,D,Resistance,Breast Cancer,Lapatinib
356,Expression,D,Sensitivity/Response,Cancer,Anti-ErbB3 Monoclonal Antibody AV-203
357,V7 EXPRESSION,B,Resistance,Prostate Cancer,Enzalutamide+Abiraterone
358,Loss,B,Resistance,Gastric Adenocarcinoma,Trastuzumab+Lapatinib
359,EXPRESSION,D,Sensitivity/Response,Pancreatic Ductal Adenocarcinoma,9F7-F11+Pertuzumab
360,EXPRESSION,D,Resistance,Colorectal Cancer,Ganetespib
361,NUCLEAR TRANSLOCATION,D,Resistance,Breast Cancer,Trastuzumab
362,EXPRESSION,D,Resistance,Breast Cancer,Trastuzumab
363,EXPRESSION,D,Resistance,Breast Cancer,Lapatinib
364,EXPRESSION,D,Sensitivity/Response,Colorectal Cancer,7-Ethyl-10-Hydroxycamptothecin
365,Overexpression,B,Resistance,Lung Non-small Cell Carcinoma,Cisplatin
366,RS61764370,B,Resistance,Head And Neck Squamous Cell Carcinoma,Cisplatin
367,P29S,D,Resistance,Melanoma,Dabrafenib+Vemurafenib
368,NUCLEAR EXPRESSION,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Taxane Compound+Platinum Compound
369,Wildtype,B,Sensitivity/Response,Colorectal Cancer,Cetuximab+Oxaliplatin+Capecitabine
370,LOSS,D,Sensitivity/Response,Endometrial Cancer,Talazoparib
371,LOSS,C,Sensitivity/Response,Prostate Cancer,
372,Underexpression,D,Sensitivity/Response,Gastric Adenocarcinoma,Olaparib
373,L858R,B,Sensitivity/Response,Lung Adenocarcinoma,Afatinib
374,Exon 19 Deletion,B,Sensitivity/Response,Lung Adenocarcinoma,Afatinib
375,Exon 19 Deletion,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Afatinib
376,Exon 19 Deletion,B,Sensitivity/Response,Lung Adenocarcinoma,Afatinib
377,L858R,B,Sensitivity/Response,Lung Adenocarcinoma,Afatinib
378,Exon 19 Deletion,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib
379,L858R,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib
380,Amplification,D,Sensitivity/Response,Uterine Corpus Endometrial Carcinoma,Afatinib
381,Amplification,B,Sensitivity/Response,Her2-receptor Positive Breast Cancer,Lapatinib+Trastuzumab+Afatinib
382,AMPLIFICATION,B,Sensitivity/Response,Colorectal Cancer,Irinotecan
383,EXPRESSION,B,Sensitivity/Response,Head And Neck Squamous Cell Carcinoma,Fluorouracil+Cisplatin
384,Amplification,C,Sensitivity/Response,Lung Squamous Cell Carcinoma,Crizotinib
385,EXPRESSION,B,Resistance,Breast Cancer,Tamoxifen
386,Expression,D,Sensitivity/Response,Colorectal Cancer,Infigratinib
387,PROMOTER HYPERMETHYLATION,D,Sensitivity/Response,Cancer,GNE-617
388,Exon 18 Overexpression,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Bevacizumab+Erlotinib
389,Expression,D,Resistance,Mantle Cell Lymphoma,Doxorubicin+Cytarabine+Gemcitabine
390,Expression,D,Sensitivity/Response,Mantle Cell Lymphoma,Salinomycin+Doxorubicin
391,OVEREXPRESSION,D,Resistance,Breast Cancer,Fulvestrant
392,OVEREXPRESSION,D,Sensitivity/Response,Colorectal Cancer,Cetuximab
393,Amplification,B,Resistance,Lung Adenocarcinoma,Pemetrexed
394,EXPRESSION,D,Resistance,Lung Non-small Cell Carcinoma,Gefitinib
395,EXPRESSION,B,Resistance,Colorectal Cancer,Bevacizumab
396,Wildtype,B,Sensitivity/Response,Esophageal Carcinoma,Chemotherapy
397,Underexpression,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Pemetrexed
398,Underexpression,C,Sensitivity/Response,Prostate Cancer,Pemetrexed
399,EXPRESSION,B,Sensitivity/Response,Breast Cancer,Doxorubicin
400,EXPRESSION,B,Sensitivity/Response,Ovarian Cancer,Carboplatin+Cyclophosphamide+Topotecan
401,Amplification,B,Sensitivity/Response,Colorectal Cancer,Cetuximab
402,EXPRESSION,B,Sensitivity/Response,Colorectal Cancer,Irinotecan
403,T172 PHOSPHORYLATION,E,Sensitivity/Response,Cancer,ACLY SiRNA
404,EXPRESSION,B,Sensitivity/Response,Colorectal Cancer,Fluorouracil
405,Mutation,B,Resistance,Colorectal Cancer,Anti-EGFR Monoclonal Antibody
406,PHOSPHORYLATION,D,Sensitivity/Response,Gastric Adenocarcinoma,Everolimus
407,MUTATION,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Imatinib+Pictilisib
408,EXPRESSION,D,Resistance,Cancer,Paclitaxel
409,EXPRESSION,B,Sensitivity/Response,Breast Cancer,Taxane Compound
410,Overexpression,B,Resistance,Lung Non-small Cell Carcinoma,Pemetrexed
411,Y1092 PHOSPHORYLATION,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib+Erlotinib
412,NUCLEAR EXPRESSION,B,Sensitivity/Response,Sarcoma,IGF1R Monoclonal Antibody
413,EXPRESSION,D,Resistance,Prostate Cancer,Bicalutamide
414,EXPRESSION,B,Resistance,Hepatocellular Carcinoma,Sorafenib
415,OVEREXPRESSION,B,Resistance,Breast Cancer,Paclitaxel
416,EXPRESSION,B,Sensitivity/Response,Breast Cancer,Epirubicin
417,Overexpression,B,Resistance,Gastric Adenocarcinoma,Raltitrexed
418,PHOSPHORYLATION,D,Sensitivity/Response,Gastric Adenocarcinoma,Everolimus
419,OVEREXPRESSION,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Enzastaurin
420,PHOSPHORYLATION,D,Resistance,Colorectal Cancer,MTOR Kinase Inhibitor PP242+Dactolisib+WYE354
421,Expression,D,Sensitivity/Response,Malignant Mesothelioma,Vinorelbine
422,EXPRESSION,D,Sensitivity/Response,Cancer,Trametinib
423,Mutation,D,Sensitivity/Response,Cancer,Trametinib
424,Mutation,D,Sensitivity/Response,Cancer,Trametinib
425,G12D,C,Sensitivity/Response,Pancreatic Carcinoma,Akt Inhibitor MK2206
426,Loss,C,Sensitivity/Response,Pancreatic Carcinoma,Akt Inhibitor MK2206
427,EXPRESSION,D,Sensitivity/Response,Pancreatic Ductal Adenocarcinoma,Gemcitabine
428,EXPRESSION,D,Resistance,Lung Cancer,Amrubicin
429,P187S,D,Sensitivity/Response,Lung Cancer,Amrubicin
430,Underexpression,B,Sensitivity/Response,Ovarian Cancer,Platinum Compound+Taxane Compound
431,Mutation,D,Sensitivity/Response,Colorectal Cancer,Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor+Immunomodulatory Oligonucleotide
432,Overexpression,D,Resistance,Lung Non-small Cell Carcinoma,Paclitaxel
433,Fusion,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Pemetrexed
434,EXPRESSION,B,Resistance,Gastric Adenocarcinoma,Cisplatin
435,Mutation,D,Sensitivity/Response,Colorectal Cancer,Dasatinib+Cetuximab
436,Amplification,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
437,EXPRESSION,B,Resistance,Gastric Adenocarcinoma,Docetaxel
438,EXPRESSION,D,Resistance,Bile Duct Adenocarcinoma,Gemcitabine
439,AMPLIFICATION,D,Resistance,Breast Cancer,Paclitaxel+Monomethyl Auristatin E
440,Overexpression,D,Resistance,Lung Non-small Cell Carcinoma,Paclitaxel
441,AMPLIFICATION,D,Resistance,Ovarian Cancer,Asparaginase
442,Overexpression,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
443,Expression,B,Sensitivity/Response,Breast Cancer,Trastuzumab
444,EXPRESSION,D,Resistance,Colon Cancer,Oxaliplatin
445,Kinase Domain Mutation,C,Sensitivity/Response,Lung Adenocarcinoma,Afatinib
446,Y772_A775DUP,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Afatinib+Sirolimus
447,Amplification,B,Sensitivity/Response,Her2-receptor Positive Breast Cancer,Afatinib
448,Amplification,D,Sensitivity/Response,Pancreatic Adenocarcinoma,Afatinib
449,T790M,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Osimertinib
450,C797S,B,Resistance,Lung Non-small Cell Carcinoma,Osimertinib
451,T790M,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Osimertinib
452,T790M,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Osimertinib
453,T790M,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Rociletinib+Osimertinib
454,L858R,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Afatinib
455,Exon 19 Deletion,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Afatinib
456,VIII,B,Sensitivity/Response,Glioblastoma,Rindopepimut
457,SERUM LEVELS,B,Sensitivity/Response,Breast Cancer,Lapatinib
458,Fusion,D,Sensitivity/Response,Colorectal Cancer,Larotrectinib
459,R132H,D,Sensitivity/Response,Oligodendroglioma,AGI-5198
460,Exon 19 Deletion,B,Sensitivity/Response,Lung Adenocarcinoma,Afatinib
461,L858R,B,Sensitivity/Response,Lung Adenocarcinoma,Afatinib
462,Exon 19 Deletion,B,Sensitivity/Response,Lung Adenocarcinoma,Afatinib
463,EXPRESSION,B,Sensitivity/Response,Skin Melanoma,Nivolumab+Pembrolizumab+Atezolizumab
464,L265P,B,Sensitivity/Response,Waldenstroem's Macroglobulinemia,Ibrutinib
465,Mutation,D,Sensitivity/Response,Colorectal Cancer,B-Raf/VEGFR-2 Inhibitor RAF265+Selumetinib
466,Mutation,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,B-Raf/VEGFR-2 Inhibitor RAF265+Selumetinib
467,Mutation,D,Sensitivity/Response,Colorectal Cancer,Trametinib+Afatinib
468,Mutation,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Trametinib+Afatinib
469,Exon 2 Mutation,A,Resistance,Colorectal Cancer,Cetuximab
470,Mutation,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Selumetinib+Docetaxel
471,V600,C,Resistance,Melanoma,Refametinib
472,Q61K,D,Sensitivity/Response,Neuroblastoma,Everolimus+Binimetinib
473,Mutation,D,Sensitivity/Response,Pancreatic Adenocarcinoma,PI3Kbeta Inhibitor AZD8186+SCH772984
474,Mutation,D,Sensitivity/Response,Colorectal Cancer,Selumetinib+Teprotumumab
475,V600E,D,Sensitivity/Response,Melanoma,Dactolisib+Selumetinib
476,Amplification,D,Sensitivity/Response,Breast Cancer,Lapatinib+Trastuzumab
477,Amplification,B,Sensitivity/Response,Her2-receptor Positive Breast Cancer,Trastuzumab+Lapatinib
478,Amplification,B,Sensitivity/Response,Her2-receptor Positive Breast Cancer,Lapatinib+Trastuzumab
479,Amplification,B,Sensitivity/Response,Her2-receptor Positive Breast Cancer,Afatinib
480,Amplification,B,Sensitivity/Response,Her2-receptor Positive Breast Cancer,Afatinib
481,Amplification,B,Sensitivity/Response,Her2-receptor Positive Breast Cancer,Afatinib+Trastuzumab
482,FRAMESHIFT MUTATION,B,Sensitivity/Response,Prostate Cancer,Olaparib
483,VIII,D,Sensitivity/Response,Brain Glioma,Nimotuzumab
484,Fusion,D,Sensitivity/Response,Lung Adenocarcinoma,Lestaurtinib+Crizotinib+Larotrectinib
485,Expression,B,Sensitivity/Response,Colorectal Cancer,Panitumumab
486,EXPRESSION,B,Sensitivity/Response,Colorectal Cancer,Panitumumab
487,Amplification,B,Sensitivity/Response,Gastric Adenocarcinoma,Trastuzumab
488,Amplification,B,Sensitivity/Response,Gastric Adenocarcinoma,Lapatinib
489,EXPRESSION,C,Sensitivity/Response,Endometrial Cancer,Imatinib
490,EXPRESSION,C,Sensitivity/Response,Endometrial Cancer,Imatinib
491,REARRANGEMENT,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Crizotinib
492,LOSS,D,Sensitivity/Response,Renal Carcinoma,Temsirolimus
493,D835,D,Resistance,Acute Myeloid Leukemia,Ponatinib+Quizartinib
494,D835,D,Resistance,Acute Myeloid Leukemia,SU5614
495,D835,B,Resistance,Acute Myeloid Leukemia,Quizartinib+Sorafenib
496,D835,B,Resistance,Acute Myeloid Leukemia,Sorafenib
497,ITD,B,Sensitivity/Response,Acute Myeloid Leukemia,Sorafenib
498,Kinase Domain Mutation,C,Sensitivity/Response,Lung Adenocarcinoma,Trastuzumab
499,Amplification,C,Sensitivity/Response,Lung Small Cell Carcinoma,Trastuzumab+Irinotecan
500,Y772_A775DUP,C,Sensitivity/Response,Lung Adenocarcinoma,Afatinib
501,Y772_A775DUP,D,Sensitivity/Response,Lung Carcinoma,Afatinib+Sirolimus
502,Y772_A775DUP,D,Sensitivity/Response,Lung Carcinoma,Afatinib
503,P780INS,C,Sensitivity/Response,Lung Adenocarcinoma,Dacomitinib
504,Amplification,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Trastuzumab Emtansine
505,Mutation,D,Sensitivity/Response,Colorectal Cancer,Futuximab/Modotuximab Mixture
506,G465R,C,Sensitivity/Response,Colorectal Cancer,Futuximab/Modotuximab Mixture
507,G465R,C,Resistance,Colorectal Cancer,Cetuximab+Panitumumab
508,RS461155,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Paclitaxel+Cisplatin
509,Amplification,B,Sensitivity/Response,Her2-receptor Positive Breast Cancer,Pertuzumab+Docetaxel+Trastuzumab
510,S492R,C,Sensitivity/Response,Colorectal Cancer,Panitumumab
511,S492R,D,Sensitivity/Response,Colorectal Cancer,Futuximab/Modotuximab Mixture+Panitumumab
512,S492R,D,Resistance,Colorectal Cancer,Cetuximab
513,R451C,D,Sensitivity/Response,Colorectal Cancer,Panitumumab+Cetuximab+Futuximab/Modotuximab Mixture
514,K467T,D,Sensitivity/Response,Colorectal Cancer,Panitumumab+Futuximab/Modotuximab Mixture
515,K467T,D,Resistance,Colorectal Cancer,Cetuximab
516,P753S,C,Sensitivity/Response,Skin Squamous Cell Carcinoma,Sirolimus+Cetuximab
517,PML-RARA,A,Sensitivity/Response,Acute Promyelocytic Leukemia,Arsenic Trioxide+Tretinoin
518,B2 DOMAIN MUTATION,B,Resistance,Acute Promyelocytic Leukemia,Tretinoin
519,PML-RARA A216V,C,Resistance,Acute Promyelocytic Leukemia,Tretinoin
520,PML-RARA L218P,C,Resistance,Acute Promyelocytic Leukemia,Tretinoin
521,EXON 14 MUTATION and AMPLIFICATION,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Crizotinib
522,Amplification,C,Sensitivity/Response,Endometrial Serous Adenocarcinoma,Trastuzumab
523,D473H,D,Sensitivity/Response,Medulloblastoma,Patidegib
524,CD74-ROS1 G2032R,C,Resistance,Lung Adenocarcinoma,Crizotinib
525,CD74-ROS1 G2032R,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Cabozantinib
526,N-TERMINAL FRAME SHIFT,D,Sensitivity/Response,Acute Myeloid Leukemia,OICR-9429
527,ZNF198-FGFR1,C,Sensitivity/Response,Myeloproliferative Neoplasm,Midostaurin
528,Amplification,D,Resistance,Breast Cancer,Afimoxifene
529,A1065T,D,Sensitivity/Response,Angiosarcoma,Sunitinib+Sorafenib
530,D717V,D,Sensitivity/Response,Angiosarcoma,Sorafenib+Sunitinib
531,Q1178*,C,Sensitivity/Response,Thyroid Gland Carcinoma,Everolimus
532,F2108L,C,Resistance,Thyroid Gland Carcinoma,Everolimus
533,ITD,B,Resistance,Acute Promyelocytic Leukemia,Anthracycline Antineoplastic Antibiotic+Tretinoin
534,Amplification,A,Sensitivity/Response,Her2-receptor Positive Breast Cancer,Neratinib+Trastuzumab
535,Underexpression,D,Sensitivity/Response,Head And Neck Squamous Cell Carcinoma,Tretinoin
536,UNDEREXPRESSION,D,Sensitivity/Response,Pancreatic Ductal Adenocarcinoma,Gemcitabine
537,EML4-ALK,C,Resistance,Lung Acinar Adenocarcinoma,Erlotinib
538,Amplification,A,Sensitivity/Response,Her2-receptor Positive Breast Cancer,Trastuzumab
539,Y772_A775DUP,C,Sensitivity/Response,Lung Adenocarcinoma,Trastuzumab Emtansine
540,VIII,B,Sensitivity/Response,Glioblastoma,Erlotinib+Gefitinib
541,Expression,B,Sensitivity/Response,Glioblastoma,Erlotinib+Gefitinib
542,Q22*,C,Resistance,Colon Mucinous Adenocarcinoma,Panitumumab
543,Amplification,B,Sensitivity/Response,Her2-receptor Positive Breast Cancer,Capecitabine+Lapatinib
544,Amplification,B,Sensitivity/Response,Her2-receptor Positive Breast Cancer,Trastuzumab+Capecitabine
545,P904L,E,Sensitivity/Response,Myelodysplastic Syndrome,Decitabine+5-Fluoro-2-Deoxycytidine+Guadecitabine+Azacitidine
546,OVEREXPRESSION,D,Resistance,Uveal Melanoma,Selumetinib+Trametinib+Mirdametinib
547,RS3733542,B,Sensitivity/Response,Acute Myeloid Leukemia,Selumetinib
548,ITD,B,Resistance,Acute Myeloid Leukemia,Selumetinib
549,OVEREXPRESSION,D,Sensitivity/Response,Melanoma,AZ909+Selumetinib
550,Mutation,B,Resistance,Colorectal Cancer,Bevacizumab+Chemotherapy
551,Mutation,D,Sensitivity/Response,Cancer,G-573+MEK Inhibitor GDC-0623
552,V600E,D,Sensitivity/Response,Cancer,Cobimetinib
553,G12C,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Selumetinib+Docetaxel
554,G12V,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Docetaxel+Selumetinib
555,LOSS,D,Resistance,Lung Non-small Cell Carcinoma,Selumetinib+Docetaxel
556,Mutation,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Selumetinib+Docetaxel
557,Mutation,D,Resistance,Lung Non-small Cell Carcinoma,Docetaxel
558,Wildtype,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Adjuvant Chemotherapy
559,OVEREXPRESSION,C,Resistance,Lung Non-small Cell Carcinoma,PD1 Inhibitor
560,OVEREXPRESSION,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Anti-TIM-3 Monoclonal Antibody+PD1 Inhibitor
561,Overexpression,D,Sensitivity/Response,Cancer,Selumetinib+Afatinib
562,Overexpression,D,Resistance,Cancer,"HER2 Inhibitor CP-724,714+Selumetinib+Gefitinib"
563,p16 Expression,B,Resistance,Head And Neck Squamous Cell Carcinoma,Afatinib
564,SERUM LEVELS,B,Sensitivity/Response,Inflammatory Breast Carcinoma,Bevacizumab
565,SERUM LEVELS,B,Resistance,Inflammatory Breast Carcinoma,Bevacizumab
566,SERUM LEVELS,B,Sensitivity/Response,Brain Glioma,Bevacizumab
567,Amplification,B,Sensitivity/Response,Her2-receptor Positive Breast Cancer,Trastuzumab Emtansine
568,Amplification,B,Sensitivity/Response,Her2-receptor Positive Breast Cancer,Trastuzumab Emtansine
569,NUCLEAR EXPRESSION,D,Sensitivity/Response,Gastric Adenocarcinoma,Cisplatin+Fluorouracil
570,T17 DELETION,B,Sensitivity/Response,Colorectal Cancer,Oxaliplatin+Fluorouracil
571,Expression,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Nivolumab+Pembrolizumab+Avelumab+Atezolizumab
572,Deleterious Mutation,B,Sensitivity/Response,Sarcoma,Pazopanib
573,E545K,D,Resistance,Lung Adenocarcinoma,Gefitinib
574,Expression,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Atezolizumab
575,G12C,D,Sensitivity/Response,Cancer,ARS-853+Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
576,V842I,D,Sensitivity/Response,Colon Cancer,Trastuzumab+Lapatinib+Neratinib
577,Fusion,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Ceritinib
578,L755S,D,Sensitivity/Response,Colon Cancer,Lapatinib+Neratinib+Trastuzumab
579,V777L,D,Sensitivity/Response,Colon Cancer,Trastuzumab+Lapatinib+Neratinib
580,L866M,D,Sensitivity/Response,Colon Cancer,Trastuzumab+Neratinib+Lapatinib
581,S310F/Y,D,Sensitivity/Response,Colon Cancer,Neratinib+Trastuzumab+Lapatinib
582,G13D,B,Resistance,Colorectal Cancer,Cetuximab
583,G13D,B,Resistance,Colorectal Cancer,Cetuximab
584,Mutation,D,Resistance,Colorectal Cancer,Ixazomib
585,Mutation,D,Sensitivity/Response,Cancer,AZD5438
586,EXON 14 SKIPPING MUTATION,C,Sensitivity/Response,Lung Adenocarcinoma,Crizotinib
587,EXON 14 SKIPPING MUTATION,C,Sensitivity/Response,Lung Adenocarcinoma,Capmatinib
588,Fusion,A,Sensitivity/Response,Lung Non-small Cell Carcinoma,Crizotinib
589,EML4-ALK,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,WHI-P154
590,EML4::ALK e20-e20,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Crizotinib
591,EML4::ALK e2-e20,E,Sensitivity/Response,Lung Non-small Cell Carcinoma,Crizotinib
592,R961W,C,Sensitivity/Response,Colorectal Adenocarcinoma,Regorafenib
593,EML4::ALK e6-e20,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,"2,4-pyrimidinediamine"
594,EML4::ALK e6-e20,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Crizotinib
595,EML4::ALK e6-e20,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,TAE684
596,EML4::ALK e20-e20,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Crizotinib
597,Fusion,A,Sensitivity/Response,Lung Non-small Cell Carcinoma,Crizotinib
598,Fusion,A,Sensitivity/Response,Lung Non-small Cell Carcinoma,Crizotinib
599,Fusion,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Crizotinib
600,Fusion,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Crizotinib
601,Fusion,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Retaspimycin Hydrochloride
602,EML4-ALK,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Crizotinib+Retaspimycin Hydrochloride
603,EML4::ALK e20-e20,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Alvespimycin+Crizotinib
604,EML4-ALK,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Alvespimycin+Crizotinib
605,EML4-ALK,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Crizotinib
606,Exon 2 Mutation,B,Resistance,Colorectal Cancer,Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
607,P47S,E,Resistance,Cancer,Cisplatin
608,MUTATION,D,Sensitivity/Response,Uveal Melanoma,JQ1
609,MUTATION,D,Sensitivity/Response,Uveal Melanoma,JQ1
610,K706FS*19,C,Sensitivity/Response,Glioblastoma,Nivolumab
611,G12C,B,Resistance,Colorectal Cancer,Gefitinib+Erlotinib
612,Exon 2 Mutation,B,Resistance,Pancreatic Cancer,Gemcitabine+Erlotinib
613,Mutation,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Trametinib
614,Exon 9 Mutation,B,Sensitivity/Response,Gastrointestinal Stromal Tumor,Imatinib
615,MUTATION,B,Sensitivity/Response,Melanoma,Imatinib
616,Exon 9 Mutation,B,Sensitivity/Response,Gastrointestinal Stromal Tumor,Sunitinib
617,Exon 11 Mutation,C,Sensitivity/Response,Melanoma,Sunitinib
618,Mutation,B,Sensitivity/Response,Skin Melanoma,Trametinib+Docetaxel
619,Q61,B,Sensitivity/Response,Skin Melanoma,Binimetinib
620,MUTATION,C,Sensitivity/Response,Uveal Melanoma,Trametinib
621,MUTATION,B,Sensitivity/Response,Uveal Melanoma,Trametinib
622,Mutation,D,Sensitivity/Response,Cancer,Metformin+Trametinib
623,Deletion,B,Sensitivity/Response,Prostate Cancer,Everolimus
624,Q209,C,Sensitivity/Response,Uveal Melanoma,Refametinib
625,Mutation,D,Sensitivity/Response,Uveal Melanoma,Trichostatin A+Vorinostat+Valproic Acid+Panobinostat
626,Mutation,E,Sensitivity/Response,Malignant Mesothelioma,MC1568+Mocetinostat+Vorinostat
627,Mutation,D,Sensitivity/Response,Endometrial Cancer,Ponatinib
628,Mutation,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Ceritinib
629,NPM-ALK,D,Sensitivity/Response,Anaplastic Large Cell Lymphoma,Crizotinib
630,Fusion,C,Sensitivity/Response,Anaplastic Large Cell Lymphoma,Crizotinib
631,NPM-ALK,B,Sensitivity/Response,Anaplastic Large Cell Lymphoma,Crizotinib
632,Fusion,C,Sensitivity/Response,Anaplastic Large Cell Lymphoma,Crizotinib
633,Fusion,B,Sensitivity/Response,Inflammatory Myofibroblastic Tumor,Crizotinib
634,RANBP2-ALK,C,Sensitivity/Response,Inflammatory Myofibroblastic Tumor,Crizotinib
635,EML4::ALK e20-e20,C,Sensitivity/Response,Cancer,Crizotinib
636,N546K,E,Sensitivity/Response,Ewing Sarcoma Of Bone,Ponatinib
637,Amplification,D,Sensitivity/Response,Ewing Sarcoma Of Bone,Ponatinib
638,REARRANGEMENT,C,Sensitivity/Response,Lung Adenocarcinoma,Ceritinib
639,CD74-ROS1 G2032R,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Foretinib+Cabozantinib
640,CD74-ROS1 G2032R,D,Resistance,Lung Non-small Cell Carcinoma,Ceritinib+Crizotinib+AZD3463+Brigatinib
641,CD74-ROS1 G2032R,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Lorlatinib
642,CD74-ROS1 L2026M,D,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
643,CD74-ROS1 L2026M,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Lorlatinib
644,CD74-ROS1 G2032R,C,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
645,CD74-ROS1 G2032R,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Foretinib
646,CD74-ROS1 L2155S,D,Resistance,Lung Non-small Cell Carcinoma,Foretinib+Crizotinib+TAE684
647,CD74-ROS1 L2026M,D,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
648,CD74-ROS1 L2026M,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Foretinib
649,CD74-ROS1 G2101A,D,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
650,CD74-ROS1 G2101A,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Foretinib
651,CLTC-ALK,D,Sensitivity/Response,Diffuse Large B-cell Lymphoma,TAE684
652,Fusion,C,Sensitivity/Response,Diffuse Large B-cell Lymphoma,Crizotinib
653,CLTC-ALK,C,Sensitivity/Response,Diffuse Large B-cell Lymphoma,Crizotinib
654,EML4::ALK e2-e20,E,Sensitivity/Response,Renal Cell Carcinoma,
655,DEL 485-490,D,Sensitivity/Response,Cancer,Pan-RAF Inhibitor LY3009120
656,NPM-ALK,D,Sensitivity/Response,Cancer,Crizotinib
657,R1275Q,C,Sensitivity/Response,Neuroblastoma,Crizotinib
658,R1275Q,C,Sensitivity/Response,Neuroblastoma,Crizotinib
659,Fusion,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Alectinib
660,Fusion,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Alectinib
661,Fusion,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Alectinib
662,DELETION POLYMORPHISM,B,Resistance,Chronic Myeloid Leukemia,Imatinib
663,DELETION POLYMORPHISM,B,Resistance,Lung Non-small Cell Carcinoma,Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
664,Fusion,A,Sensitivity/Response,Lung Non-small Cell Carcinoma,Alectinib
665,ALK Fusion I1171,C,Resistance,Lung Non-small Cell Carcinoma,Alectinib
666,ALK Fusion I1171,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Ceritinib
667,ALK Fusion I1171,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,TAE684
668,EML4-ALK  V1180L,D,Resistance,Lung Non-small Cell Carcinoma,Alectinib
669,ALK Fusion I1171,D,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
670,EML4-ALK  V1180L,D,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
671,EML4-ALK  V1180L,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Ceritinib
672,EML4-ALK  V1180L,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,TAE684
673,EML4-ALK  V1180L,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Brigatinib
674,OVEREXPRESSION,D,Resistance,Pancreatic Cancer,Niacinamide
675,TKD MUTATION,B,Sensitivity/Response,Acute Myeloid Leukemia,Midostaurin
676,Mutation,B,Sensitivity/Response,Her2-receptor Positive Breast Cancer,Everolimus
677,Loss,B,Sensitivity/Response,Her2-receptor Positive Breast Cancer,Everolimus
678,REARRANGEMENT,E,Sensitivity/Response,Colorectal Adenocarcinoma,Crizotinib
679,Biallelic Inactivation,C,Sensitivity/Response,Pancreatic Cancer,Mitomycin
680,LOSS-OF-FUNCTION,D,Sensitivity/Response,Pancreatic Cancer,Melphalan+Gemcitabine+Mitomycin+Cisplatin+Chlorambucil
681,Loss-of-function,D,Sensitivity/Response,Pancreatic Cancer,Mitomycin
682,I843DEL,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Imatinib
683,EBF1-PDGFRB,C,Sensitivity/Response,Childhood B-cell Acute Lymphoblastic Leukemia,Imatinib
684,SNP,B,Resistance,Prostate Cancer,Abiraterone Acetate
685,METHYLATION,B,Resistance,Stomach Carcinoma,Oxaliplatin
686,T227M,B,Adverse Response,Renal Cell Carcinoma,Sunitinib
687,S2215Y,D,Sensitivity/Response,Endometrial Adenocarcinoma,Sirolimus
688,C1483Y,D,Sensitivity/Response,T-cell Acute Lymphoblastic Leukemia,Sirolimus
689,E1799K,D,Sensitivity/Response,Clear Cell Renal Cell Carcinoma,Sirolimus
690,N550K,D,Sensitivity/Response,Endometrial Cancer,PD173074
691,Fusion,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Brigatinib
692,OVEREXPRESSION,D,Resistance,Pancreatic Adenocarcinoma,Doxorubicin+Gemcitabine+Fluorouracil+Mitomycin
693,RS557806,B,Sensitivity/Response,Colorectal Cancer,FOLFIRI Regimen+Bevacizumab
694,Exon 2 Mutation,B,Sensitivity/Response,Colorectal Cancer,Irinotecan+Selumetinib
695,F1174L,D,Sensitivity/Response,Neuroblastoma,AZD3463
696,F1174L,D,Sensitivity/Response,Neuroblastoma,Lorlatinib
697,F1245C,D,Sensitivity/Response,Neuroblastoma,Lorlatinib
698,R1275Q,D,Sensitivity/Response,Neuroblastoma,Lorlatinib
699,EML4-ALK,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Lorlatinib
700,F1245C,C,Resistance,Neuroblastoma,Crizotinib
701,Fusion,E,Sensitivity/Response,Colorectal Adenocarcinoma,Crizotinib
702,Fusion,E,Sensitivity/Response,Breast Cancer,Crizotinib
703,Exon 4-11 Deletion,D,Sensitivity/Response,Neuroblastoma,Brigatinib
704,ALK Fusion F1245C,D,Resistance,Cancer,Crizotinib
705,ALK Fusion F1245C,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Ceritinib
706,ALK Fusion F1245C,C,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
707,EML4::ALK e6-e20,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Ceritinib
708,EML4-ALK L1196M,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Ceritinib
709,ALK Fusion G1269A,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Ceritinib
710,EML4-ALK S1206Y,D,Sensitivity/Response,Cancer,Ceritinib
711,ALK Fusion I1171,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Ceritinib
712,ALK Fusion G1202R,D,Resistance,Lung Non-small Cell Carcinoma,Ceritinib
713,EML4-ALK C1156Y,D,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
714,EML4-ALK T1151INST,D,Resistance,Lung Non-small Cell Carcinoma,Alectinib
715,EML4-ALK T1151INST,D,Resistance,Lung Non-small Cell Carcinoma,TAE684
716,EML4-ALK T1151INST,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Tanespimycin
717,ALK Fusion G1202R,D,Resistance,Cancer,Alectinib
718,ALK Fusion G1202R,D,Resistance,Cancer,Brigatinib
719,ALK Fusion G1202R,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Tanespimycin
720,ALK Fusion G1269A,D,Sensitivity/Response,Cancer,Brigatinib
721,ALK Fusion G1269A,D,Resistance,Cancer,Alectinib
722,ALK Fusion G1269A,D,Sensitivity/Response,Cancer,Ceritinib
723,NPM-ALK,D,Sensitivity/Response,Cancer,Crizotinib
724,ALK Fusion G1202R,C,Resistance,Lung Adenocarcinoma,Crizotinib
725,Mutation,D,Sensitivity/Response,Head And Neck Cancer,Dactolisib
726,H1047R,D,Sensitivity/Response,Head And Neck Cancer,Dactolisib
727,H1047R,D,Sensitivity/Response,Head And Neck Cancer,Dactolisib
728,H1047R,D,Sensitivity/Response,Head And Neck Cancer,Dactolisib+Cetuximab
729,M918T,B,Sensitivity/Response,Thyroid Gland Medullary Carcinoma,Sorafenib
730,AMPLIFICATION,B,Sensitivity/Response,Liposarcoma,Palbociclib
731,ALK Fusion I1171,C,Resistance,Lung Non-small Cell Carcinoma,Alectinib
732,ALK Fusion I1171,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Ceritinib
733,Mutation,A,Sensitivity/Response,Cancer,Olaparib
734,Mutation,A,Sensitivity/Response,Cancer,Olaparib
735,Loss,D,Sensitivity/Response,Skin Melanoma,Alvocidib
736,Loss,D,Sensitivity/Response,Renal Cell Carcinoma,Palbociclib
737,LOSS,D,Sensitivity/Response,Renal Cell Carcinoma,Palbociclib
738,Loss,D,Sensitivity/Response,Skin Melanoma,Palbociclib
739,R24C,D,Sensitivity/Response,Skin Melanoma,Palbociclib
740,Loss,D,Sensitivity/Response,Ovarian Cancer,Palbociclib
741,Amplification,D,Sensitivity/Response,Her2-receptor Positive Breast Cancer,Pictilisib
742,Amplification,D,Sensitivity/Response,Her2-receptor Positive Breast Cancer,A66
743,Loss,D,Resistance,Her2-receptor Positive Breast Cancer,Trastuzumab
744,Mutation,B,Resistance,Her2-receptor Positive Breast Cancer,Trastuzumab
745,Loss,B,Resistance,Her2-receptor Positive Breast Cancer,Trastuzumab
746,BCR-ABL T315I,B,Sensitivity/Response,Chronic Myeloid Leukemia,Ponatinib
747,T790M,B,Resistance,Lung Adenocarcinoma,Gefitinib+Erlotinib
748,Amplification,C,Resistance,Lung Adenocarcinoma,Gefitinib+Erlotinib
749,Amplification,C,Resistance,Lung Adenocarcinoma,Erlotinib+Gefitinib
750,S768I,C,Sensitivity/Response,Lung Adenocarcinoma,Erlotinib
751,S768I,C,Sensitivity/Response,Lung Adenocarcinoma,Gefitinib
752,C797S,C,Resistance,Lung Adenocarcinoma,Osimertinib
753,T790M,C,Sensitivity/Response,Lung Adenocarcinoma,Osimertinib
754,V600E,B,Sensitivity/Response,Melanoma,Vemurafenib
755,V600K,B,Sensitivity/Response,Melanoma,Vemurafenib
756,V600K,C,Sensitivity/Response,Melanoma,Vemurafenib
757,H1047R,D,Sensitivity/Response,Head And Neck Cancer,Alpelisib
758,Mutation,D,Sensitivity/Response,Cancer,Alpelisib
759,Amplification,D,Sensitivity/Response,Stomach Carcinoma,Alpelisib
760,V600,B,Sensitivity/Response,Melanoma,Dabrafenib
761,V600E,D,Sensitivity/Response,Colorectal Cancer,Vemurafenib+Cetuximab+Gefitinib
762,V600E,A,Sensitivity/Response,Skin Melanoma,Vemurafenib
763,V600E,B,Sensitivity/Response,Skin Melanoma,Vemurafenib
764,V600,A,Sensitivity/Response,Skin Melanoma,Trametinib+Dabrafenib
765,V600E,C,Sensitivity/Response,Thyroid Gland Papillary Carcinoma,Vemurafenib
766,V600,B,Sensitivity/Response,Colorectal Cancer,Trametinib+Dabrafenib
767,TRIM24-BRAF,D,Resistance,Skin Melanoma,Vemurafenib
768,K700E,D,Sensitivity/Response,Breast Cancer,Spliceostatin A
769,K666N,D,Sensitivity/Response,Breast Cancer,Spliceostatin A
770,Fusion,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Crizotinib
771,V600E,B,Sensitivity/Response,Melanoma,Cobimetinib+Vemurafenib
772,V600,B,Sensitivity/Response,Melanoma,Vemurafenib+Cobimetinib
773,M541L,C,Sensitivity/Response,Chronic Leukemia,Imatinib
774,Exon 9 Mutation,B,Sensitivity/Response,Gastrointestinal Stromal Tumor,Sunitinib
775,V600E,D,Sensitivity/Response,Colorectal Cancer,Dactolisib+GDC-0879
776,Mutation,D,Sensitivity/Response,Melanoma,Omipalisib+Trametinib
777,V600E,C,Sensitivity/Response,Gastrointestinal Neuroendocrine Tumor,Dabrafenib+Vemurafenib+Trametinib
778,Amplification,B,Sensitivity/Response,Her2-receptor Positive Breast Cancer,Trastuzumab Emtansine
779,Amplification,B,Sensitivity/Response,Her2-receptor Positive Breast Cancer,Docetaxel+Pertuzumab+Trastuzumab
780,E2014K and E2419K,C,Sensitivity/Response,Transitional Cell Carcinoma,Everolimus+Pazopanib
781,Amplification,B,Sensitivity/Response,Her2-receptor Positive Breast Cancer,Lapatinib+Trastuzumab
782,AMPLIFICATION,C,Sensitivity/Response,Lung Adenocarcinoma,Sapanisertib+Onatasertib
783,FIP1L1-PDGFRA,B,Sensitivity/Response,"Myeloid And Lymphoid Neoplasms With Eosinophilia And Abnormalities Of PDGFRA, PDGFRB, And FGFR1",Imatinib
784,REARRANGEMENT,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Crizotinib
785,REARRANGEMENT,C,Sensitivity/Response,Bronchiolo-alveolar Adenocarcinoma,Crizotinib
786,TFG-ROS1,C,Sensitivity/Response,Inflammatory Myofibroblastic Tumor,Crizotinib
787,FIP1L1-PDGFRA,A,Sensitivity/Response,"Myeloid And Lymphoid Neoplasms With Eosinophilia And Abnormalities Of PDGFRA, PDGFRB, And FGFR1",Imatinib
788,FIP1L1-PDGFRA T674I,C,Resistance,"Myeloid And Lymphoid Neoplasms With Eosinophilia And Abnormalities Of PDGFRA, PDGFRB, And FGFR1",Imatinib
789,H1047R,D,Sensitivity/Response,Lung Adenocarcinoma,Dactolisib
790,Amplification,D,Sensitivity/Response,Her2-receptor Positive Breast Cancer,Pilaralisib+Trastuzumab
791,OVEREXPRESSION,B,Resistance,Her2-receptor Positive Breast Cancer,Trastuzumab
792,E545K,D,Resistance,Her2-receptor Positive Breast Cancer,Trastuzumab
793,D594A,E,Sensitivity/Response,Skin Melanoma,Sorafenib+Mitogen-Activated Protein Kinase Kinase Inhibitor
794,Loss,D,Sensitivity/Response,Her2-receptor Positive Breast Cancer,Trastuzumab+PI3K/BET Inhibitor LY294002
795,D594V,E,Sensitivity/Response,Skin Melanoma,Sorafenib+Trametinib
796,K483M,E,Sensitivity/Response,Skin Melanoma,Mitogen-Activated Protein Kinase Kinase Inhibitor+Sorafenib
797,L597R,D,Sensitivity/Response,Skin Melanoma,Vemurafenib+Trametinib
798,L597S,D,Sensitivity/Response,Skin Melanoma,Vemurafenib+Trametinib
799,L597S,C,Sensitivity/Response,Skin Melanoma,MEK Inhibitor TAK-733
800,L597Q,D,Sensitivity/Response,Skin Melanoma,Trametinib+Vemurafenib
801,K601E,D,Sensitivity/Response,Skin Melanoma,Vemurafenib+Trametinib
802,L597V,C,Sensitivity/Response,Skin Melanoma,Trametinib
803,Amplification,D,Sensitivity/Response,Head And Neck Squamous Cell Carcinoma,Taselisib
804,H1047R,D,Sensitivity/Response,Head And Neck Squamous Cell Carcinoma,Taselisib
805,Amplification,B,Resistance,Mucosal Melanoma,Imatinib
806,Mutation,D,Resistance,Head And Neck Squamous Cell Carcinoma,Taselisib
807,Mutation,D,Resistance,Skin Melanoma,Vemurafenib
808,Mutation,D,Sensitivity/Response,Skin Melanoma,Sirolimus+Mirdametinib
809,Mutation,C,Resistance,Skin Melanoma,Vemurafenib
810,Mutation,D,Sensitivity/Response,Skin Melanoma,AZ628+VTX-11e
811,Mutation,B,Sensitivity/Response,Skin Melanoma,Binimetinib
812,Q61,C,Sensitivity/Response,Skin Melanoma,Selumetinib
813,Q61K,D,Resistance,Skin Melanoma,Vemurafenib
814,Q61K,D,Sensitivity/Response,Skin Melanoma,Selumetinib
815,Mutation,D,Sensitivity/Response,Skin Melanoma,Amuvatinib
816,Mutation,B,Resistance,Basal Cell Carcinoma,Vismodegib+Sonidegib
817,Mutation,B,Sensitivity/Response,Chronic Lymphocytic Leukemia,Alemtuzumab
818,EXON 9 FRAMESHIFT,B,Sensitivity/Response,Myeloproliferative Neoplasm,Peginterferon Alfa-2a
819,HIP1-ALK I1171N,C,Resistance,Lung Non-small Cell Carcinoma,Crizotinib+Alectinib
820,EML4-ALK I1171S,C,Resistance,Lung Non-small Cell Carcinoma,Alectinib+Crizotinib
821,Mutation,D,Sensitivity/Response,Head And Neck Squamous Cell Carcinoma,Radiation Therapy+Taselisib
822,Mutation,D,Sensitivity/Response,Cancer,Ipatasertib
823,Loss,D,Resistance,Ovarian Cancer,Cisplatin
824,Loss,B,Resistance,Stomach Carcinoma,Chemotherapy
825,Y646,D,Sensitivity/Response,Skin Melanoma,GSK126
826,Amplification,B,Sensitivity/Response,Skin Melanoma,Carboplatin+Paclitaxel+Sorafenib
827,AMPLIFICATION,B,Sensitivity/Response,Skin Melanoma,Carboplatin+Paclitaxel+Sorafenib
828,Amplification,B,Sensitivity/Response,Skin Melanoma,Carboplatin+Docetaxel+Sorafenib
829,Fusion,A,Sensitivity/Response,Myeloproliferative Neoplasm,Imatinib
830,Amplification,A,Sensitivity/Response,Gastric Adenocarcinoma,Trastuzumab
831,Loss,D,Sensitivity/Response,Stomach Cancer,Docetaxel+Capivasertib
832,Mutation,D,Sensitivity/Response,Stomach Cancer,Capivasertib
833,Loss,D,Sensitivity/Response,Cancer,Capivasertib
834,Mutation,D,Sensitivity/Response,Cancer,Capivasertib
835,Mutation,D,Sensitivity/Response,Her2-receptor Positive Breast Cancer,Capivasertib
836,H1047R,D,Sensitivity/Response,Her2-receptor Positive Breast Cancer,Trastuzumab+Capivasertib
837,H1047R,D,Sensitivity/Response,Her2-receptor Positive Breast Cancer,Capivasertib+Lapatinib
838,Mutation,D,Sensitivity/Response,Melanoma,Binimetinib
839,Expression,B,Sensitivity/Response,Cancer,Nivolumab
840,Overexpression,C,Sensitivity/Response,Papillary Adenocarcinoma,Sunitinib
841,PML-RARA,C,Sensitivity/Response,Acute Promyelocytic Leukemia,Tretinoin
842,CTLA4-CD28,C,Sensitivity/Response,Sezary's Disease,Ipilimumab
843,MUTATION,B,Resistance,Prostate Cancer,Flutamide+Cyproterone Acetate+Bicalutamide+Nilutamide
844,Mutation,D,Sensitivity/Response,Prostate Cancer,Alpelisib+Enzalutamide+PI3Kbeta Inhibitor AZD8186
845,LOSS-OF-FUNCTION,D,Sensitivity/Response,Head And Neck Squamous Cell Carcinoma,Porcupine Inhibitor WNT974
846,OVEREXPRESSION,B,Resistance,Estrogen-receptor Positive Breast Cancer,Fulvestrant
847,OVEREXPRESSION,D,Sensitivity/Response,Estrogen-receptor Positive Breast Cancer,Palbociclib+Fulvestrant
848,Overexpression,C,Sensitivity/Response,B-cell Adult Acute Lymphocytic Leukemia,Sunitinib
849,Mutation,B,Sensitivity/Response,Ovarian Carcinoma,Platinum Compound
850,Mutation,B,Sensitivity/Response,Ovarian Carcinoma,Platinum Compound
851,Mutation,B,Sensitivity/Response,Ovarian Carcinoma,Platinum Compound
852,Mutation,B,Sensitivity/Response,Ovarian Carcinoma,Platinum Compound
853,Q209P,C,Resistance,Skin Melanoma,Vemurafenib
854,V317FS,D,Sensitivity/Response,Skin Melanoma,Akt Inhibitor MK2206+MEK Inhibitor CI-1040
855,LOSS-OF-FUNCTION,D,Resistance,Breast Cancer,Palbociclib
856,Q209P,D,Resistance,Skin Melanoma,PLX4720
857,Overexpression,B,Sensitivity/Response,Breast Cancer,Letrozole+Palbociclib
858,F2108L,D,Resistance,Breast Cancer,Sirolimus
859,M2327I,D,Resistance,Breast Cancer,MTOR Kinase Inhibitor AZD8055
860,M2327I,D,Resistance,Breast Cancer,Sirolimus
861,A2034V,D,Resistance,Breast Cancer,Sirolimus
862,E542K,C,Sensitivity/Response,Head And Neck Squamous Cell Carcinoma,Apitolisib
863,E545K,C,Sensitivity/Response,Cancer,Apitolisib
864,ITD,C,Sensitivity/Response,Acute Myeloid Leukemia,Sorafenib
865,D835H,C,Resistance,Acute Myeloid Leukemia,Sorafenib
866,D835H/Y,D,Resistance,Acute Myeloid Leukemia,Sorafenib
867,Loss,D,Sensitivity/Response,Glioblastoma,Palbociclib
868,Amplification,D,Sensitivity/Response,Her2-receptor Positive Breast Cancer,Palbociclib+Trastuzumab
869,Amplification,D,Sensitivity/Response,Breast Cancer,Palbociclib
870,Overexpression,D,Sensitivity/Response,Mantle Cell Lymphoma,Palbociclib
871,Amplification,C,Sensitivity/Response,Glioblastoma,Crizotinib
872,Amplification,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Crizotinib
873,Q503*,C,Resistance,Skin Melanoma,Pembrolizumab
874,c.1641+1dup,C,Resistance,Skin Melanoma,Pembrolizumab
875,S14FS,C,Resistance,Skin Melanoma,Pembrolizumab
876,PPFIBP2-BRAF,C,Sensitivity/Response,Skin Melanoma,Trametinib
877,KIAA1549-BRAF,C,Sensitivity/Response,Skin Melanoma,Trametinib
878,Expression,B,Sensitivity/Response,Colorectal Cancer,Cetuximab
879,OVEREXPRESSION,B,Sensitivity/Response,Colorectal Cancer,Aspirin
880,V600,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Vemurafenib
881,V600,B,Sensitivity/Response,Langerhans-cell Histiocytosis,Vemurafenib
882,V600,B,Resistance,Colorectal Cancer,Vemurafenib
883,Fusion,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Crizotinib
884,V600E,B,Sensitivity/Response,Hairy Cell Leukemia,Vemurafenib
885,G12D,C,Resistance,Hairy Cell Leukemia,Vemurafenib
886,Overexpression,B,Resistance,Skin Melanoma,Vemurafenib
887,Overexpression,E,Sensitivity/Response,Uveal Melanoma,Crizotinib
888,Overexpression,D,Sensitivity/Response,Uveal Melanoma,Crizotinib
889,Mutation,B,Sensitivity/Response,Acute Myeloid Leukemia,Decitabine
890,Amplification,C,Sensitivity/Response,Colorectal Cancer,Crizotinib+Vemurafenib
891,V600E,C,Sensitivity/Response,Colorectal Cancer,Panitumumab+Vemurafenib
892,V600E,B,Sensitivity/Response,Thyroid Gland Papillary Carcinoma,Vemurafenib
893,T790M,A,Sensitivity/Response,Lung Non-small Cell Carcinoma,Osimertinib
894,LOSS-OF-FUNCTION,D,Resistance,Glioblastoma,Palbociclib
895,EXPRESSION,D,Sensitivity/Response,Sarcoma,Vorinostat
896,Mutation,D,Sensitivity/Response,Breast Cancer,Ribociclib+Phosphatidylinositide 3-Kinase Inhibitor
897,CCDC6-RET,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Nintedanib
898,C121S,C,Resistance,Melanoma,Vemurafenib
899,S249C,C,Sensitivity/Response,Transitional Cell Carcinoma,Pazopanib
900,Amplification,B,Sensitivity/Response,Breast Cancer,Dovitinib
901,Amplification,B,Sensitivity/Response,Breast Cancer,Dovitinib
902,AMPLIFICATION,B,Sensitivity/Response,Breast Cancer,Dovitinib
903,Mutation,D,Sensitivity/Response,Breast Cancer,Phosphatidylinositide 3-Kinase Inhibitor+Palbociclib
904,R200W (c.598C>T),C,Sensitivity/Response,Chuvash Polycythemia,Ruxolitinib
905,PHOSPHORYLATION,B,Resistance,Breast Cancer,Alpelisib
906,Mutation,D,Sensitivity/Response,Breast Cancer,Everolimus+MTOR Kinase Inhibitor PP242
907,MUTATION,D,Sensitivity/Response,Breast Cancer,MTOR Kinase Inhibitor PP242
908,Amplification,D,Sensitivity/Response,Breast Cancer,MTOR Kinase Inhibitor PP242
909,Loss,D,Sensitivity/Response,Endometrial Cancer,Temsirolimus
910,Mutation,D,Sensitivity/Response,Endometrial Cancer,Pictilisib
911,D194E,C,Sensitivity/Response,Pancreatic Cancer,Everolimus
912,LOSS,D,Sensitivity/Response,Peutz-Jeghers Syndrome,Sirolimus
913,LOSS,D,Sensitivity/Response,Peutz-Jeghers Syndrome,Sirolimus
914,Amplification,C,Sensitivity/Response,Lung Adenocarcinoma,Vandetanib+Everolimus
915,KIF5B-RET,C,Sensitivity/Response,Lung Adenocarcinoma,Vandetanib+Everolimus
916,H1047R,C,Sensitivity/Response,Her2-receptor Positive Breast Cancer,Fulvestrant+Everolimus
917,Expression,C,Resistance,Her2-receptor Positive Breast Cancer,Fulvestrant+Everolimus
918,H1047R,D,Sensitivity/Response,Thyroid Gland Cancer,Perifosine+Temsirolimus
919,E542K,D,Sensitivity/Response,Thyroid Gland Cancer,Perifosine+Temsirolimus
920,R130*,D,Sensitivity/Response,Thyroid Gland Cancer,Temsirolimus+Perifosine
921,LOSS-OF-FUNCTION,E,Sensitivity/Response,Renal Cell Carcinoma,Everolimus
922,Amplification,D,Resistance,Estrogen-receptor Positive Breast Cancer,Palbociclib
923,M695FS*26,D,Resistance,Estrogen-receptor Positive Breast Cancer,Palbociclib
924,MUTATION,B,Sensitivity/Response,Cancer,MTOR Inhibitor
925,LOSS-OF-FUNCTION,D,Sensitivity/Response,Cancer,Sirolimus
926,OVEREXPRESSION,C,Sensitivity/Response,Colorectal Adenocarcinoma,Irbesartan
927,OVEREXPRESSION,C,Sensitivity/Response,Colon Adenocarcinoma,Irbesartan
928,L265P,D,Sensitivity/Response,Waldenstroem's Macroglobulinemia,IRAK-1/4 Inhibitor+IMG-2005-5
929,Mutation,B,Sensitivity/Response,Hepatocellular Carcinoma,Refametinib+Sorafenib
930,Deletion,B,Resistance,Colorectal Cancer,Fluorouracil
931,Underexpression,B,Sensitivity/Response,Malignant Astrocytoma,PCV Regimen+Temozolomide
932,Overexpression,B,Resistance,Ovarian Serous Carcinoma,Platinum Compound
933,EXON 14 SKIPPING MUTATION,C,Sensitivity/Response,Lung Adenocarcinoma,Crizotinib
934,D1228N,C,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
935,EXPRESSION,B,Sensitivity/Response,Esophagus Squamous Cell Carcinoma,Fluorouracil+Cisplatin+Radiation Therapy
936,EXPRESSION,D,Resistance,Prostate Cancer,Docetaxel
937,UNDEREXPRESSION,D,Resistance,Melanoma,Vemurafenib
938,UNDEREXPRESSION,D,Resistance,Melanoma,Vemurafenib
939,Q56_V60del,C,Sensitivity/Response,Ovarian Serous Carcinoma,Selumetinib
940,BRAF-CUL1,C,Sensitivity/Response,Ovarian Serous Carcinoma,Mitogen-Activated Protein Kinase Kinase Inhibitor
941,ZKSCAN1-BRAF,C,Sensitivity/Response,Melanoma,Trametinib
942,KIAA1549-BRAF,C,Sensitivity/Response,Spindle Cell Sarcoma,Bevacizumab+Temsirolimus+Sorafenib
943,L858R,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
944,Exon 19 Deletion,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
945,T790M,B,Resistance,Lung Non-small Cell Carcinoma,Gefitinib+Erlotinib
946,L505H,D,Resistance,Melanoma,Vemurafenib
947,L505H,B,Resistance,Melanoma,Vemurafenib
948,E545K,C,Resistance,Lung Adenocarcinoma,Gefitinib+Erlotinib
949,Mutation,B,Sensitivity/Response,Ovarian Cancer,Cediranib+Olaparib
950,Mutation,B,Sensitivity/Response,Ovarian Cancer,Cediranib+Olaparib
951,Mutation,B,Sensitivity/Response,Triple-receptor Negative Breast Cancer,Cisplatin+Carboplatin
952,Mutation,B,Sensitivity/Response,Triple-receptor Negative Breast Cancer,Carboplatin+Cisplatin
953,Amplification,B,Resistance,Colorectal Cancer,Cetuximab
954,Amplification,B,Resistance,Colorectal Cancer,Cetuximab
955,Amplification,B,Resistance,Colorectal Cancer,Cetuximab+Panitumumab
956,Amplification,B,Sensitivity/Response,Colorectal Cancer,Trastuzumab+Lapatinib
957,REARRANGEMENT,C,Sensitivity/Response,Lung Adenocarcinoma,Crizotinib
958,Fusion,C,Sensitivity/Response,Lung Adenocarcinoma,Crizotinib
959,Amplification,C,Sensitivity/Response,Lung Adenocarcinoma,Crizotinib
960,Amplification,C,Sensitivity/Response,Scrotum Paget's Disease,Trastuzumab
961,Mutation,C,Sensitivity/Response,Bladder Carcinoma,Platinum Compound
962,V600E,C,Sensitivity/Response,Multiple Myeloma,Vemurafenib
963,V600E,C,Sensitivity/Response,Multiple Myeloma,Vemurafenib
964,Mutation,D,Resistance,Colorectal Cancer,Cetuximab
965,Mutation,D,Resistance,Colorectal Cancer,Cetuximab
966,Mutation,D,Resistance,Colorectal Cancer,Cetuximab
967,Mutation,D,Resistance,Colorectal Cancer,Cetuximab
968,EXPRESSION,D,Sensitivity/Response,Multiple Myeloma,I-BET151+JQ1
969,EXPRESSION,D,Sensitivity/Response,Glioblastoma,MET Tyrosine Kinase Inhibitor SGX523
970,Expression,B,Sensitivity/Response,Colorectal Cancer,Panitumumab
971,Expression,B,Sensitivity/Response,Colorectal Cancer,Cetuximab
972,LOSS,D,Resistance,Melanoma,Vemurafenib
973,EXPRESSION,D,Resistance,Acute Myeloid Leukemia,Quizartinib
974,Amplification,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Crizotinib
975,Amplification,C,Sensitivity/Response,Cancer,Crizotinib
976,E384*,C,Sensitivity/Response,Cholangiocarcinoma,Erlotinib
977,D816V,B,Sensitivity/Response,Systemic Mastocytosis,Midostaurin
978,S463P,D,Resistance,Estrogen-receptor Positive Breast Cancer,Aromatase Inhibitor
979,Mutation,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Afatinib
980,Overexpression,D,Resistance,Breast Cancer,Alpelisib
981,Overexpression,B,Resistance,Breast Cancer,Alpelisib
982,Overexpression,D,Sensitivity/Response,Breast Cancer,SGK1-Inh+Alpelisib
983,Expression,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Pembrolizumab
984,Overexpression,D,Sensitivity/Response,Ovarian Cancer,CDK Inhibitor SNS-032
985,Amplification,D,Sensitivity/Response,Ovarian Serous Cystadenocarcinoma,Akt Inhibitor MK2206+Dinaciclib
986,G719S,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib+Gefitinib
987,G596C,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Dabrafenib+Trametinib
988,UNDEREXPRESSION,D,Sensitivity/Response,Synovial Sarcoma,Tazemetostat
989,DELETION,D,Sensitivity/Response,Rhabdoid Cancer,Tazemetostat
990,Loss,D,Sensitivity/Response,Thyroid Gland Carcinoma,Selumetinib
991,Loss,D,Sensitivity/Response,Malignant Peripheral Nerve Sheath Tumor,JQ1 Compound
992,V104M,B,Sensitivity/Response,Transitional Cell Carcinoma,Afatinib
993,R103G,B,Sensitivity/Response,Transitional Cell Carcinoma,Afatinib
994,G284R,B,Sensitivity/Response,Transitional Cell Carcinoma,Afatinib
995,V600E,B,Sensitivity/Response,Melanoma,Vemurafenib
996,V600,B,Sensitivity/Response,Melanoma,Trametinib
997,A222V,B,Sensitivity/Response,Rectum Cancer,Fluorouracil
998,D761Y,C,Resistance,Lung Non-small Cell Carcinoma,Gefitinib+Erlotinib
999,Amplification,B,Sensitivity/Response,Her2-receptor Positive Breast Cancer,Trastuzumab Emtansine
1000,Loss,C,Sensitivity/Response,Her2-receptor Negative Breast Cancer,Palbociclib+Letrozole
1001,MUTATION,C,Resistance,Multiple Myeloma,Pomalidomide+Lenalidomide
1002,Amplification,D,Sensitivity/Response,Estrogen-receptor Positive Breast Cancer,Ponatinib
1003,C481S,B,Resistance,Chronic Lymphocytic Leukemia,Ibrutinib
1004,Amplification,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Sunitinib
1005,Mutation,B,Sensitivity/Response,Ovarian Cancer,Olaparib
1006,Mutation,B,Sensitivity/Response,Ovarian Cancer,Olaparib
1007,FIP1L1-PDGFRA,C,Sensitivity/Response,"Myeloid And Lymphoid Neoplasms With Eosinophilia And Abnormalities Of PDGFRA, PDGFRB, And FGFR1",Imatinib
1008,Mutation,B,Resistance,Triple-receptor Negative Breast Cancer,Olaparib
1009,FIP1L1-PDGFRA,D,Sensitivity/Response,"Myeloid And Lymphoid Neoplasms With Eosinophilia And Abnormalities Of PDGFRA, PDGFRB, And FGFR1",Ponatinib
1010,FIP1L1-PDGFRA T674I,D,Sensitivity/Response,"Myeloid And Lymphoid Neoplasms With Eosinophilia And Abnormalities Of PDGFRA, PDGFRB, And FGFR1",Ponatinib
1011,G719,B,Sensitivity/Response,Lung Adenocarcinoma,Erlotinib
1012,BRD4-NUTM1,D,Sensitivity/Response,NUT Midline Carcinoma,JQ1
1013,S720,C,Resistance,Lung Adenocarcinoma,Erlotinib
1014,K757R,C,Sensitivity/Response,Lung Adenocarcinoma,Erlotinib
1015,E746G,C,Sensitivity/Response,Lung Adenocarcinoma,Erlotinib
1016,Exon 20 Insertion,C,Resistance,Lung Adenocarcinoma,Erlotinib
1017,UGT1A1*28,A,Adverse Response,Cancer,Belinostat
1018,UGT1A1*60,B,Adverse Response,Cancer,Belinostat
1019,V769_770insASV,C,Sensitivity/Response,Lung Adenocarcinoma,Erlotinib
1020,DPYD*2A HOMOZYGOSITY,A,Adverse Response,Cancer,Tegafur+Capecitabine+Fluorouracil
1021,DPYD*13 HOMOZYGOSITY,A,Adverse Response,Cancer,Capecitabine+Fluorouracil+Tegafur
1022,RS67376798 HOMOZYGOSITY,A,Adverse Response,Cancer,Capecitabine+Tegafur+Fluorouracil
1023,Exon 20 Insertion,B,Resistance,Lung Adenocarcinoma,Afatinib
1024,TNKS2-PDGFRA,C,Sensitivity/Response,"Myeloid And Lymphoid Neoplasms With Eosinophilia And Abnormalities Of PDGFRA, PDGFRB, And FGFR1",Imatinib
1025,RS4149056,B,Adverse Response,Cancer,Methotrexate
1026,N130D,B,Adverse Response,Cancer,Methotrexate
1027,RS34743033,B,Adverse Response,Cancer,Methotrexate
1028,V855A,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Afatinib+Pertuzumab
1029,FGFR2-BICC1,D,Sensitivity/Response,Cholangiocarcinoma,PD173074+Infigratinib
1030,FGFR2-AHCYL1,D,Sensitivity/Response,Cholangiocarcinoma,Infigratinib+PD173074
1031,V253I,C,Sensitivity/Response,Ewing Sarcoma Of Bone,Cixutumumab+Teprotumumab
1032,Overexpression,D,Resistance,Pancreatic Cancer,Gemcitabine
1033,OVEREXPRESSION,D,Resistance,Pancreatic Cancer,Gemcitabine
1034,MUTATION,C,Sensitivity/Response,Glioblastoma,Pembrolizumab
1035,MUTATION,C,Sensitivity/Response,Endometrial Cancer,Pembrolizumab
1036,T790M,B,Resistance,Lung Non-small Cell Carcinoma,Afatinib
1037,D1228V,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Cabozantinib
1038,D1228V,C,Resistance,Lung Non-small Cell Carcinoma,Savolitinib
1039,MUTATION,B,Sensitivity/Response,Lung Small Cell Carcinoma,Chemotherapy
1040,T790M,A,Sensitivity/Response,Lung Non-small Cell Carcinoma,Osimertinib
1041,SQSTM1-NTRK1,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Entrectinib
1042,ETV6-NTRK3,C,Sensitivity/Response,Mammary Analogue Secretory Carcinoma,Entrectinib
1043,ETV6-NTRK3 G623R,C,Resistance,Mammary Analogue Secretory Carcinoma,Entrectinib
1044,LOSS,C,Sensitivity/Response,Transitional Cell Carcinoma,Anti-PD-1 Monoclonal Antibody MEDI0680+Durvalumab
1045,LOSS,C,Sensitivity/Response,Transitional Cell Carcinoma,Anti-PD-1 Monoclonal Antibody MEDI0680+Durvalumab
1046,Loss,D,Sensitivity/Response,Ewing Sarcoma,Palbociclib+Linsitinib
1047,LOSS,D,Sensitivity/Response,Ewing Sarcoma,Palbociclib+Linsitinib
1048,Loss,D,Sensitivity/Response,Dermatofibrosarcoma Protuberans,Palbociclib
1049,Y772_A775DUP,C,Sensitivity/Response,Lung Adenocarcinoma,Afatinib
1050,G776L,C,Sensitivity/Response,Lung Adenocarcinoma,Afatinib
1051,G778_P780DUP,C,Sensitivity/Response,Lung Adenocarcinoma,Afatinib
1052,G778_P780DUP,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Dacomitinib
1053,M774DELINSWLV,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Dacomitinib
1054,Loss-of-function,D,Sensitivity/Response,Angiosarcoma,Sunitinib+Vatalanib
1055,Mutation,B,Sensitivity/Response,Ovarian Cancer,Rucaparib
1056,G12D,C,Sensitivity/Response,Colorectal Cancer,Therapeutic Tumor Infiltrating Lymphocytes
1057,COPY-NEUTRAL LOSS OF HETEROZYGOSITY,C,Resistance,Colorectal Cancer,Therapeutic Tumor Infiltrating Lymphocytes
1058,S703I,D,Sensitivity/Response,Hepatocellular Carcinoma,Ruxolitinib
1059,V600E,B,Sensitivity/Response,Colorectal Cancer,Irinotecan+Vemurafenib+Cetuximab
1060,C121S,C,Resistance,Colorectal Cancer,Cetuximab+Vemurafenib+Irinotecan
1061,K57T,C,Resistance,Colorectal Cancer,Vemurafenib+Cetuximab+Irinotecan
1062,S490T,C,Resistance,Colorectal Cancer,Vemurafenib+Cetuximab+Irinotecan
1063,R201C,C,Resistance,Colorectal Cancer,Irinotecan+Vemurafenib+Cetuximab
1064,Mutation,D,Sensitivity/Response,Mantle Cell Lymphoma,Olaparib
1065,Amplification,B,Sensitivity/Response,Lung Squamous Cell Carcinoma,Infigratinib
1066,Mutation,B,Sensitivity/Response,Bladder Carcinoma,Infigratinib
1067,Mutation,C,Sensitivity/Response,Cholangiocarcinoma,Infigratinib
1068,Fusion,C,Sensitivity/Response,Cholangiocarcinoma,Infigratinib
1069,AMPLIFICATION,D,Sensitivity/Response,Gastric Adenocarcinoma,Vistusertib
1070,AMPLIFICATION,D,Sensitivity/Response,Lung Small Cell Carcinoma,Sapanisertib+Vistusertib+MTOR Kinase Inhibitor AZD8055
1071,FGFR2-BICC1,C,Sensitivity/Response,Transitional Cell Carcinoma,Erdafitinib
1072,Fusion,B,Sensitivity/Response,Cancer,Erdafitinib
1073,FGFR3-TACC3,B,Sensitivity/Response,Cancer,Erdafitinib
1074,FGFR2-BICC1,C,Sensitivity/Response,Endometrial Cancer,Erdafitinib
1075,OVEREXPRESSION,D,Resistance,Breast Cancer,Akt Inhibitor MK2206
1076,OVEREXPRESSION,E,Sensitivity/Response,Triple-receptor Negative Breast Cancer,Pan-AKT Kinase Inhibitor GSK690693
1077,Loss-of-function,D,Sensitivity/Response,Breast Cancer,Pidnarulex+Quarfloxin
1078,Loss-of-function,D,Sensitivity/Response,Breast Cancer,Pidnarulex+Quarfloxin
1079,Alternative Transcript (ATI),C,Sensitivity/Response,Skin Melanoma,Crizotinib
1080,Mutation,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
1081,G469R,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Sorafenib
1082,G469V,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Sorafenib
1083,MUTATION,D,Sensitivity/Response,Uveal Melanoma,Mirdametinib+Sotrastaurin Acetate
1084,MUTATION,D,Sensitivity/Response,Uveal Melanoma,Sotrastaurin Acetate+Mirdametinib
1085,LOSS,D,Sensitivity/Response,Head And Neck Cancer,GPI-15427
1086,Q61L,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Everolimus+Selumetinib
1087,Loss,D,Sensitivity/Response,Neuroblastoma,Binimetinib
1088,Loss,D,Resistance,Melanoma,Dabrafenib
1089,Mutation,B,Sensitivity/Response,Plexiform Neurofibroma,Selumetinib
1090,EXPRESSION,D,Resistance,Estrogen-receptor Positive Breast Cancer,Tamoxifen
1091,Mutation,C,Sensitivity/Response,Prostate Cancer,Olaparib
1092,D419del,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Imatinib
1093,Biallelic Inactivation,C,Sensitivity/Response,Prostate Cancer,Olaparib
1094,DELETION,D,Sensitivity/Response,Rhabdoid Cancer,Panobinostat
1095,DELETION,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,C646
1096,AMPLIFICATION,C,Sensitivity/Response,Hepatocellular Carcinoma,Sorafenib
1097,Expression,D,Resistance,Breast Cancer,Lapatinib
1098,OVEREXPRESSION,B,Sensitivity/Response,Tenosynovial Giant Cell Tumor,Pexidartinib
1099,Overexpression,D,Resistance,Glioblastoma,Gefitinib
1100,Amplification,D,Resistance,Colorectal Cancer,Anti-EGFR Monoclonal Antibody
1101,P577S,D,Sensitivity/Response,Melanoma,Imatinib+Crenolanib
1102,R841K,D,Sensitivity/Response,Melanoma,Crenolanib+Imatinib
1103,H845Y,D,Sensitivity/Response,Melanoma,Imatinib+Crenolanib
1104,G853D,D,Sensitivity/Response,Melanoma,Crenolanib+Imatinib
1105,OVEREXPRESSION,D,Resistance,Melanoma,PLX4720+Selumetinib
1106,Amplification,D,Sensitivity/Response,Colorectal Cancer,Cetuximab+Crizotinib
1107,Underexpression,D,Sensitivity/Response,Breast Cancer,Pyrimidine Antagonist
1108,UNDEREXPRESSION,D,Resistance,Ovarian Cancer,Cetuximab
1109,OVEREXPRESSION,D,Resistance,Esophageal Cancer,Docetaxel+Fluorouracil
1110,OVEREXPRESSION,D,Sensitivity/Response,Esophageal Cancer,Verteporfin
1111,Expression,B,Sensitivity/Response,Chordoma,Lapatinib
1112,T316A,C,Resistance,Chronic Lymphocytic Leukemia,Ibrutinib
1113,T862A,D,Sensitivity/Response,Stomach Carcinoma,Lapatinib
1114,V773A,D,Sensitivity/Response,Breast Cancer,Lapatinib
1115,N857S,D,Sensitivity/Response,Breast Cancer,Lapatinib
1116,H878Y,D,Sensitivity/Response,Hepatocellular Carcinoma,Lapatinib
1117,Amplification,B,Sensitivity/Response,Stomach Carcinoma,FGFR Inhibitor AZD4547
1118,Amplification,C,Sensitivity/Response,Breast Cancer,FGFR Inhibitor AZD4547
1119,Overexpression,C,Sensitivity/Response,Head And Neck Squamous Cell Carcinoma,Lapatinib
1120,Amplification,B,Resistance,Colorectal Cancer,Cetuximab
1121,c.393T>C,B,Resistance,Lung Non-small Cell Carcinoma,Erlotinib+Gefitinib
1122,G12D,D,Sensitivity/Response,Colorectal Cancer,Dactolisib
1123,G12D,C,Sensitivity/Response,Colorectal Cancer,Dactolisib
1124,G12V,D,Sensitivity/Response,Colorectal Cancer,Selumetinib+Dactolisib
1125,G12D,C,Resistance,Colorectal Cancer,Cetuximab+Irinotecan
1126,G12D,C,Sensitivity/Response,Colorectal Cancer,Selumetinib
1127,G12/G13,B,Resistance,Colorectal Cancer,Panitumumab
1128,G12A,C,Resistance,Colorectal Cancer,Panitumumab
1129,G12A,C,Resistance,Colorectal Cancer,Panitumumab
1130,G12A,C,Resistance,Colorectal Cancer,Panitumumab
1131,G12A,B,Resistance,Lung Cancer,Gefitinib
1132,G12A,B,Resistance,Multiple Myeloma,Melphalan
1133,G12A,B,Resistance,Multiple Myeloma,Melphalan
1134,G12A,B,Resistance,Multiple Myeloma,Melphalan
1135,G12A,D,Resistance,Multiple Myeloma,Melphalan
1136,G12A,D,Resistance,Multiple Myeloma,Melphalan
1137,G12A,D,Resistance,Multiple Myeloma,Melphalan
1138,R132L,B,Sensitivity/Response,Brain Glioma,Temozolomide
1139,R132L,B,Sensitivity/Response,Brain Glioma,Temozolomide
1140,R132L,B,Sensitivity/Response,Brain Glioma,Temozolomide
1141,R132,B,Sensitivity/Response,High Grade Glioma,Bevacizumab+Sunitinib
1142,R132L,B,Sensitivity/Response,Acute Myeloid Leukemia,Ivosidenib
1143,E542K,D,Sensitivity/Response,Her2-receptor Positive Breast Cancer,Pictilisib
1144,E542K,D,Sensitivity/Response,Breast Cancer,Pictilisib
1145,E545K,D,Sensitivity/Response,Breast Cancer,Pictilisib
1146,Loss,B,Resistance,Her2-receptor Positive Breast Cancer,Trastuzumab
1147,E545K,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,PI103
1148,G13D,D,Resistance,Breast Cancer,Pictilisib
1149,Loss,B,Resistance,Breast Cancer,Trastuzumab
1150,Loss,D,Sensitivity/Response,Her2-receptor Positive Breast Cancer,Pictilisib
1151,Mutation,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib+Gefitinib
1152,E542K,D,Sensitivity/Response,Her2-receptor Positive Breast Cancer,PI-103
1153,E545K,D,Sensitivity/Response,Her2-receptor Positive Breast Cancer,Pictilisib
1154,Amplification,D,Sensitivity/Response,Breast Cancer,Pictilisib
1155,Mutation,C,Resistance,Breast Cancer,Trastuzumab
1156,C420R,D,Sensitivity/Response,Her2-receptor Positive Breast Cancer,Pictilisib
1157,K111N,D,Sensitivity/Response,Her2-receptor Positive Breast Cancer,Pictilisib
1158,Mutation,B,Resistance,Breast Cancer,Trastuzumab
1159,H1047L,D,Sensitivity/Response,Breast Cancer,Pictilisib
1160,H1047R,D,Sensitivity/Response,Her2-receptor Positive Breast Cancer,Pictilisib
1161,Mutation,B,Resistance,Her2-receptor Positive Breast Cancer,Trastuzumab
1162,H1047R,D,Sensitivity/Response,Breast Cancer,Pictilisib
1163,H1047R,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,PI103
1164,V600E,B,Resistance,Colorectal Cancer,Panitumumab+Cetuximab
1165,V600E,B,Resistance,Colorectal Cancer,Oxaliplatin
1166,V600E,B,Resistance,Colorectal Cancer,Irinotecan
1167,V600E,C,Resistance,Colorectal Cancer,Irinotecan
1168,V600E,B,Resistance,Colorectal Cancer,Capecitabine+Oxaliplatin+Bevacizumab
1169,V600E,D,Sensitivity/Response,Melanoma,Sorafenib
1170,V600E,D,Sensitivity/Response,Melanoma,Sorafenib
1171,V600E,D,Sensitivity/Response,Melanoma,Mirdametinib
1172,V600E,D,Sensitivity/Response,Melanoma,Mirdametinib
1173,V600E,B,Sensitivity/Response,Melanoma,Dabrafenib
1174,V600E,D,Sensitivity/Response,Melanoma,Dabrafenib
1175,V600E,D,Sensitivity/Response,Melanoma,Dabrafenib
1176,V600E,D,Sensitivity/Response,Melanoma,Selumetinib
1177,V600E,D,Sensitivity/Response,Melanoma,Selumetinib
1178,V600E,D,Sensitivity/Response,Melanoma,Trametinib
1179,V600E,D,Sensitivity/Response,Melanoma,Dabrafenib
1180,V600E,D,Sensitivity/Response,Melanoma,Dabrafenib
1181,V600E,D,Sensitivity/Response,Melanoma,Trametinib
1182,V600E,B,Sensitivity/Response,Melanoma,Trametinib
1183,V600E,D,Sensitivity/Response,Thyroid Gland Cancer,MEK Inhibitor CI-1040
1184,V600E,B,Sensitivity/Response,Thyroid Gland Cancer,MEK Inhibitor CI-1040
1185,V600E,D,Sensitivity/Response,Thyroid Gland Cancer,RDEA 119
1186,V600E,B,Sensitivity/Response,Thyroid Gland Cancer,RDEA 119
1187,V600E,B,Sensitivity/Response,Thyroid Gland Cancer,RDEA 119
1188,V600E,D,Sensitivity/Response,Thyroid Gland Cancer,Sorafenib
1189,V600E,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Mirdametinib
1190,V600E,D,Sensitivity/Response,High Grade Glioma,Selumetinib
1191,V600E,B,Sensitivity/Response,High Grade Glioma,Selumetinib
1192,V600E,B,Sensitivity/Response,Skin Melanoma,Dabrafenib
1193,Mutation,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
1194,L747_S752del,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
1195,L747_S752del,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
1196,L747_S752del,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
1197,L747_S752del,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
1198,Mutation,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Afatinib
1199,L747_S752del,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Afatinib
1200,Ex19 del L858R,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
1201,T790M,C,Sensitivity/Response,Lung Adenocarcinoma,Osimertinib
1202,T790M,C,Resistance,Lung Non-small Cell Carcinoma,Erlotinib+Gefitinib
1203,T790M,C,Resistance,Lung Non-small Cell Carcinoma,Gefitinib
1204,T790M,D,Resistance,Lung Non-small Cell Carcinoma,Lapatinib
1205,T790M,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Dacomitinib
1206,T790M,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Neratinib
1207,T790M,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Afatinib
1208,T790M,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Afatinib
1209,T790M,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Canertinib
1210,T790M,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Osimertinib
1211,BCR-ABL F359V,D,Resistance,Chronic Myeloid Leukemia,Imatinib
1212,BCR-ABL F359V,C,Resistance,Chronic Myeloid Leukemia,Imatinib
1213,BCR-ABL F359V,C,Resistance,Chronic Myeloid Leukemia,Imatinib
1214,BCR-ABL F359V,D,Resistance,Chronic Myeloid Leukemia,Nilotinib
1215,Q61H,D,Sensitivity/Response,Colorectal Cancer,Dactolisib
1216,Q61H,C,Sensitivity/Response,Colorectal Cancer,Dactolisib
1217,Q61H,C,Sensitivity/Response,Colorectal Cancer,Dactolisib
1218,Q61H,D,Sensitivity/Response,Colorectal Cancer,Selumetinib
1219,Q61H,C,Sensitivity/Response,Colorectal Cancer,Selumetinib
1220,Q61H,C,Sensitivity/Response,Colorectal Cancer,Selumetinib
1221,Q61L,D,Sensitivity/Response,Colorectal Cancer,Dactolisib
1222,G13D,C,Resistance,Colorectal Cancer,Panitumumab
1223,Q61L,C,Sensitivity/Response,Colorectal Cancer,Dactolisib
1224,Q61L,D,Sensitivity/Response,Colorectal Cancer,Selumetinib
1225,Q61L,C,Resistance,Colorectal Cancer,Irinotecan+Cetuximab
1226,Q61L,C,Sensitivity/Response,Colorectal Cancer,Selumetinib
1227,G13D,D,Sensitivity/Response,Colorectal Cancer,Selumetinib+Dactolisib
1228,Q61R,C,Resistance,Colorectal Cancer,Cetuximab
1229,Q61R,C,Sensitivity/Response,Colorectal Cancer,Selumetinib
1230,Q61R,D,Sensitivity/Response,Colorectal Cancer,Dactolisib
1231,Mutation,B,Resistance,Colorectal Cancer,Cetuximab+Chemotherapy
1232,Q61R,C,Sensitivity/Response,Colorectal Cancer,Dactolisib
1233,Q61K,C,Resistance,Colorectal Cancer,Cetuximab+Chemotherapy
1234,Q61K,C,Sensitivity/Response,Colorectal Cancer,Selumetinib
1235,Q61K,C,Resistance,Melanoma,Vemurafenib
1236,Q61K,D,Sensitivity/Response,Colorectal Cancer,Selumetinib+Dactolisib
1237,G12D,C,Resistance,Colorectal Cancer,Panitumumab
1238,Q61K,B,Sensitivity/Response,Colorectal Cancer,Dactolisib
1239,Q61K,C,Sensitivity/Response,Colorectal Cancer,Dactolisib
1240,Q61K,D,Sensitivity/Response,Colorectal Cancer,Dactolisib
1241,G13C,D,Sensitivity/Response,Colorectal Cancer,Dactolisib
1242,G13C,C,Sensitivity/Response,Colorectal Cancer,Dactolisib
1243,G13C,D,Sensitivity/Response,Colorectal Cancer,Selumetinib
1244,G13C,C,Sensitivity/Response,Colorectal Cancer,Selumetinib
1245,G13R,D,Sensitivity/Response,Colorectal Cancer,Dactolisib
1246,G13R,C,Resistance,Colorectal Cancer,Cetuximab+Irinotecan
1247,G13R,C,Sensitivity/Response,Colorectal Cancer,Dactolisib
1248,A146T,D,Sensitivity/Response,Colorectal Cancer,Dactolisib+Selumetinib
1249,G12D,B,Resistance,Colorectal Cancer,Cetuximab
1250,G13R,C,Sensitivity/Response,Colorectal Cancer,Selumetinib
1251,A146V,D,Sensitivity/Response,Colorectal Cancer,Selumetinib+Dactolisib
1252,Mutation,B,Resistance,Colorectal Cancer,Cetuximab+Chemotherapy
1253,G12C,C,Sensitivity/Response,Colorectal Cancer,Dactolisib
1254,G12C,D,Sensitivity/Response,Colorectal Cancer,Dactolisib+Selumetinib
1255,G12C,C,Sensitivity/Response,Colorectal Cancer,Selumetinib
1256,G12S,D,Sensitivity/Response,Colorectal Cancer,Dactolisib
1257,G12S,C,Sensitivity/Response,Colorectal Cancer,Dactolisib
1258,G12D,D,Sensitivity/Response,Colorectal Cancer,Dactolisib+Selumetinib
1259,G12V,B,Resistance,Colorectal Cancer,Cetuximab
1260,G12S,C,Sensitivity/Response,Colorectal Cancer,Selumetinib
1261,T2666A,D,Resistance,Chronic Lymphocytic Leukemia,Doxorubicin
1262,Mutation,D,Resistance,Chronic Lymphocytic Leukemia,Doxorubicin
1263,R3008C,D,Resistance,Chronic Lymphocytic Leukemia,Doxorubicin
1264,c.902-1G>T,D,Resistance,Chronic Lymphocytic Leukemia,Doxorubicin
1265,A146P,C,Resistance,Colorectal Cancer,Cetuximab+Irinotecan
1266,A146T,B,Resistance,Colorectal Cancer,Cetuximab
1267,Q61H,B,Resistance,Colorectal Cancer,Cetuximab
1268,Q61L,B,Resistance,Colorectal Cancer,Cetuximab
1269,Q61R,B,Resistance,Colorectal Cancer,Cetuximab
1270,Q61K,B,Resistance,Colorectal Cancer,Cetuximab
1271,G12V,C,Resistance,Colorectal Cancer,Panitumumab
1272,G12V,C,Resistance,Colorectal Cancer,Panitumumab
1273,G12V,C,Resistance,Colorectal Cancer,Panitumumab
1274,G12V,C,Resistance,Colorectal Cancer,Panitumumab
1275,G12D,C,Resistance,Colorectal Cancer,Panitumumab
1276,G12D,C,Resistance,Colorectal Cancer,Panitumumab
1277,G12D,C,Resistance,Colorectal Cancer,Panitumumab
1278,G12D,C,Resistance,Colorectal Cancer,Panitumumab
1279,G12D,B,Resistance,Lung Cancer,Gefitinib
1280,G12D,B,Resistance,Lung Cancer,Gefitinib
1281,Mutation,B,Resistance,Lung Non-small Cell Carcinoma,Erlotinib
1282,G12D,B,Resistance,Lung Cancer,Gefitinib
1283,G12D,B,Resistance,Lung Cancer,Gefitinib
1284,G12D,B,Resistance,Lung Cancer,Gefitinib
1285,G12D,C,Resistance,Lung Cancer,Gefitinib
1286,G12D,B,Resistance,Multiple Myeloma,Melphalan
1287,G12D,B,Resistance,Multiple Myeloma,Melphalan
1288,G12D,B,Resistance,Multiple Myeloma,Melphalan
1289,G12D,D,Resistance,Multiple Myeloma,Melphalan
1290,G12D,D,Resistance,Multiple Myeloma,Melphalan
1291,G12D,D,Resistance,Multiple Myeloma,Melphalan
1292,G12C,C,Resistance,Colorectal Cancer,Panitumumab
1293,G12C,C,Resistance,Colorectal Cancer,Panitumumab
1294,G12C,C,Resistance,Colorectal Cancer,Panitumumab
1295,G12C,C,Resistance,Colorectal Cancer,Panitumumab
1296,G12C,B,Resistance,Lung Cancer,Gefitinib
1297,G12C,B,Resistance,Multiple Myeloma,Melphalan
1298,G12C,B,Resistance,Multiple Myeloma,Melphalan
1299,G12C,B,Resistance,Multiple Myeloma,Melphalan
1300,G12C,D,Resistance,Multiple Myeloma,Melphalan
1301,G12C,D,Resistance,Multiple Myeloma,Melphalan
1302,G12C,D,Resistance,Multiple Myeloma,Melphalan
1303,G12R,C,Resistance,Colorectal Cancer,Panitumumab
1304,G12R,C,Resistance,Colorectal Cancer,Panitumumab
1305,G12R,C,Resistance,Colorectal Cancer,Panitumumab
1306,G12R,C,Resistance,Colorectal Cancer,Panitumumab
1307,G12V,C,Resistance,Lung Cancer,Gefitinib
1308,G12S,C,Resistance,Colorectal Cancer,Panitumumab
1309,G12S,C,Resistance,Colorectal Cancer,Panitumumab
1310,G12S,C,Resistance,Colorectal Cancer,Panitumumab
1311,G12S,C,Resistance,Colorectal Cancer,Panitumumab
1312,G12S,B,Resistance,Lung Cancer,Gefitinib
1313,G12S,B,Resistance,Multiple Myeloma,Melphalan
1314,G12S,B,Resistance,Multiple Myeloma,Melphalan
1315,G12S,B,Resistance,Multiple Myeloma,Melphalan
1316,G12S,D,Resistance,Multiple Myeloma,Melphalan
1317,G12S,D,Resistance,Multiple Myeloma,Melphalan
1318,G12S,D,Resistance,Multiple Myeloma,Melphalan
1319,R273L,C,Resistance,Ovarian Cancer,Cisplatin+Carboplatin
1320,Y220C,C,Sensitivity/Response,Stomach Carcinoma,Etoposide+Cisplatin+Mitomycin
1321,R175H,C,Sensitivity/Response,Stomach Carcinoma,EAP Protocol
1322,LOSS,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Sirolimus
1323,LOSS,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Sirolimus
1324,LOSS,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Sirolimus
1325,LOSS,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Sirolimus
1326,LOSS,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Sirolimus
1327,LOSS,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,MEK Inhibitor CI-1040
1328,LOSS,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,MEK Inhibitor CI-1040
1329,LOSS,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,MEK Inhibitor CI-1040
1330,LOSS,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,MEK Inhibitor CI-1040
1331,LOSS,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,MEK Inhibitor CI-1040
1332,R132H,B,Sensitivity/Response,Brain Glioma,Temozolomide
1333,R132H,D,Sensitivity/Response,Brain Glioma,BPTES
1334,R132H,D,Sensitivity/Response,Glioblastoma,Pan-Mutant-IDH1 Inhibitor Bay-1436032
1335,R132C,B,Sensitivity/Response,Brain Glioma,Temozolomide
1336,R132C,B,Sensitivity/Response,Brain Glioma,Temozolomide
1337,R132C,B,Sensitivity/Response,Brain Glioma,Temozolomide
1338,R132C,D,Sensitivity/Response,High Grade Glioma,AGI-5198
1339,R132,B,Sensitivity/Response,High Grade Glioma,Bevacizumab
1340,R132C,B,Sensitivity/Response,Acute Myeloid Leukemia,Ivosidenib
1341,R132C,D,Sensitivity/Response,Acute Myeloid Leukemia,BPTES
1342,R132G,B,Sensitivity/Response,Brain Glioma,Temozolomide
1343,R132G,B,Sensitivity/Response,Brain Glioma,Temozolomide
1344,R132G,B,Sensitivity/Response,Brain Glioma,Temozolomide
1345,R132S,B,Sensitivity/Response,Brain Glioma,Temozolomide
1346,R132S,B,Sensitivity/Response,Brain Glioma,Temozolomide
1347,R132S,B,Sensitivity/Response,Brain Glioma,Temozolomide
1348,R132S,B,Sensitivity/Response,High Grade Glioma,Bevacizumab
1349,R132S,B,Sensitivity/Response,Acute Myeloid Leukemia,Ivosidenib
1350,R1275Q,B,Sensitivity/Response,Neuroblastoma,Crizotinib
1351,R1275Q,B,Sensitivity/Response,Neuroblastoma,Crizotinib
1352,EML4-ALK L1196M,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Ceritinib
1353,F1174L,B,Resistance,Neuroblastoma,Crizotinib
1354,F1174L,B,Resistance,Neuroblastoma,Crizotinib
1355,Mutation,B,Resistance,Lung Non-small Cell Carcinoma,Erlotinib+Gefitinib
1356,Mutation,B,Resistance,Lung Non-small Cell Carcinoma,Gefitinib+Erlotinib
1357,Y503_F504insAY,B,Sensitivity/Response,Gastrointestinal Stromal Tumor,Imatinib
1358,K550_W557del,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Imatinib
1359,K550_K558del,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Imatinib
1360,P551L,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Imatinib
1361,M552_W557DEL,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Imatinib
1362,Y553D,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Imatinib
1363,Y553_K558DEL,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Imatinib
1364,DEL 554-558,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Imatinib
1365,E554D,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Imatinib
1366,T417_D419delinsY,C,Sensitivity/Response,Gastrointestinal Stromal Tumor,Imatinib
1367,V555_Q556DEL,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Imatinib
1368,V555_P573DEL,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Imatinib
1369,W557R,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Imatinib
1370,W557G,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Imatinib
1371,W557T,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Imatinib
1372,W557_K558del,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Imatinib
1373,W557_E561del,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Imatinib
1374,K558Q,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Imatinib
1375,K558_V559del,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Imatinib
1376,K558R,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Imatinib
1377,V559DEL,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Imatinib
1378,D816V,D,Resistance,Cancer,Imatinib
1379,V559_V560DEL,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Imatinib
1380,V559A,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Imatinib
1381,V559G,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Imatinib
1382,V560DEL,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Imatinib
1383,D842V,D,Resistance,Cancer,Imatinib
1384,V560D,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Imatinib
1385,K484_G487DEL,C,Sensitivity/Response,Gastrointestinal Stromal Tumor,Imatinib
1386,Exon 9 Mutation,B,Sensitivity/Response,Gastrointestinal Stromal Tumor,Imatinib
1387,V560G,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Imatinib
1388,V560G,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Imatinib
1389,Exon 11 Mutation,B,Sensitivity/Response,Gastrointestinal Stromal Tumor,Imatinib
1390,T574A,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Imatinib
1391,V561D,C,Sensitivity/Response,Gastrointestinal Stromal Tumor,Imatinib
1392,Exon 13 Mutation,C,Sensitivity/Response,Gastrointestinal Stromal Tumor,Imatinib
1393,Q575L,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Imatinib
1394,Exon 9 Mutation,B,Reduced Sensitivity,Gastrointestinal Stromal Tumor,Imatinib
1395,D842V,C,Resistance,Gastrointestinal Stromal Tumor,Imatinib
1396,L576P,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Imatinib
1397,EXPRESSION,B,Sensitivity/Response,Gastrointestinal Stromal Tumor,Imatinib
1398,P577L,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Imatinib
1399,D579del,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Imatinib
1400,Mutation,C,Sensitivity/Response,Gastrointestinal Stromal Tumor,Imatinib
1401,EXPRESSION,B,Resistance,Gastrointestinal Stromal Tumor,Imatinib
1402,T661I,D,Resistance,Gastrointestinal Stromal Tumor,Imatinib
1403,T661I,D,Resistance,Gastrointestinal Stromal Tumor,Imatinib
1404,T661I,B,Resistance,Gastrointestinal Stromal Tumor,Imatinib
1405,T661I,B,Resistance,Gastrointestinal Stromal Tumor,Imatinib
1406,S692L,B,Resistance,Gastrointestinal Stromal Tumor,Imatinib
1407,S692L,D,Resistance,Gastrointestinal Stromal Tumor,Imatinib
1408,S692L,D,Resistance,Gastrointestinal Stromal Tumor,Imatinib
1409,S692L,B,Resistance,Gastrointestinal Stromal Tumor,Imatinib
1410,S692L,B,Resistance,Gastrointestinal Stromal Tumor,Imatinib
1411,Q694K,B,Resistance,Gastrointestinal Stromal Tumor,Imatinib
1412,Q694K,D,Resistance,Gastrointestinal Stromal Tumor,Imatinib
1413,Q694K,D,Resistance,Gastrointestinal Stromal Tumor,Imatinib
1414,Q694K,B,Resistance,Gastrointestinal Stromal Tumor,Imatinib
1415,Q694K,B,Resistance,Gastrointestinal Stromal Tumor,Imatinib
1416,V600E,B,Sensitivity/Response,Thyroid Gland Cancer,Sorafenib
1417,V600K,B,Sensitivity/Response,Melanoma,Dabrafenib
1418,V600K,B,Sensitivity/Response,Melanoma,Trametinib
1419,V600K,B,Sensitivity/Response,Melanoma,Dabrafenib
1420,G719A,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
1421,E746_A750del,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
1422,E746_A750del,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
1423,Wildtype,B,Resistance,Lung Non-small Cell Carcinoma,Gefitinib
1424,E746_A750del,C,Sensitivity/Response,Bronchiolo-alveolar Adenocarcinoma,Erlotinib
1425,E746_A750del,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
1426,E746_A750del,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Afatinib
1427,E746_A750del,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Afatinib
1428,E746_A750del,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Durvalumab
1429,Exon 19 Deletion,B,Sensitivity/Response,Lung Adenocarcinoma,Gefitinib
1430,E746_T751>I,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
1431,E746_T751>I,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
1432,E746_T751>I,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
1433,E746_T751>I,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Afatinib
1434,E746_T751>I,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Afatinib
1435,E746_T751delinsA,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
1436,E746_T751delinsA,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
1437,E746_T751delinsA,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
1438,E746V,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
1439,E746V,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
1440,E746V,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
1441,E746V,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Afatinib
1442,E746V,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Afatinib
1443,L747_A750>P,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
1444,L747_A750>P,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
1445,L747_A750>P,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
1446,L747_A750>P,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Afatinib
1447,L747_A750>P,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Afatinib
1448,L747_T751delLREAT,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Afatinib
1449,L747_T751>Q,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
1450,L747_T751>Q,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
1451,Mutation,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
1452,L747_T751>Q,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
1453,L747_T751>Q,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Afatinib
1454,L747_T751>Q,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Afatinib
1455,E746_S752>D,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
1456,E746_S752>D,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
1457,E746_S752>D,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
1458,E746_S752>D,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Afatinib
1459,E746_S752>D,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Afatinib
1460,L747_T751delinsP,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
1461,L747_T751delinsP,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
1462,L747_T751delinsP,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
1463,L747_T751delinsP,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
1464,L747_T751delinsP,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Afatinib
1465,L747_T751delinsP,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Afatinib
1466,L747_T751delLREAT,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
1467,L747_T751delLREAT,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
1468,L747_T751delLREAT,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Afatinib
1469,L747_P753>Q,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
1470,L747_P753>Q,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
1471,L747_P753>Q,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
1472,L747_P753>Q,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Afatinib
1473,L747_P753>Q,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Afatinib
1474,L747_T751delLREAT,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
1475,L747_P753delinsS,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
1476,L747_P753delinsS,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
1477,L747_P753delinsS,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
1478,L747_P753delinsS,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Afatinib
1479,L747_P753delinsS,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Afatinib
1480,S768I,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
1481,S768I,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
1482,S768I,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
1483,G719S,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
1484,R831H,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
1485,R831H,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
1486,R831H,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
1487,L858R,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
1488,L858R,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
1489,L858R,C,Sensitivity/Response,Lung Adenocarcinoma,Gefitinib
1490,E746_A750del,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
1491,L858R,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Lapatinib
1492,L858R,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Dacomitinib
1493,L858R,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Neratinib
1494,L858R,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Afatinib
1495,L858R,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Afatinib
1496,L858R,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Canertinib
1497,L858R,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib
1498,L858R,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Durvalumab
1499,L858R,B,Sensitivity/Response,Lung Adenocarcinoma,Gefitinib
1500,BCR-ABL M244V,C,Sensitivity/Response,Chronic Myeloid Leukemia,Imatinib
1501,BCR-ABL M244V,D,Sensitivity/Response,Cancer,Imatinib
1502,BCR-ABL M244V,C,Sensitivity/Response,Chronic Myeloid Leukemia,Nilotinib
1503,BCR-ABL L248V,D,Resistance,Chronic Myeloid Leukemia,Imatinib
1504,BCR-ABL L248V,C,Resistance,Chronic Myeloid Leukemia,Imatinib
1505,BCR-ABL L248V,C,Resistance,Chronic Myeloid Leukemia,Imatinib
1506,BCR-ABL L248V,D,Resistance,Chronic Myeloid Leukemia,Dasatinib+Imatinib Mesylate+Nilotinib
1507,BCR-ABL G250E,D,Resistance,Chronic Myeloid Leukemia,Imatinib
1508,BCR-ABL G250E,C,Resistance,Chronic Myeloid Leukemia,Imatinib
1509,BCR-ABL G250E,C,Resistance,Chronic Myeloid Leukemia,Imatinib
1510,BCR-ABL G250E,D,Resistance,Chronic Myeloid Leukemia,Nilotinib
1511,BCR-ABL Q252H,D,Sensitivity/Response,Chronic Myeloid Leukemia,Imatinib
1512,BCR-ABL Q252H,C,Resistance,Chronic Myeloid Leukemia,Imatinib
1513,BCR-ABL Q252H,C,Sensitivity/Response,Chronic Myeloid Leukemia,Imatinib
1514,BCR-ABL Y253H,D,Resistance,Chronic Myeloid Leukemia,Nilotinib+Imatinib Mesylate
1515,BCR-ABL Y253F,D,Resistance,Chronic Myeloid Leukemia,Imatinib
1516,BCR-ABL E255V,C,Resistance,Chronic Myeloid Leukemia,Imatinib
1517,BCR-ABL Y253F,C,Resistance,Chronic Myeloid Leukemia,Imatinib
1518,BCR-ABL E255K,D,Resistance,Chronic Myeloid Leukemia,Imatinib
1519,BCR-ABL E255K,C,Resistance,Chronic Myeloid Leukemia,Imatinib
1520,BCR-ABL E255K,D,Resistance,Chronic Myeloid Leukemia,Imatinib
1521,BCR-ABL E255K,D,Resistance,Chronic Myeloid Leukemia,Nilotinib
1522,BCR-ABL D276G,D,Resistance,Chronic Myeloid Leukemia,Imatinib
1523,BCR-ABL D276G,C,Resistance,Chronic Myeloid Leukemia,Imatinib
1524,BCR-ABL D276G,D,Sensitivity/Response,Chronic Myeloid Leukemia,Nilotinib
1525,BCR-ABL T315I,D,Resistance,Chronic Myeloid Leukemia,Imatinib
1526,BCR-ABL T315I,C,Resistance,Chronic Myeloid Leukemia,Imatinib
1527,BCR-ABL T315I,D,Resistance,Chronic Myeloid Leukemia,Imatinib
1528,BCR-ABL T315I,D,Resistance,Chronic Myeloid Leukemia,Nilotinib
1529,BCR-ABL T315I,D,Resistance,Cancer,Bafetinib+Nilotinib+Imatinib+Dasatinib
1530,BCR-ABL T315I,B,Sensitivity/Response,Chronic Myeloid Leukemia,Ponatinib
1531,BCR-ABL T315I,D,Sensitivity/Response,Acute Lymphoblastic Leukemia,Ponatinib
1532,BCR-ABL F317L,D,Resistance,Chronic Myeloid Leukemia,Imatinib
1533,BCR-ABL F317L,C,Resistance,Chronic Myeloid Leukemia,Imatinib
1534,BCR-ABL F317L,C,Resistance,Chronic Myeloid Leukemia,Imatinib
1535,BCR-ABL F317L,C,Resistance,Chronic Myeloid Leukemia,Imatinib
1536,BCR-ABL S417Y,C,Resistance,Chronic Myeloid Leukemia,Imatinib
1537,BCR-ABL F317L,C,Resistance,Chronic Myeloid Leukemia,Imatinib
1538,Overexpression,D,Resistance,Chronic Myeloid Leukemia,Dasatinib+Bafetinib
1539,BCR-ABL M351T,D,Sensitivity/Response,Chronic Myeloid Leukemia,Imatinib
1540,BCR-ABL M351T,C,Resistance,Chronic Myeloid Leukemia,Imatinib
1541,BCR-ABL M351T,C,Sensitivity/Response,Chronic Myeloid Leukemia,Imatinib
1542,BCR-ABL M351T,D,Sensitivity/Response,Chronic Myeloid Leukemia,Nilotinib
1543,BCR-ABL H396R,D,Resistance,Chronic Myeloid Leukemia,Imatinib
1544,BCR-ABL H396R,C,Resistance,Chronic Myeloid Leukemia,Imatinib
1545,BCR-ABL H396R,C,Resistance,Chronic Myeloid Leukemia,Imatinib
1546,L1600P,C,Sensitivity/Response,T-cell Acute Lymphoblastic Leukemia,Prednisone
1547,L1574P,C,Sensitivity/Response,T-cell Acute Lymphoblastic Leukemia,Prednisone
1548,Mutation,C,Sensitivity/Response,T-cell Acute Lymphoblastic Leukemia,Prednisone
1549,Mutation,C,Sensitivity/Response,T-cell Acute Lymphoblastic Leukemia,Prednisone
1550,Y234C,C,Resistance,Ovarian Cancer,Carboplatin+Cisplatin
1551,ALTERATION,B,Resistance,Ovarian Cancer,Carboplatin+Cisplatin
1552,DNA Binding Domain Mutation,B,Resistance,Breast Cancer,Tamoxifen
1553,Mutation,C,Resistance,Breast Cancer,Tamoxifen
1554,Overexpression,B,Sensitivity/Response,Stomach Cancer,Etoposide+Cisplatin+Mitomycin
1555,Q61P,B,Resistance,Colorectal Cancer,Cetuximab
1556,Q61P,B,Resistance,Colorectal Cancer,Irinotecan
1557,Q61E,B,Resistance,Colorectal Cancer,Cetuximab
1558,Q61E,B,Resistance,Colorectal Cancer,Irinotecan
1559,Q61FS,B,Resistance,Colorectal Cancer,Cetuximab
1560,G464V,D,Sensitivity/Response,Breast Cancer,Sorafenib
1561,K601E,B,Sensitivity/Response,Skin Melanoma,Dabrafenib
1562,D594N,B,Sensitivity/Response,Skin Melanoma,Dabrafenib
1563,D594N,D,Sensitivity/Response,Skin Melanoma,Dabrafenib
1564,D594N,D,Sensitivity/Response,Skin Melanoma,Dabrafenib
1565,D594N,D,Sensitivity/Response,Skin Melanoma,Dabrafenib
1566,D594N,D,Sensitivity/Response,Skin Melanoma,Dabrafenib
1567,R282L,C,Sensitivity/Response,Stomach Carcinoma,EAP Protocol
1568,R213P,C,Sensitivity/Response,Stomach Carcinoma,EAP Protocol
1569,Mutation,C,Sensitivity/Response,Stomach Carcinoma,Doxorubicin+Cisplatin+Etoposide
1570,F1592S,C,Sensitivity/Response,T-cell Acute Lymphoblastic Leukemia,Prednisone
1571,L1600Q,C,Sensitivity/Response,T-cell Acute Lymphoblastic Leukemia,Prednisone
1572,L1585R,C,Sensitivity/Response,T-cell Acute Lymphoblastic Leukemia,Prednisone
1573,V1577A,C,Sensitivity/Response,T-cell Acute Lymphoblastic Leukemia,Prednisone
1574,V1577E,C,Sensitivity/Response,T-cell Acute Lymphoblastic Leukemia,Prednisone
1575,L1574Q,C,Sensitivity/Response,T-cell Acute Lymphoblastic Leukemia,Prednisone
1576,BCR-ABL F486S,D,Sensitivity/Response,Chronic Myeloid Leukemia,Nilotinib
1577,c.7089+1del,D,Resistance,Chronic Lymphocytic Leukemia,Doxorubicin
1578,c.7515+1_2del,D,Resistance,Chronic Lymphocytic Leukemia,Doxorubicin
1579,K293*,D,Resistance,Chronic Lymphocytic Leukemia,Doxorubicin
1580,R2459C,D,Resistance,Chronic Lymphocytic Leukemia,Doxorubicin
1581,Q984E,D,Resistance,Chronic Lymphocytic Leukemia,Doxorubicin
1582,F1025L,D,Resistance,Chronic Lymphocytic Leukemia,Doxorubicin
1583,Q1084*,D,Resistance,Chronic Lymphocytic Leukemia,Doxorubicin
1584,D1930V,D,Resistance,Chronic Lymphocytic Leukemia,Doxorubicin
1585,R2034P,D,Resistance,Chronic Lymphocytic Leukemia,Doxorubicin
1586,E2187*,D,Resistance,Chronic Lymphocytic Leukemia,Doxorubicin
1587,L2427P,D,Resistance,Chronic Lymphocytic Leukemia,Doxorubicin
1588,F2732V,D,Resistance,Chronic Lymphocytic Leukemia,Doxorubicin
1589,R777FS,D,Resistance,Chronic Lymphocytic Leukemia,Doxorubicin
1590,V1268FS,D,Resistance,Chronic Lymphocytic Leukemia,Doxorubicin
1591,D1682H,D,Resistance,Chronic Lymphocytic Leukemia,Doxorubicin
1592,A2062V,D,Resistance,Chronic Lymphocytic Leukemia,Doxorubicin
1593,R1575H,D,Resistance,Chronic Lymphocytic Leukemia,Doxorubicin
1594,A2274T,D,Resistance,Chronic Lymphocytic Leukemia,Doxorubicin
1595,C2488Y,D,Resistance,Chronic Lymphocytic Leukemia,Doxorubicin
1596,BCR-ABL E255V,D,Resistance,Chronic Myeloid Leukemia,Nilotinib
1597,BCR-ABL E255V,D,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate+Nilotinib
1598,F1592C,C,Sensitivity/Response,T-cell Acute Lymphoblastic Leukemia,Prednisone
1599,BCR-ABL E292V,D,Resistance,Chronic Myeloid Leukemia,Nilotinib
1600,BCR-ABL F359C,D,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate+Nilotinib
1601,S501_A502INSAY,B,Resistance,Gastrointestinal Stromal Tumor,Imatinib
1602,S501_A502INSAY,B,Resistance,Gastrointestinal Stromal Tumor,Imatinib
1603,S501_A502INSAY,B,Resistance,Gastrointestinal Stromal Tumor,Imatinib
1604,S501_A502INSAY,B,Resistance,Gastrointestinal Stromal Tumor,Imatinib
1605,E746_T751delinsVA,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Afatinib
1606,BCR-ABL L384M,D,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate+Nilotinib
1607,BCR-ABL V299L,D,Sensitivity/Response,Chronic Myeloid Leukemia,Nilotinib
1608,BCR-ABL L387F,D,Resistance,Chronic Myeloid Leukemia,Nilotinib
1609,BCR-ABL G398R,D,Sensitivity/Response,Chronic Myeloid Leukemia,Nilotinib
1610,EML4-ALK S1206Y,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Ceritinib
1611,Mutation,B,Sensitivity/Response,Ovarian Cancer,Rucaparib
1612,Q1467*,C,Sensitivity/Response,Ovarian Cancer,Rucaparib
1613,M1R,C,Sensitivity/Response,Ovarian Cancer,Rucaparib
1614,M1I,C,Sensitivity/Response,Ovarian Cancer,Rucaparib
1615,V159M,C,Sensitivity/Response,Ovarian Cancer,Rucaparib
1616,V211L,C,Sensitivity/Response,Ovarian Cancer,Rucaparib
1617,V211I,C,Sensitivity/Response,Ovarian Cancer,Rucaparib
1618,R2336P,C,Sensitivity/Response,Ovarian Cancer,Rucaparib
1619,D820Y,C,Resistance,Melanoma,Imatinib
1620,D820Y,D,Sensitivity/Response,Melanoma,Sunitinib
1621,K642E,C,Sensitivity/Response,Mucosal Melanoma,Imatinib
1622,V600E,D,Sensitivity/Response,Colorectal Cancer,Sorafenib+Cetuximab
1623,c.393T>C,B,Resistance,Esophageal Cancer,Fluorouracil+Cisplatin
1624,Underexpression,B,Sensitivity/Response,Glioblastoma,Temozolomide
1625,OVEREXPRESSION,D,Sensitivity/Response,Clear Cell Renal Cell Carcinoma,UO126
1626,Underexpression,B,Sensitivity/Response,High Grade Glioma,Temozolomide
1627,Underexpression,B,Sensitivity/Response,Oligodendroglioma,Temozolomide
1628,Underexpression,B,Sensitivity/Response,Glioblastoma,Temozolomide
1629,Underexpression,B,Sensitivity/Response,Neuroendocrine Tumor,Temozolomide
1630,Underexpression,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gemcitabine+Cisplatin
1631,Q61K,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Selumetinib+Trametinib
1632,Q61K,D,Sensitivity/Response,Lung Cancer,Selumetinib+Trametinib
1633,EXPRESSION,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib Hydrochloride
1634,OVEREXPRESSION,D,Resistance,Skin Melanoma,Vemurafenib
1635,EXPRESSION,D,Resistance,Lung Non-small Cell Carcinoma,Cisplatin
1636,Expression,D,Sensitivity/Response,Sarcoma,"Infigratinib+FGFR Inhibitor AZD4547+FGF/VEGF Receptor Tyrosine Kinase Inhibitor, PD173074"
1637,AMPLIFICATION,B,Adverse Response,Cancer,Pembrolizumab+Nivolumab+Ipilimumab
1638,EXPRESSION,B,Adverse Response,Cancer,Atezolizumab+Pembrolizumab+Nivolumab
1639,N822K,C,Resistance,Gastrointestinal Stromal Tumor,Imatinib
1640,Y823D,C,Resistance,Gastrointestinal Stromal Tumor,Imatinib
1641,C809G,C,Resistance,Gastrointestinal Stromal Tumor,Imatinib
1642,D820A,C,Resistance,Gastrointestinal Stromal Tumor,Imatinib
1643,D820G,C,Resistance,Gastrointestinal Stromal Tumor,Imatinib
1644,D816H,C,Resistance,Gastrointestinal Stromal Tumor,Imatinib
1645,T670I,C,Resistance,Gastrointestinal Stromal Tumor,Imatinib
1646,AMPLIFICATION,B,Adverse Response,Cancer,Atezolizumab+Nivolumab+Pembrolizumab
1647,Mutation,B,Resistance,Cancer,Pembrolizumab+Nivolumab+Atezolizumab
1648,Amplification,B,Resistance,Colorectal Cancer,Cetuximab+Encorafenib
1649,Amplification,C,Resistance,Colorectal Cancer,Dabrafenib+Panitumumab
1650,F53L,C,Resistance,Colorectal Cancer,Trametinib+Dabrafenib
1651,Mutation,B,Sensitivity/Response,Skin Melanoma,Binimetinib+Ribociclib
1652,Mutation,D,Sensitivity/Response,Brain Glioma,Olaparib
1653,Mutation,D,Sensitivity/Response,Brain Glioma,Olaparib
1654,G2032R,C,Resistance,Lung Adenocarcinoma,Crizotinib
1655,K57N,D,Sensitivity/Response,Lung Adenocarcinoma,Selumetinib
1656,Mutation,B,Sensitivity/Response,Skin Melanoma,Binimetinib
1657,G12,B,Resistance,Lung Cancer,Gefitinib
1658,Mutation,B,Sensitivity/Response,Lung Cancer,Gefitinib
1659,Overexpression,B,Sensitivity/Response,Multiple Myeloma,Letetresgene Autoleucel
1660,Overexpression,B,Sensitivity/Response,Multiple Myeloma,Letetresgene Autoleucel
1661,A146T,D,Resistance,Colorectal Cancer,Cetuximab
1662,A146T,D,Sensitivity/Response,Colorectal Cancer,Mirdametinib
1663,AMPLIFICATION,D,Resistance,Lung Non-small Cell Carcinoma,Gefitinib
1664,AMPLIFICATION,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Sonidegib+Gefitinib
1665,Fusion,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Entrectinib
1666,Fusion,B,Sensitivity/Response,Cancer,Entrectinib
1667,Fusion,B,Sensitivity/Response,Cancer,Entrectinib
1668,SQSTM1-NTRK1,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Entrectinib
1669,REARRANGEMENT,B,Sensitivity/Response,Cancer,Entrectinib
1670,Fusion,B,Sensitivity/Response,Cancer,Entrectinib
1671,Fusion,C,Sensitivity/Response,Cancer,Larotrectinib
1672,Fusion,B,Sensitivity/Response,Cancer,Larotrectinib
1673,LMNA::NTRK1 e2-e11,C,Sensitivity/Response,Sarcoma,Larotrectinib
1674,Fusion,C,Sensitivity/Response,Sarcoma,Larotrectinib
1675,OVEREXPRESSION,D,Sensitivity/Response,Clear Cell Renal Cell Carcinoma,JQ1
1676,LMNA::NTRK1 e11-e10,C,Sensitivity/Response,Colorectal Adenocarcinoma,Entrectinib
1677,LMNA-NTRK1 G595R and G667C,C,Resistance,Colorectal Adenocarcinoma,Entrectinib
1678,Wildtype,D,Sensitivity/Response,Cancer,Nutlin-3a
1679,Wildtype,D,Sensitivity/Response,Cancer,MDM2 Inhibitor AMGMDS3
1680,Wildtype,B,Sensitivity/Response,Leukemia,RG7112
1681,Deleterious Mutation,B,Resistance,Leukemia,RG7112
1682,Deleterious Mutation,D,Resistance,Cancer,MDM2 Inhibitor AMGMDS3
1683,Deleterious Mutation,D,Resistance,Cancer,Nutlin-3a
1684,CYTOPLASMIC EXPRESSION,B,Sensitivity/Response,Triple-receptor Negative Breast Cancer,Carboplatin+Eribulin
1685,Q61H,C,Resistance,Colorectal Cancer,Panitumumab+Trametinib
1686,K57T,C,Resistance,Colorectal Cancer,Cetuximab
1687,M511I,D,Sensitivity/Response,T-cell Acute Lymphoblastic Leukemia,Tofacitinib
1688,V722I,C,Sensitivity/Response,Lung Adenocarcinoma,Atezolizumab
1689,S61C,C,Sensitivity/Response,Lung Adenocarcinoma,Atezolizumab
1690,P429S,C,Resistance,Melanoma,Pembrolizumab
1691,W690*,C,Resistance,Colon Carcinoma,Pembrolizumab
1692,LOSS-OF-FUNCTION,D,Sensitivity/Response,Ovarian Clear Cell Carcinoma,Dasatinib
1693,LOSS-OF-FUNCTION,D,Sensitivity/Response,Ovarian Clear Cell Carcinoma,GSK126
1694,E545K,D,Sensitivity/Response,Cervix Carcinoma,Cisplatin+Pictilisib
1695,E545K,D,Resistance,Cervical Cancer,Cisplatin
1696,F1245V,C,Sensitivity/Response,Neuroblastoma,Entrectinib
1697,Activating Mutation,D,Resistance,Melanoma,Anti-PD-L1 Monoclonal Antibody+Anti-CTLA-4 Monoclonal Antibody
1698,OVEREXPRESSION,D,Sensitivity/Response,Melanoma,UNC1062
1699,Overexpression,D,Sensitivity/Response,Estrogen-receptor Negative Breast Cancer,Vandetanib
1700,L858R,A,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib
1701,Exon 19 Deletion,A,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib
1702,Exon 19 Deletion,A,Sensitivity/Response,Lung Non-small Cell Carcinoma,Afatinib
1703,L858R,A,Sensitivity/Response,Lung Non-small Cell Carcinoma,Afatinib
1704,Mutation,A,Resistance,Lung Non-small Cell Carcinoma,Selumetinib+Docetaxel
1705,Expression,B,Resistance,Head And Neck Squamous Cell Carcinoma,Radiation Therapy
1706,OVEREXPRESSION,D,Resistance,Breast Cancer,Pan-AKT Kinase Inhibitor GSK690693
1707,Overexpression,D,Sensitivity/Response,Lung Small Cell Carcinoma,Cisplatin+Prexasertib+Olaparib
1708,L755S,D,Resistance,Breast Cancer,Lapatinib
1709,L755P,D,Resistance,Breast Cancer,Lapatinib
1710,T798M,D,Resistance,Breast Cancer,Lapatinib
1711,D835V,D,Resistance,Acute Myeloid Leukemia,Tandutinib
1712,D835V,D,Sensitivity/Response,Acute Myeloid Leukemia,Sunitinib+Cytarabine
1713,D835V,D,Sensitivity/Response,Acute Myeloid Leukemia,Daunorubicin+Sunitinib
1714,Overexpression,B,Resistance,Ovarian Cancer,Cisplatin+Carboplatin
1715,Amplification,D,Resistance,Lung Non-small Cell Carcinoma,Rociletinib+Osimertinib
1716,Mutation,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
1717,V600E,A,Sensitivity/Response,Lung Non-small Cell Carcinoma,Trametinib+Dabrafenib
1718,Q61L,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Trametinib+Selumetinib
1719,Q61R,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Trametinib+Selumetinib
1720,L768S,D,Sensitivity/Response,Breast Cancer,Trastuzumab
1721,L638S,D,Sensitivity/Response,Breast Cancer,Lapatinib
1722,V773,D,Sensitivity/Response,Breast Cancer,Trastuzumab
1723,V773L,D,Sensitivity/Response,Breast Cancer,Lapatinib
1724,K753E,D,Resistance,Breast Cancer,Lapatinib
1725,L753E,B,Resistance,Breast Cancer,Trastuzumab
1726,K755S,B,Resistance,Breast Cancer,Trastuzumab
1727,Amplification,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Dovitinib
1728,V559D,C,Sensitivity/Response,Gastrointestinal Stromal Tumor,Imatinib
1729,V559D,D,Sensitivity/Response,Cancer,Dasatinib+Sunitinib+PD-180970+Tandutinib+Imatinib
1730,V559,D,Sensitivity/Response,Gastrointestinal System Cancer,Imatinib+Dasatinib
1731,D835V,D,Sensitivity/Response,Acute Myeloid Leukemia,JQ-1
1732,V559D,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Nilotinib+Sorafenib+Dasatinib+Imatinib
1733,D835V,D,Sensitivity/Response,Acute Myeloid Leukemia,AS602868+Tyrphostin AG 1296
1734,G13V,B,Resistance,Head And Neck Squamous Cell Carcinoma,Cetuximab
1735,L3 Domain Mutation,B,Resistance,Breast Cancer,Tamoxifen
1736,Overexpression,D,Sensitivity/Response,Uveal Melanoma,Mitogen-Activated Protein Kinase Kinase Inhibitor+C-Met Inhibitor+ERBB3 Inhibitor
1737,Overexpression,D,Resistance,Uveal Melanoma,Selumetinib+Trametinib
1738,E17K,B,Sensitivity/Response,Cancer,Capivasertib
1739,Mutation,B,Sensitivity/Response,Cancer,Capivasertib
1740,R248Q,D,Resistance,Cancer,MDM2 Inhibitor AMGMDS3
1741,R201H,C,Sensitivity/Response,Thyroid Gland Follicular Carcinoma,Radioactive Iodine
1742,MUTATION,B,Sensitivity/Response,Uveal Melanoma,Cabozantinib
1743,Overexpression,D,Resistance,Uveal Melanoma,Selumetinib+Trametinib
1744,EXPRESSION,D,Sensitivity/Response,Melanoma,Pertuzumab
1745,NON-AMPLIFICATION,B,Sensitivity/Response,Her2-receptor Negative Breast Cancer,Lapatinib
1746,Overexpression,B,Sensitivity/Response,Breast Cancer,Lapatinib
1747,Q61H,C,Resistance,Colorectal Cancer,Cetuximab+Irinotecan
1748,G12D,D,Resistance,Colorectal Cancer,Cetuximab
1749,G12D,D,Resistance,Colorectal Cancer,Cetuximab
1750,G12D,B,Resistance,Colorectal Cancer,Cetuximab
1751,C634W,D,Resistance,Thyroid Gland Medullary Carcinoma,Axitinib
1752,C634W,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Regorafenib
1753,M918T,D,Resistance,Thyroid Gland Medullary Carcinoma,Axitinib
1754,G12D,D,Resistance,Head And Neck Cancer,Erlotinib
1755,G12D,C,Resistance,Skin Squamous Cell Carcinoma,Vemurafenib
1756,G12A,C,Resistance,Colorectal Cancer,Cetuximab
1757,G12A,C,Resistance,Colorectal Cancer,Cetuximab
1758,G12A,C,Resistance,Colorectal Cancer,Cetuximab
1759,G12A,C,Resistance,Colorectal Cancer,Cetuximab
1760,Mutation,B,Resistance,Colorectal Cancer,Chemotherapy+Cetuximab
1761,G12A,C,Resistance,Colorectal Cancer,Cetuximab
1762,G12A,C,Resistance,Colorectal Cancer,Cetuximab
1763,G12A,C,Resistance,Colorectal Cancer,Cetuximab
1764,G12A,C,Resistance,Colorectal Cancer,Cetuximab
1765,G12A,C,Resistance,Colorectal Cancer,Cetuximab
1766,G12A,D,Resistance,Colorectal Cancer,Regorafenib
1767,G12A,D,Resistance,Colorectal Cancer,Sunitinib
1768,G12A,C,Resistance,Lung Cancer,Erlotinib
1769,Mutation,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib+Teprotumumab
1770,G12A,C,Resistance,Lung Non-small Cell Carcinoma,Erlotinib
1771,G12A,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Regorafenib
1772,G12A,C,Resistance,Colon Cancer,Cetuximab
1773,R132,B,Sensitivity/Response,Glioblastoma,Cetuximab
1774,E545K,D,Resistance,Melanoma,Vemurafenib
1775,E545G,D,Resistance,Melanoma,Vemurafenib
1776,H1047R,D,Resistance,Colorectal Cancer,Vemurafenib
1777,W535L,D,Resistance,Basal Cell Carcinoma,Vismodegib
1778,W535L,C,Resistance,Basal Cell Carcinoma,Vismodegib
1779,V600E,B,Resistance,Colorectal Cancer,Cetuximab
1780,V600E,C,Resistance,Colorectal Cancer,Irinotecan+Cetuximab
1781,V600E,B,Resistance,Colorectal Cancer,Cetuximab+FOLFOX-4 Regimen
1782,V600E,C,Resistance,Colorectal Cancer,Cetuximab
1783,V600E,D,Sensitivity/Response,Colorectal Cancer,Vemurafenib
1784,V600E,C,Sensitivity/Response,Colorectal Cancer,Vemurafenib
1785,V600E,C,Sensitivity/Response,Thyroid Gland Anaplastic Carcinoma,Vemurafenib+Radiation Therapy
1786,V600E,C,Sensitivity/Response,Thyroid Gland Anaplastic Carcinoma,Vemurafenib
1787,V600E,D,Sensitivity/Response,Melanoma,Vemurafenib
1788,V600E,D,Sensitivity/Response,Melanoma,Vemurafenib
1789,V600E,D,Sensitivity/Response,Melanoma,Vemurafenib
1790,V600E,D,Sensitivity/Response,Melanoma,Vemurafenib
1791,V600E,C,Sensitivity/Response,Melanoma,Vemurafenib
1792,V600E,B,Sensitivity/Response,Melanoma,Vemurafenib
1793,V600E,D,Sensitivity/Response,Melanoma,Vemurafenib
1794,V600E,D,Sensitivity/Response,Melanoma,Vemurafenib
1795,V600E,D,Sensitivity/Response,Melanoma,Vemurafenib
1796,V600E,C,Sensitivity/Response,Melanoma,Vemurafenib
1797,V600E,B,Sensitivity/Response,Melanoma,Vemurafenib
1798,V600E,D,Sensitivity/Response,Melanoma,Vemurafenib
1799,V600E,B,Sensitivity/Response,Melanoma,Vemurafenib
1800,V600E,B,Sensitivity/Response,Skin Melanoma,Trametinib+Dabrafenib
1801,V600E,D,Resistance,Melanoma,Dasatinib
1802,V600E,D,Sensitivity/Response,Thyroid Gland Cancer,Vemurafenib
1803,V600E,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Vemurafenib
1804,V600E,D,Sensitivity/Response,High Grade Glioma,Vemurafenib
1805,V600E,B,Sensitivity/Response,High Grade Glioma,Vemurafenib
1806,V600E,B,Sensitivity/Response,High Grade Glioma,Vemurafenib
1807,V600E,B,Sensitivity/Response,High Grade Glioma,Vemurafenib
1808,V600E,C,Sensitivity/Response,Hairy Cell Leukemia,Vemurafenib
1809,V600E,C,Sensitivity/Response,Hairy Cell Leukemia,Vemurafenib
1810,V600E,C,Sensitivity/Response,Hairy Cell Leukemia,Vemurafenib
1811,V600E,C,Sensitivity/Response,Hairy Cell Leukemia,Vemurafenib
1812,V600E,C,Sensitivity/Response,Hairy Cell Leukemia,Vemurafenib
1813,V600E,C,Sensitivity/Response,Glioblastoma,Vemurafenib
1814,V600E,C,Sensitivity/Response,Pilocytic Astrocytoma,Vemurafenib
1815,V600E,C,Sensitivity/Response,Thyroid Gland Papillary Carcinoma,Vemurafenib
1816,V600E,C,Sensitivity/Response,Thyroid Gland Papillary Carcinoma,Vemurafenib
1817,V600E,D,Sensitivity/Response,Thyroid Gland Papillary Carcinoma,Dasatinib
1818,V600E,D,Sensitivity/Response,Colon Cancer,Regorafenib
1819,V600E,C,Sensitivity/Response,Childhood Pilocytic Astrocytoma,Vemurafenib
1820,V600E,C,Sensitivity/Response,Ganglioglioma,Vemurafenib
1821,V600E,C,Sensitivity/Response,Clear Cell Sarcoma,Vemurafenib
1822,V600E,C,Sensitivity/Response,Lung Adenocarcinoma,Vemurafenib
1823,V600E,C,Sensitivity/Response,Lung Adenocarcinoma,Vemurafenib
1824,V600E,B,Sensitivity/Response,Lung Adenocarcinoma,Vemurafenib
1825,V600E,C,Sensitivity/Response,Lung Adenocarcinoma,Vemurafenib
1826,V600E,D,Sensitivity/Response,Thyroid Gland Carcinoma,Vemurafenib
1827,V600E,D,Sensitivity/Response,Thyroid Gland Carcinoma,Vemurafenib
1828,V600E,C,Sensitivity/Response,Pleomorphic Xanthoastrocytoma,Vemurafenib
1829,V600E,C,Sensitivity/Response,Ovarian Serous Carcinoma,Vemurafenib
1830,V600E,C,Sensitivity/Response,Malignant Peripheral Nerve Sheath Tumor,Vemurafenib
1831,V600E,C,Sensitivity/Response,Histiocytoma,Vemurafenib
1832,V600E,C,Sensitivity/Response,Malignant Conjunctival Melanoma,Vemurafenib
1833,Ex19 del L858R,B,Sensitivity/Response,Lung Adenocarcinoma,Erlotinib
1834,E709_T710>D,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
1835,Mutation,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib
1836,L747_S752del,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib
1837,Overexpression,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib
1838,L747_S752del,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib
1839,T790M,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib
1840,L861Q,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
1841,S752_I759delSPKANKEI,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib
1842,T790M,C,Resistance,Lung Adenocarcinoma,Erlotinib
1843,T790M,C,Resistance,Lung Non-small Cell Carcinoma,Erlotinib
1844,T790M,D,Resistance,Lung Non-small Cell Carcinoma,Erlotinib
1845,T790M,D,Resistance,Lung Non-small Cell Carcinoma,Erlotinib
1846,T790M,D,Resistance,Cancer,Multikinase Inhibitor AEE788+Erlotinib+Gefitinib
1847,L858R,D,Sensitivity/Response,Cancer,Multikinase Inhibitor AEE788+Erlotinib+Gefitinib
1848,E884K,C,Resistance,Lung Adenocarcinoma,Erlotinib
1849,BCR-ABL F359V,D,Sensitivity/Response,Chronic Myeloid Leukemia,Bosutinib
1850,BCR-ABL F359V,C,Reduced Sensitivity,Chronic Myeloid Leukemia,Dasatinib
1851,BCR-ABL F359V,C,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
1852,BCR-ABL F359V,C,Resistance,Chronic Myeloid Leukemia,Dasatinib
1853,BCR-ABL F359V,D,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
1854,Q61H,C,Resistance,Colorectal Cancer,Cetuximab
1855,G12V,C,Resistance,Colorectal Cancer,Panitumumab
1856,Q61L,D,Resistance,Melanoma,Vemurafenib
1857,V600E,C,Resistance,Colorectal Cancer,Panitumumab
1858,Q61R,D,Resistance,Colorectal Cancer,Cetuximab
1859,Q61R,D,Resistance,Skin Melanoma,Vemurafenib
1860,Q61R,D,Resistance,Thyroid Gland Carcinoma,Vemurafenib
1861,Q61K,B,Resistance,Colorectal Cancer,Cetuximab
1862,Q61K,D,Resistance,Colorectal Cancer,Cetuximab
1863,Q61K,D,Resistance,Melanoma,Vemurafenib
1864,Q61K,D,Resistance,Melanoma,Vemurafenib
1865,Q61K,D,Resistance,Skin Melanoma,Vemurafenib
1866,Q61K,D,Resistance,Lung Non-small Cell Carcinoma,Erlotinib
1867,G13D,D,Resistance,Colorectal Cancer,Cetuximab
1868,H1047R,C,Resistance,Colorectal Cancer,Cetuximab+Irinotecan
1869,G13R,C,Resistance,Colorectal Cancer,Panitumumab
1870,G13R,C,Resistance,Melanoma,Vemurafenib
1871,G12C,C,Resistance,Colorectal Cancer,Cetuximab+Chemotherapy
1872,G12C,D,Resistance,Colorectal Cancer,Cetuximab
1873,G1049R,C,Resistance,Colorectal Cancer,Cetuximab
1874,Q61L,C,Resistance,Skin Squamous Cell Carcinoma,Vemurafenib
1875,Q61R,C,Resistance,Skin Squamous Cell Carcinoma,Vemurafenib
1876,Q61K,C,Resistance,Skin Squamous Cell Carcinoma,Vemurafenib
1877,G13D,C,Resistance,Skin Squamous Cell Carcinoma,Vemurafenib
1878,G13D,D,Resistance,Colorectal Cancer,Cetuximab
1879,G13R,D,Resistance,Thyroid Gland Carcinoma,Vemurafenib
1880,G12V,D,Resistance,Head And Neck Cancer,Erlotinib
1881,G12V,D,Resistance,Colorectal Cancer,Cetuximab
1882,A146P,C,Resistance,Colorectal Cancer,Cetuximab
1883,A146T,C,Resistance,Colorectal Cancer,Cetuximab
1884,A146T,B,Resistance,Colorectal Cancer,Cetuximab+FOLFOX-4 Regimen
1885,A146T,C,Resistance,Colorectal Cancer,Cetuximab
1886,Q61H,C,Resistance,Colorectal Cancer,Cetuximab
1887,Q61H,C,Resistance,Colorectal Cancer,Cetuximab+Chemotherapy
1888,Q61H,C,Resistance,Colorectal Cancer,Cetuximab
1889,Q61H,C,Resistance,Colorectal Cancer,Cetuximab
1890,Mutation,B,Sensitivity/Response,Lung Cancer,Erlotinib
1891,Q61H,D,Resistance,Lung Non-small Cell Carcinoma,Vemurafenib
1892,Q61L,C,Resistance,Colorectal Cancer,Cetuximab
1893,Q61L,C,Resistance,Colorectal Cancer,Cetuximab+Chemotherapy
1894,Q61L,C,Resistance,Colorectal Cancer,Cetuximab
1895,Q61R,C,Resistance,Colorectal Cancer,Cetuximab
1896,Q61R,C,Resistance,Colorectal Cancer,Cetuximab+Irinotecan
1897,Q61K,C,Resistance,Colorectal Cancer,Cetuximab
1898,Q61K,C,Resistance,Colorectal Cancer,Chemotherapy+Cetuximab
1899,G13D,C,Resistance,Colorectal Cancer,Cetuximab
1900,G13D,C,Resistance,Colorectal Cancer,Cetuximab
1901,G13D,C,Resistance,Colorectal Cancer,Cetuximab
1902,G13D,C,Resistance,Colorectal Cancer,Cetuximab
1903,G13D,D,Resistance,Colorectal Cancer,Cetuximab
1904,G13D,B,Resistance,Colorectal Cancer,Cetuximab
1905,G13D,C,Resistance,Colorectal Cancer,Cetuximab
1906,G13D,B,Resistance,Colorectal Cancer,Cetuximab
1907,G13D,B,Resistance,Colorectal Cancer,Cetuximab
1908,G13D,C,Resistance,Colorectal Cancer,Cetuximab
1909,G13D,B,Resistance,Colorectal Cancer,Cetuximab
1910,G13D,C,Resistance,Colorectal Cancer,Cetuximab
1911,G13D,C,Resistance,Colorectal Cancer,Cetuximab
1912,G13D,C,Resistance,Colorectal Cancer,Cetuximab
1913,G13D,C,Resistance,Colorectal Cancer,Cetuximab
1914,G13D,D,Resistance,Colorectal Cancer,Regorafenib
1915,G13D,D,Resistance,Colorectal Cancer,Sunitinib
1916,G13D,D,Sensitivity/Response,Colorectal Cancer,Palbociclib
1917,G13D,C,Resistance,Lung Non-small Cell Carcinoma,Erlotinib
1918,G13D,C,Resistance,Lung Non-small Cell Carcinoma,Erlotinib
1919,Mutation,B,Resistance,Lung Non-small Cell Carcinoma,Erlotinib
1920,G13D,C,Resistance,Colon Cancer,Cetuximab
1921,G13D,D,Sensitivity/Response,Colon Cancer,Regorafenib
1922,G13C,C,Resistance,Colorectal Cancer,Cetuximab
1923,G13C,C,Resistance,Colorectal Cancer,Cetuximab
1924,G13C,C,Resistance,Lung Non-small Cell Carcinoma,Erlotinib
1925,G13C,C,Resistance,Lung Non-small Cell Carcinoma,Erlotinib
1926,G13R,C,Resistance,Colorectal Cancer,Cetuximab
1927,G13R,C,Resistance,Colorectal Cancer,Cetuximab
1928,G13S,C,Resistance,Colorectal Cancer,Cetuximab
1929,G13S,C,Resistance,Colorectal Cancer,Cetuximab
1930,G12V,C,Resistance,Colorectal Cancer,Cetuximab
1931,G12V,C,Resistance,Colorectal Cancer,Cetuximab
1932,G12V,C,Resistance,Colorectal Cancer,Cetuximab
1933,G12V,C,Resistance,Colorectal Cancer,Cetuximab
1934,G12V,B,Resistance,Colorectal Cancer,Cetuximab
1935,Q61,B,Resistance,Colorectal Cancer,Chemotherapy+Cetuximab
1936,G12V,C,Resistance,Colorectal Cancer,Cetuximab
1937,G12V,B,Resistance,Colorectal Cancer,Cetuximab
1938,G12V,C,Resistance,Colorectal Cancer,Cetuximab
1939,G12V,C,Resistance,Colorectal Cancer,Cetuximab
1940,G12V,C,Resistance,Colorectal Cancer,Cetuximab
1941,G12V,C,Resistance,Colorectal Cancer,Cetuximab
1942,G12V,D,Resistance,Colorectal Cancer,Regorafenib
1943,G12V,D,Resistance,Colorectal Cancer,Sunitinib
1944,G12V,D,Sensitivity/Response,Colorectal Cancer,Palbociclib
1945,G12V,C,Resistance,Lung Non-small Cell Carcinoma,Erlotinib
1946,G12V,C,Resistance,Lung Non-small Cell Carcinoma,Erlotinib
1947,G12V,C,Resistance,Colon Cancer,Cetuximab
1948,G12V,D,Sensitivity/Response,Colon Cancer,Regorafenib
1949,G12D,C,Resistance,Colorectal Cancer,Cetuximab
1950,G12D,C,Resistance,Colorectal Cancer,Cetuximab
1951,G12D,C,Resistance,Colorectal Cancer,Cetuximab
1952,G12D,C,Resistance,Colorectal Cancer,Cetuximab
1953,G12D,B,Resistance,Colorectal Cancer,Cetuximab
1954,G12D,C,Resistance,Colorectal Cancer,Cetuximab
1955,G12D,C,Resistance,Colorectal Cancer,Cetuximab
1956,G12D,C,Resistance,Colorectal Cancer,Cetuximab
1957,G12D,C,Resistance,Colorectal Cancer,Cetuximab
1958,G12D,C,Resistance,Colorectal Cancer,Cetuximab
1959,G12D,C,Resistance,Colorectal Cancer,Cetuximab
1960,G12D,D,Resistance,Colorectal Cancer,Regorafenib
1961,G12D,C,Resistance,Colorectal Cancer,Regorafenib
1962,G12D,D,Resistance,Colorectal Cancer,Sunitinib
1963,G12D,C,Resistance,Lung Cancer,Erlotinib
1964,G12D,B,Resistance,Lung Cancer,Erlotinib
1965,G12D,B,Resistance,Lung Cancer,Erlotinib
1966,G12D,B,Resistance,Lung Cancer,Erlotinib
1967,G12D,B,Resistance,Lung Cancer,Erlotinib
1968,G12D,C,Resistance,Lung Non-small Cell Carcinoma,Erlotinib
1969,G12D,D,Resistance,Melanoma,Vemurafenib
1970,G12D,D,Resistance,Ovarian Cancer,Cetuximab
1971,G12D,D,Resistance,Pancreatic Cancer,Vemurafenib
1972,G12D,C,Resistance,Colon Cancer,Cetuximab
1973,G12D,C,Resistance,Skin Squamous Cell Carcinoma,Vemurafenib
1974,G12C,C,Resistance,Colorectal Cancer,Cetuximab
1975,G12C,C,Resistance,Colorectal Cancer,Cetuximab
1976,G12C,C,Resistance,Colorectal Cancer,Cetuximab
1977,G12C,C,Resistance,Colorectal Cancer,Cetuximab
1978,G12C,B,Resistance,Colorectal Cancer,Cetuximab+Chemotherapy
1979,G12C,C,Resistance,Colorectal Cancer,Cetuximab
1980,G12C,C,Resistance,Colorectal Cancer,Cetuximab
1981,G12C,C,Resistance,Colorectal Cancer,Cetuximab
1982,G12C,C,Resistance,Colorectal Cancer,Cetuximab
1983,G12C,C,Resistance,Colorectal Cancer,Cetuximab
1984,G12C,D,Resistance,Colorectal Cancer,Regorafenib
1985,G12C,D,Resistance,Colorectal Cancer,Sunitinib
1986,G12C,D,Sensitivity/Response,Colorectal Cancer,Palbociclib
1987,G12C,C,Resistance,Lung Non-small Cell Carcinoma,Erlotinib
1988,G12C,C,Resistance,Lung Non-small Cell Carcinoma,Erlotinib
1989,G12C,C,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
1990,G12C,C,Resistance,Colon Cancer,Cetuximab
1991,G12C,C,Resistance,Skin Squamous Cell Carcinoma,Vemurafenib
1992,G12C,C,Resistance,Lung Adenocarcinoma,Crizotinib
1993,G12R,C,Resistance,Colorectal Cancer,Cetuximab
1994,G12R,C,Resistance,Colorectal Cancer,Cetuximab
1995,G12R,C,Resistance,Colorectal Cancer,Chemotherapy+Cetuximab
1996,G12R,C,Resistance,Colorectal Cancer,Cetuximab
1997,G12R,D,Resistance,Colorectal Cancer,Cetuximab
1998,G12R,C,Resistance,Colorectal Cancer,Cetuximab
1999,G12R,D,Resistance,Colorectal Cancer,Regorafenib
2000,G12R,D,Resistance,Colorectal Cancer,Sunitinib
2001,G12R,C,Resistance,Lung Non-small Cell Carcinoma,Erlotinib
2002,G12R,C,Resistance,Lung Non-small Cell Carcinoma,Erlotinib
2003,G12R,D,Sensitivity/Response,Thyroid Gland Cancer,Dasatinib
2004,G12R,C,Resistance,Colon Cancer,Cetuximab
2005,G12R,D,Resistance,Thyroid Gland Carcinoma,Vemurafenib
2006,G12S,C,Resistance,Colorectal Cancer,Cetuximab
2007,G12S,C,Resistance,Colorectal Cancer,Cetuximab
2008,G12S,C,Resistance,Colorectal Cancer,Cetuximab
2009,G12S,C,Resistance,Colorectal Cancer,Cetuximab
2010,G12S,B,Resistance,Colorectal Cancer,Cetuximab
2011,G12S,B,Resistance,Colorectal Cancer,Cetuximab
2012,G12S,C,Resistance,Colorectal Cancer,Cetuximab
2013,G12S,C,Resistance,Colorectal Cancer,Cetuximab
2014,G12S,C,Resistance,Colorectal Cancer,Cetuximab
2015,G12S,C,Resistance,Colorectal Cancer,Cetuximab
2016,G12S,C,Resistance,Colorectal Cancer,Cetuximab
2017,G12S,D,Resistance,Colorectal Cancer,Regorafenib
2018,G12S,C,Resistance,Lung Non-small Cell Carcinoma,Erlotinib
2019,G12S,D,Resistance,Colorectal Cancer,Sunitinib
2020,G12S,C,Resistance,Lung Non-small Cell Carcinoma,Erlotinib
2021,G12S,D,Resistance,Lung Non-small Cell Carcinoma,Erlotinib
2022,G12S,D,Resistance,Lung Non-small Cell Carcinoma,Vemurafenib
2023,G12S,D,Resistance,Lung Squamous Cell Carcinoma,Dasatinib
2024,D835E,C,Sensitivity/Response,Acute Myeloid Leukemia,Sunitinib
2025,D835V,C,Sensitivity/Response,Acute Myeloid Leukemia,Sunitinib
2026,D835V,D,Sensitivity/Response,Acute Myeloid Leukemia,Sunitinib
2027,D835,C,Sensitivity/Response,Acute Myeloid Leukemia,Sunitinib
2028,D835,C,Sensitivity/Response,Acute Myeloid Leukemia,Sunitinib
2029,D835,D,Sensitivity/Response,Acute Myeloid Leukemia,Sunitinib
2030,D835H,C,Sensitivity/Response,Acute Myeloid Leukemia,Sunitinib
2031,D835H,D,Sensitivity/Response,Acute Myeloid Leukemia,Sunitinib
2032,E17K,D,Resistance,Melanoma,Vemurafenib
2033,F57C,C,Sensitivity/Response,Melanoma,Vemurafenib
2034,R132,B,Sensitivity/Response,Glioblastoma,Cetuximab
2035,R132S,B,Sensitivity/Response,Glioblastoma,Cetuximab
2036,EML4-ALK L1196M,C,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
2037,EML4-ALK L1196M,C,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
2038,EML4-ALK L1196M,C,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
2039,EML4-ALK L1196M,D,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
2040,EML4-ALK L1196M,D,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
2041,EML4-ALK L1196M,D,Resistance,Lung Adenocarcinoma,Crizotinib
2042,EML4-ALK L1196M,C,Resistance,Lung Adenocarcinoma,Crizotinib
2043,F1174L,D,Resistance,Lung Large Cell Carcinoma,Crizotinib
2044,EML4-ALK C1156Y,C,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
2045,EML4-ALK C1156Y,D,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
2046,EML4-ALK C1156Y,D,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
2047,EML4-ALK C1156Y,D,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
2048,EML4-ALK C1156Y,C,Resistance,Lung Adenocarcinoma,Crizotinib
2049,N345K,C,Resistance,Colorectal Cancer,Cetuximab
2050,K650E,D,Resistance,Skin Melanoma,Vemurafenib
2051,D842V,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Dasatinib
2052,D842V,B,Resistance,Gastrointestinal Stromal Tumor,Sunitinib
2053,D842V,D,Resistance,Gastrointestinal Stromal Tumor,Sunitinib
2054,D842V,D,Resistance,Cancer,Sunitinib
2055,V560_L576DEL,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Regorafenib
2056,K550_K558del,C,Resistance,Gastrointestinal Stromal Tumor,Sunitinib
2057,K550_K558del,C,Resistance,Gastrointestinal Stromal Tumor,Sunitinib
2058,Y553_K558DEL,C,Resistance,Gastrointestinal Stromal Tumor,Sunitinib
2059,Y553_K558DEL,C,Resistance,Gastrointestinal Stromal Tumor,Sunitinib
2060,Exon 11 Mutation,B,Resistance,Gastrointestinal Stromal Tumor,Sunitinib
2061,DEL 554-558,C,Resistance,Gastrointestinal Stromal Tumor,Sunitinib
2062,W557G,C,Resistance,Gastrointestinal Stromal Tumor,Sunitinib
2063,W557_K558del,C,Resistance,Gastrointestinal Stromal Tumor,Sunitinib
2064,W557_K558del,D,Resistance,Gastrointestinal Stromal Tumor,Sunitinib
2065,W557_K558del,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Imatinib+Ponatinib
2066,W557_K558del,C,Resistance,Gastrointestinal Stromal Tumor,Sunitinib
2067,W557_K558del,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Sunitinib+Regorafenib
2068,W557_E561del,C,Resistance,Gastrointestinal Stromal Tumor,Sunitinib
2069,W557_E561del,C,Resistance,Gastrointestinal Stromal Tumor,Sunitinib
2070,K558_V559del,C,Resistance,Gastrointestinal Stromal Tumor,Sunitinib
2071,K558_V559del,C,Resistance,Gastrointestinal Stromal Tumor,Sunitinib
2072,V559DEL,C,Resistance,Gastrointestinal Stromal Tumor,Sunitinib
2073,Exon 9 Mutation,C,Reduced Sensitivity,Gastrointestinal Stromal Tumor,Regorafenib
2074,V559_V560DEL,C,Sensitivity/Response,Gastrointestinal Stromal Tumor,Sunitinib
2075,V559_V560DEL,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Sunitinib
2076,V559D,D,Sensitivity/Response,Melanoma,Dasatinib
2077,V559D,C,Resistance,Gastrointestinal Stromal Tumor,Sunitinib
2078,V559D,D,Resistance,Gastrointestinal Stromal Tumor,Sunitinib
2079,V559D,C,Resistance,Gastrointestinal Stromal Tumor,Sunitinib
2080,V559D,D,Sensitivity/Response,Solid Tumor,Dasatinib
2081,V559G,C,Sensitivity/Response,Thymus Squamous Cell Carcinoma,Sunitinib
2082,V560DEL,C,Resistance,Gastrointestinal Stromal Tumor,Sunitinib
2083,V560DEL,C,Resistance,Gastrointestinal Stromal Tumor,Sunitinib
2084,V560D,C,Resistance,Gastrointestinal Stromal Tumor,Sunitinib
2085,V560D,C,Sensitivity/Response,Gastrointestinal Stromal Tumor,Sunitinib
2086,V560D,C,Sensitivity/Response,Gastrointestinal Stromal Tumor,Sunitinib
2087,P551_E554delPMYE,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Ponatinib
2088,V560D,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Imatinib+Ponatinib+Regorafenib+Sunitinib
2089,V560G,C,Resistance,Gastrointestinal Stromal Tumor,Sunitinib
2090,V560G,C,Resistance,Gastrointestinal Stromal Tumor,Sunitinib
2091,V560G,D,Sensitivity/Response,Chronic Myeloid Leukemia,Bosutinib
2092,V560G,D,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2093,L576P,C,Resistance,Gastrointestinal Stromal Tumor,Sunitinib
2094,L576P,C,Resistance,Gastrointestinal Stromal Tumor,Sunitinib
2095,Exon 9 Mutation,B,Reduced Sensitivity,Gastrointestinal Stromal Tumor,Regorafenib
2096,L576P,D,Sensitivity/Response,Cancer,Imatinib+Dasatinib
2097,D579del,C,Resistance,Gastrointestinal Stromal Tumor,Sunitinib
2098,D579del,C,Resistance,Gastrointestinal Stromal Tumor,Sunitinib
2099,WILDTYPE,B,Sensitivity/Response,Gastrointestinal Stromal Tumor,Regorafenib
2100,K642E,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Sunitinib
2101,K642E,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Regorafenib
2102,K642E,C,Sensitivity/Response,Melanoma,Dasatinib
2103,V654A,D,Resistance,Gastrointestinal Stromal Tumor,Regorafenib
2104,V654A,D,Sensitivity/Response,Chronic Myeloid Leukemia,Bosutinib
2105,V654A,D,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2106,D816H,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Sunitinib
2107,D816H,D,Resistance,Gastrointestinal Stromal Tumor,Regorafenib
2108,D816H,D,Sensitivity/Response,Chronic Myeloid Leukemia,Bosutinib
2109,D816H,D,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2110,D816Y,D,Resistance,Gastrointestinal Stromal Tumor,Sunitinib
2111,D816Y,D,Resistance,Gastrointestinal Stromal Tumor,Regorafenib
2112,D816G,D,Resistance,Gastrointestinal Stromal Tumor,Regorafenib
2113,D816G,C,Resistance,Lung Adenocarcinoma,Crizotinib
2114,D816V,C,Sensitivity/Response,Acute Myeloid Leukemia,Dasatinib
2115,D816V,D,Resistance,Gastrointestinal Stromal Tumor,Sunitinib
2116,D816V,D,Resistance,Chronic Myeloid Leukemia,Bosutinib
2117,D816V,D,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2118,D816V,D,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2119,D820A,D,Resistance,Gastrointestinal Stromal Tumor,Regorafenib
2120,D820G,D,Resistance,Gastrointestinal Stromal Tumor,Regorafenib
2121,N822K,D,Resistance,Gastrointestinal Stromal Tumor,Sunitinib
2122,N822K,D,Resistance,Gastrointestinal Stromal Tumor,Sunitinib
2123,N822K,D,Resistance,Gastrointestinal Stromal Tumor,Regorafenib
2124,V600R,C,Sensitivity/Response,Melanoma,Vemurafenib
2125,V600R,D,Sensitivity/Response,Melanoma,Vemurafenib
2126,V600R,C,Sensitivity/Response,Skin Melanoma,Vemurafenib
2127,V600K,D,Sensitivity/Response,Melanoma,Vemurafenib
2128,V600K,C,Sensitivity/Response,Melanoma,Vemurafenib
2129,V600K,C,Sensitivity/Response,Melanoma,Vemurafenib
2130,V600K,C,Sensitivity/Response,Melanoma,Vemurafenib
2131,V600K,B,Sensitivity/Response,Melanoma,Vemurafenib
2132,V600K,D,Sensitivity/Response,Melanoma,Vemurafenib
2133,V600K,C,Sensitivity/Response,Melanoma,Vemurafenib
2134,V600K,B,Sensitivity/Response,Melanoma,Vemurafenib
2135,V600K,B,Sensitivity/Response,Skin Melanoma,Trametinib+Dabrafenib
2136,G469A,C,Resistance,Colorectal Cancer,Cetuximab
2137,G469A,D,Resistance,Melanoma,Vemurafenib
2138,G469A,D,Resistance,Lung Non-small Cell Carcinoma,Erlotinib
2139,S768I,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib
2140,R108K,D,Sensitivity/Response,High Grade Glioma,Erlotinib
2141,T263P,D,Sensitivity/Response,High Grade Glioma,Erlotinib
2142,A289V,D,Sensitivity/Response,High Grade Glioma,Erlotinib
2143,G719,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib+Gefitinib
2144,G719S,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib
2145,G719S,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib
2146,G719S,C,Sensitivity/Response,Lung Adenocarcinoma,Erlotinib
2147,G719A,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
2148,G719A,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib
2149,G719A,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib
2150,G719A,C,Sensitivity/Response,Lung Adenocarcinoma,Erlotinib
2151,V742A,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib
2152,E746_A750del,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
2153,E746_A750del,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib
2154,Mutation,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib
2155,E746_A750del,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib
2156,E746_A750del,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib
2157,E746_A750del,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib
2158,E746_A750del,C,Sensitivity/Response,Lung Adenocarcinoma,Erlotinib
2159,E746_A750del,C,Sensitivity/Response,Lung Adenocarcinoma,Erlotinib
2160,E746_A750del,C,Sensitivity/Response,Lung Adenocarcinoma,Erlotinib
2161,E746_A750del,D,Sensitivity/Response,Hematologic Cancer,Erlotinib
2162,E746_T751>I,C,Sensitivity/Response,Lung Adenocarcinoma,Gefitinib
2163,G719D,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib+Gefitinib
2164,E746_T751>I,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib
2165,Expression,C,Sensitivity/Response,Lung Adenocarcinoma,Erlotinib
2166,E746_A750del,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib
2167,E746_A750del,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Cetuximab
2168,E746_T751delinsA,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib
2169,E746_T751delinsA,C,Sensitivity/Response,Lung Adenocarcinoma,Erlotinib
2170,V774A,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
2171,E746_S752>A,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib
2172,E746V,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib
2173,V834I,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
2174,L838P,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
2175,L858R,D,Sensitivity/Response,Cancer,Erlotinib
2176,L747_P753delinsS,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib
2177,L747_P753delinsS,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib
2178,L747_P753delinsS,C,Sensitivity/Response,Lung Adenocarcinoma,Erlotinib
2179,S768N,B,Resistance,Lung Non-small Cell Carcinoma,Erlotinib
2180,S768N,D,Resistance,Lung Non-small Cell Carcinoma,Erlotinib
2181,S768I,C,Resistance,Lung Adenocarcinoma,Erlotinib
2182,D770_N771insSVD,D,Resistance,Lung Non-small Cell Carcinoma,Erlotinib
2183,H773_V774insH,D,Resistance,Lung Non-small Cell Carcinoma,Erlotinib
2184,R831H,D,Sensitivity/Response,Malignant Mesothelioma,Erlotinib
2185,L838V,D,Resistance,Lung Non-small Cell Carcinoma,Erlotinib
2186,P848L,D,Resistance,Lung Non-small Cell Carcinoma,Erlotinib
2187,T854A,C,Resistance,Lung Adenocarcinoma,Erlotinib
2188,L858R,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib
2189,L858R,D,Sensitivity/Response,Cancer,Erlotinib
2190,L858R,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib
2191,L858R,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib
2192,L858R,C,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
2193,L858R,B,Sensitivity/Response,Lung Adenocarcinoma,Erlotinib
2194,L858R,D,Sensitivity/Response,Lung Adenocarcinoma,Erlotinib
2195,L858R,D,Sensitivity/Response,Lung Small Cell Carcinoma,Erlotinib
2196,L858R,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Osimertinib
2197,L858R,D,Sensitivity/Response,High Grade Glioma,Erlotinib
2198,A859T,D,Resistance,Lung Non-small Cell Carcinoma,Erlotinib
2199,A859T,C,Sensitivity/Response,Lung Adenocarcinoma,Erlotinib
2200,L861,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib+Erlotinib
2201,L861Q,D,Sensitivity/Response,High Grade Glioma,Erlotinib
2202,L861R,C,Resistance,Lung Adenocarcinoma,Crizotinib
2203,E868G,D,Sensitivity/Response,Malignant Mesothelioma,Erlotinib
2204,BCR-ABL M244V,C,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2205,BCR-ABL M244V,D,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2206,BCR-ABL L248V,D,Resistance,Chronic Myeloid Leukemia,Bosutinib
2207,BCR-ABL L248V,D,Resistance,Chronic Myeloid Leukemia,Axitinib
2208,BCR-ABL G250E,D,Resistance,Chronic Myeloid Leukemia,Bosutinib
2209,BCR-ABL G250E,C,Reduced Sensitivity,Chronic Myeloid Leukemia,Bosutinib
2210,BCR-ABL G250E,D,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2211,BCR-ABL G250E,C,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2212,BCR-ABL G250E,C,Reduced Sensitivity,Chronic Myeloid Leukemia,Dasatinib
2213,BCR-ABL G250E,D,Resistance,Chronic Myeloid Leukemia,Axitinib
2214,BCR-ABL G250E,D,Resistance,Chronic Myeloid Leukemia,Axitinib
2215,BCR-ABL Q252H,D,Resistance,Chronic Myeloid Leukemia,Dasatinib
2216,BCR-ABL Q252H,D,Resistance,Chronic Myeloid Leukemia,Axitinib
2217,BCR-ABL Q252H,D,Resistance,Chronic Myeloid Leukemia,Axitinib
2218,BCR-ABL Q252H,D,Sensitivity/Response,Chronic Myeloid Leukemia,Bosutinib
2219,BCR-ABL Q252H,D,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2220,BCR-ABL Q252H,D,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2221,BCR-ABL Y253H,D,Resistance,Chronic Myeloid Leukemia,Axitinib
2222,BCR-ABL Y253H,C,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2223,BCR-ABL Y253H,D,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2224,BCR-ABL Y253H,D,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2225,BCR-ABL Y253F,D,Sensitivity/Response,Chronic Myeloid Leukemia,Bosutinib
2226,BCR-ABL Y253F,D,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2227,BCR-ABL Y253F,D,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2228,BCR-ABL Y253F,C,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2229,BCR-ABL Y253F,D,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2230,BCR-ABL Y253F,D,Resistance,Chronic Myeloid Leukemia,Axitinib
2231,BCR-ABL E255K,D,Resistance,Chronic Myeloid Leukemia,Bosutinib
2232,BCR-ABL E255K,C,Resistance,Chronic Myeloid Leukemia,Bosutinib
2233,BCR-ABL E255K,D,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2234,BCR-ABL E255K,C,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2235,BCR-ABL E255K,C,Reduced Sensitivity,Chronic Myeloid Leukemia,Dasatinib
2236,BCR-ABL E255K,D,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2237,BCR-ABL E255K,D,Resistance,Chronic Myeloid Leukemia,Axitinib
2238,BCR-ABL D276G,D,Sensitivity/Response,Chronic Myeloid Leukemia,Bosutinib
2239,BCR-ABL D276G,D,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2240,BCR-ABL D276G,D,Resistance,Chronic Myeloid Leukemia,Axitinib
2241,BCR-ABL T315I,D,Resistance,Chronic Myeloid Leukemia,Bosutinib
2242,BCR-ABL T315I,C,Resistance,Chronic Myeloid Leukemia,Bosutinib
2243,BCR-ABL T315I,C,Resistance,Chronic Myeloid Leukemia,Bosutinib
2244,BCR-ABL T315I,B,Resistance,Chronic Myeloid Leukemia,Dasatinib
2245,BCR-ABL T315I,C,Resistance,Chronic Myeloid Leukemia,Dasatinib
2246,BCR-ABL T315I,D,Resistance,Chronic Myeloid Leukemia,Dasatinib
2247,BCR-ABL T315I,C,Resistance,Chronic Myeloid Leukemia,Dasatinib
2248,BCR-ABL T315I,C,Sensitivity/Response,Chronic Myeloid Leukemia,Axitinib
2249,BCR-ABL T315I,D,Sensitivity/Response,Chronic Myeloid Leukemia,Axitinib
2250,BCR-ABL T315I,D,Sensitivity/Response,Chronic Myeloid Leukemia,Axitinib
2251,BCR-ABL T315I,D,Sensitivity/Response,Chronic Myeloid Leukemia,Axitinib
2252,BCR-ABL T315I,C,Resistance,Chronic Myeloid Leukemia,Dasatinib
2253,BCR-ABL T315I,C,Resistance,Acute Lymphoblastic Leukemia,Dasatinib
2254,BCR-ABL T315I,C,Resistance,Acute Lymphoblastic Leukemia,Dasatinib
2255,BCR-ABL T315I,C,Resistance,Acute Lymphoblastic Leukemia,Dasatinib
2256,BCR-ABL T315I,D,Resistance,Acute Lymphoblastic Leukemia,Dasatinib
2257,BCR-ABL T315I,D,Resistance,Acute Lymphoblastic Leukemia,Dasatinib
2258,BCR-ABL F317L,D,Resistance,Chronic Myeloid Leukemia,Bosutinib
2259,BCR-ABL F317L,C,Reduced Sensitivity,Chronic Myeloid Leukemia,Bosutinib
2260,BCR-ABL F317L,D,Resistance,Chronic Myeloid Leukemia,Dasatinib
2261,BCR-ABL F317L,C,Resistance,Chronic Myeloid Leukemia,Dasatinib
2262,BCR-ABL F317L,C,Resistance,Chronic Myeloid Leukemia,Dasatinib
2263,BCR-ABL F317L,C,Resistance,Chronic Myeloid Leukemia,Dasatinib
2264,BCR-ABL M244V,C,Resistance,Acute Lymphoblastic Leukemia,Dasatinib
2265,BCR-ABL F317L,C,Resistance,Chronic Myeloid Leukemia,Dasatinib
2266,BCR-ABL F317L,C,Resistance,Chronic Myeloid Leukemia,Dasatinib
2267,BCR-ABL F317L,D,Resistance,Chronic Myeloid Leukemia,Axitinib
2268,BCR-ABL F317L,D,Resistance,Chronic Myeloid Leukemia,Axitinib
2269,BCR-ABL M351T,D,Sensitivity/Response,Chronic Myeloid Leukemia,Bosutinib
2270,BCR-ABL M351T,C,Sensitivity/Response,Chronic Myeloid Leukemia,Bosutinib
2271,BCR-ABL M351T,C,Reduced Sensitivity,Chronic Myeloid Leukemia,Bosutinib
2272,BCR-ABL M351T,D,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2273,BCR-ABL M351T,C,Reduced Sensitivity,Chronic Myeloid Leukemia,Dasatinib
2274,BCR-ABL M351T,D,Resistance,Chronic Myeloid Leukemia,Axitinib
2275,BCR-ABL E355G,C,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2276,BCR-ABL E355G,D,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2277,BCR-ABL L387M,D,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2278,BCR-ABL H396R,D,Sensitivity/Response,Chronic Myeloid Leukemia,Bosutinib
2279,BCR-ABL H396R,C,Resistance,Chronic Myeloid Leukemia,Bosutinib
2280,BCR-ABL H396R,D,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2281,BCR-ABL H396R,C,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2282,BCR-ABL H396R,D,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2283,BCR-ABL H396R,D,Resistance,Chronic Myeloid Leukemia,Axitinib
2284,G13V,C,Resistance,Skin Squamous Cell Carcinoma,Vemurafenib
2285,P278S,C,Resistance,Skin Squamous Cell Carcinoma,Vemurafenib
2286,FIP1L1-PDGFRA T674I,D,Resistance,"Myeloid And Lymphoid Neoplasms With Eosinophilia And Abnormalities Of PDGFRA, PDGFRB, And FGFR1",Dasatinib
2287,Q61P,C,Resistance,Colorectal Cancer,Cetuximab
2288,Q61E,C,Resistance,Colorectal Cancer,Cetuximab
2289,Q61FS,C,Resistance,Colorectal Cancer,Cetuximab
2290,K117N,D,Resistance,Clear Cell Sarcoma,Vemurafenib
2291,F595L,D,Resistance,Histiocytoma,Vemurafenib
2292,D473H,D,Resistance,Medulloblastoma,Vismodegib
2293,Y772_A775DUP,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Bosutinib
2294,G12A,B,Resistance,Colorectal Cancer,Cetuximab
2295,F1174C,D,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
2296,T1151M,D,Resistance,Lung Large Cell Carcinoma,Crizotinib
2297,H1047L,C,Resistance,Colorectal Cancer,Cetuximab+Irinotecan
2298,S438C,C,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2299,BCR-ABL,C,Sensitivity/Response,Acute Lymphoblastic Leukemia,Dasatinib
2300,E450G,C,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2301,BCR-ABL F486S,D,Resistance,Chronic Myeloid Leukemia,Dasatinib
2302,BCR-ABL F486S,C,Resistance,Chronic Myeloid Leukemia,Bosutinib
2303,BCR-ABL E255V,D,Resistance,Chronic Myeloid Leukemia,Axitinib
2304,BCR-ABL E255V,D,Resistance,Chronic Myeloid Leukemia,Axitinib
2305,BCR-ABL E255V,C,Reduced Sensitivity,Chronic Myeloid Leukemia,Bosutinib
2306,BCR-ABL E255V,D,Sensitivity/Response,Chronic Myeloid Leukemia,Bosutinib
2307,BCR-ABL E255V,D,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2308,BCR-ABL E255V,D,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2309,BCR-ABL E255V,D,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2310,V777L,D,Resistance,Colorectal Cancer,Cetuximab
2311,P551_E554delPMYE,C,Resistance,Gastrointestinal Stromal Tumor,Sunitinib
2312,P551_E554delPMYE,B,Resistance,Gastrointestinal Stromal Tumor,Sunitinib
2313,P551_E554delPMYE,C,Resistance,Gastrointestinal Stromal Tumor,Sunitinib
2314,V559D,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Ponatinib+Regorafenib+Imatinib
2315,W557_V559insC,C,Resistance,Gastrointestinal Stromal Tumor,Sunitinib
2316,W557_V559insC,C,Resistance,Gastrointestinal Stromal Tumor,Sunitinib
2317,S158L,C,Resistance,Colorectal Cancer,Cetuximab+Irinotecan
2318,G12V,D,Resistance,Colorectal Cancer,Cetuximab
2319,R93W,C,Resistance,Colorectal Cancer,Oxaliplatin+Fluorouracil+Cetuximab
2320,R776C,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib
2321,S784F,C,Resistance,Lung Non-small Cell Carcinoma,Erlotinib
2322,R505C,D,Resistance,Colorectal Cancer,Regorafenib
2323,R505H,D,Resistance,Colorectal Cancer,Regorafenib
2324,D594G,C,Resistance,Colorectal Cancer,Cetuximab+Irinotecan
2325,F1174V,C,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
2326,BCR-ABL E292V,C,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2327,L298V,C,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2328,BCR-ABL F311I,D,Resistance,Chronic Myeloid Leukemia,Axitinib
2329,BCR-ABL F311I,C,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2330,BCR-ABL F359C,C,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2331,BCR-ABL L364I,C,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2332,Q456*,D,Sensitivity/Response,Ovarian Clear Cell Carcinoma,Dasatinib
2333,V600D,D,Sensitivity/Response,Melanoma,Vemurafenib
2334,V600D,D,Sensitivity/Response,Melanoma,Vemurafenib
2335,S768_D770dup,C,Resistance,Lung Adenocarcinoma,Erlotinib
2336,D770_N771insNPG,D,Sensitivity/Response,Hematologic Cancer,Erlotinib
2337,D770_N771insNPG,D,Sensitivity/Response,Hematologic Cancer,Cetuximab
2338,H773_V774insNPH,C,Resistance,Lung Adenocarcinoma,Erlotinib
2339,D770_N771insGL,C,Resistance,Lung Adenocarcinoma,Erlotinib
2340,A864T,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib
2341,N826S,D,Resistance,Lung Non-small Cell Carcinoma,Erlotinib
2342,A763_Y764insFQEA,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib
2343,Q79K,D,Resistance,Melanoma,Vemurafenib
2344,G466A,C,Resistance,Colorectal Cancer,Cetuximab
2345,VIII,D,Sensitivity/Response,High Grade Glioma,Erlotinib
2346,S501_A502INSAY,B,Sensitivity/Response,Gastrointestinal Stromal Tumor,Sunitinib
2347,S501_A502INSAY,C,Sensitivity/Response,Gastrointestinal Stromal Tumor,Sunitinib
2348,S501_A502INSAY,C,Sensitivity/Response,Gastrointestinal Stromal Tumor,Sunitinib
2349,S501_A502INSAY,C,Sensitivity/Response,Gastrointestinal Stromal Tumor,Sunitinib
2350,A502_Y503insAY,D,Resistance,Cancer,Imatinib
2351,S501_A502INSAY,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Sunitinib
2352,S501_A502INSAY,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Sunitinib
2353,G13V,B,Resistance,Colorectal Cancer,Cetuximab
2354,T670I,D,Resistance,Solid Tumor,Dasatinib
2355,T670I,D,Resistance,Gastrointestinal Stromal Tumor,Regorafenib
2356,D842_M844del,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Dasatinib
2357,L861Q,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib
2358,S310F/Y,D,Resistance,Colorectal Cancer,Cetuximab
2359,L755S,D,Resistance,Colorectal Cancer,Cetuximab
2360,V842I,D,Resistance,Colorectal Cancer,Cetuximab
2361,E17K,D,Resistance,Melanoma,Vemurafenib
2362,Q2223K,D,Sensitivity/Response,Clear Cell Renal Cell Carcinoma,Temsirolimus
2363,W110*,D,Sensitivity/Response,Melanoma,Palbociclib
2364,A20P,D,Sensitivity/Response,Melanoma,Palbociclib
2365,BCR-ABL L384M,D,Sensitivity/Response,Chronic Myeloid Leukemia,Bosutinib
2366,BCR-ABL L384M,C,Resistance,Chronic Myeloid Leukemia,Dasatinib
2367,BCR-ABL L384M,D,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2368,BCR-ABL M343T,D,Resistance,Chronic Myeloid Leukemia,Axitinib
2369,BCR-ABL F317V,D,Resistance,Chronic Myeloid Leukemia,Axitinib
2370,BCR-ABL F317V,C,Resistance,Chronic Myeloid Leukemia,Dasatinib
2371,BCR-ABL V299L,D,Sensitivity/Response,Chronic Myeloid Leukemia,Axitinib
2372,BCR-ABL V299L,C,Reduced Sensitivity,Chronic Myeloid Leukemia,Bosutinib
2373,BCR-ABL V299L,D,Sensitivity/Response,Chronic Myeloid Leukemia,Bosutinib
2374,BCR-ABL V299L,C,Resistance,Chronic Myeloid Leukemia,Dasatinib
2375,BCR-ABL V299L,C,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2376,BCR-ABL E279K,D,Sensitivity/Response,Chronic Myeloid Leukemia,Bosutinib
2377,BCR-ABL E279K,D,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2378,BCR-ABL F311L,C,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2379,BCR-ABL F311L,D,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2380,BCR-ABL N331S,C,Sensitivity/Response,Chronic Myeloid Leukemia,Bosutinib
2381,BCR-ABL L387F,C,Resistance,Chronic Myeloid Leukemia,Bosutinib
2382,BCR-ABL L387F,C,Sensitivity/Response,Chronic Myeloid Leukemia,Bosutinib
2383,BCR-ABL H396P,D,Sensitivity/Response,Chronic Myeloid Leukemia,Bosutinib
2384,BCR-ABL H396P,C,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2385,BCR-ABL H396P,D,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2386,BCR-ABL H396P,D,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2387,BCR-ABL G398R,D,Sensitivity/Response,Chronic Myeloid Leukemia,Bosutinib
2388,BCR-ABL G398R,D,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2389,BCR-ABL I432T,C,Resistance,Chronic Myeloid Leukemia,Bosutinib
2390,BCR-ABL E450V,C,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2391,BCR-ABL E453K,C,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2392,F486Y,C,Resistance,Chronic Myeloid Leukemia,Bosutinib
2393,F486Y,D,Resistance,Chronic Myeloid Leukemia,Bosutinib
2394,BCR-ABL F486S,C,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2395,F486Y,D,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2396,W559_R560DELWR,C,Sensitivity/Response,Gastrointestinal Stromal Tumor,Sunitinib
2397,L579M,C,Sensitivity/Response,Gastrointestinal Stromal Tumor,Sunitinib
2398,Q556_I571DEL,C,Sensitivity/Response,Gastrointestinal Stromal Tumor,Sunitinib
2399,Y553_W557DELYEVQW,C,Sensitivity/Response,Gastrointestinal Stromal Tumor,Sunitinib
2400,V555_I571DEL,C,Sensitivity/Response,Gastrointestinal Stromal Tumor,Sunitinib
2401,E611_F612INS25,C,Sensitivity/Response,Acute Myeloid Leukemia,Sunitinib
2402,E611_F612INS25,D,Sensitivity/Response,Acute Myeloid Leukemia,Palbociclib
2403,K550_W557del,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Regorafenib+Ponatinib+Imatinib+Sunitinib
2404,T417_D419DELTYDINSI,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Sunitinib
2405,D579_H580insIDPTQLPYD,D,Resistance,Gastrointestinal Stromal Tumor,Sunitinib
2406,Y570_L576DEL,C,Resistance,Gastrointestinal Stromal Tumor,Sunitinib
2407,Y570_L576DEL,C,Resistance,Gastrointestinal Stromal Tumor,Sunitinib
2408,D820Y,C,Sensitivity/Response,Gastrointestinal Stromal Tumor,Regorafenib
2409,K558NP,C,Resistance,Gastrointestinal Stromal Tumor,Sunitinib
2410,K558NP,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Sunitinib+Regorafenib+Ponatinib+Imatinib
2411,N822K,C,Sensitivity/Response,Gastrointestinal Stromal Tumor,Regorafenib
2412,D842V,C,Resistance,Gastrointestinal Stromal Tumor,Sunitinib
2413,V560_L576DEL,C,Resistance,Gastrointestinal Stromal Tumor,Sunitinib
2414,Exon 11 Mutation,B,Sensitivity/Response,Gastrointestinal Stromal Tumor,Regorafenib
2415,V569_L576DEL,C,Resistance,Gastrointestinal Stromal Tumor,Sunitinib
2416,V569_L576DEL,B,Sensitivity/Response,Gastrointestinal Stromal Tumor,Sunitinib
2417,Exon 15 Mutation,C,Resistance,Gastrointestinal Stromal Tumor,Regorafenib
2418,E278E,C,Sensitivity/Response,Head And Neck Squamous Cell Carcinoma,Erlotinib
2419,EML4-ALK T1151INST,D,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
2420,L1196Q,D,Resistance,Anaplastic Large Cell Lymphoma,Crizotinib
2421,ALK Fusion I1171,C,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
2422,ALK Fusion I1171,D,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
2423,ALK Fusion I1171,D,Resistance,Anaplastic Large Cell Lymphoma,Crizotinib
2424,L1152P,D,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
2425,G2032R,C,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
2426,G2032R,D,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
2427,G2032R,D,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
2428,EML4-ALK G1269A,C,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
2429,EML4-ALK G1269A,C,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
2430,EML4-ALK G1269A,C,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
2431,EML4-ALK G1269A,C,Resistance,Lung Adenocarcinoma,Crizotinib
2432,EML4-ALK G1269A,D,Resistance,Lung Large Cell Carcinoma,Crizotinib
2433,EML4-ALK S1206Y,D,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
2434,W1815X,D,Sensitivity/Response,Endometrioid Ovary Carcinoma,Olaparib
2435,ALK Fusion G1202R,C,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
2436,ALK Fusion G1202R,D,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
2437,L1198P,D,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
2438,G776INSV_G/C,D,Resistance,Lung Non-small Cell Carcinoma,Erlotinib
2439,Exon 9 Mutation,B,Sensitivity/Response,Gastrointestinal Stromal Tumor,Regorafenib
2440,Exon 11 Mutation,B,Sensitivity/Response,Gastrointestinal Stromal Tumor,Regorafenib
2441,D816E,D,Resistance,Gastrointestinal Stromal Tumor,Imatinib+Sunitinib
2442,HIP1-ALK I1171N,D,Resistance,Anaplastic Large Cell Lymphoma,Crizotinib
2443,HIP1-ALK I1171N,C,Resistance,Lung Adenocarcinoma,Crizotinib
2444,D473G,C,Resistance,Basal Cell Carcinoma,Vismodegib
2445,D473Y,C,Resistance,Basal Cell Carcinoma,Vismodegib
2446,S278I,C,Resistance,Basal Cell Carcinoma,Vismodegib
2447,W281C,D,Resistance,Basal Cell Carcinoma,Vismodegib
2448,W281C,D,Resistance,Basal Cell Carcinoma,Vismodegib
2449,Q477E,D,Resistance,Basal Cell Carcinoma,Vismodegib
2450,D770_N771insSVD,D,Resistance,Lung Non-small Cell Carcinoma,Erlotinib
2451,E746_A750del,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib
2452,D770_N771insGT,C,Resistance,Lung Adenocarcinoma,Erlotinib
2453,V774_C775insHV,C,Resistance,Lung Adenocarcinoma,Erlotinib
2454,Exon 20 Insertion,C,Resistance,Lung Adenocarcinoma,Gefitinib
2455,A763_Y764insFQEA,C,Sensitivity/Response,Lung Adenocarcinoma,Erlotinib
2456,A763_Y764insFQEA,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib
2457,V769_770insASV,C,Resistance,Lung Adenocarcinoma,Gefitinib
2458,Exon 20 Insertion,C,Resistance,Lung Adenocarcinoma,Erlotinib
2459,D770_N771insNPG,D,Resistance,Lung Non-small Cell Carcinoma,Erlotinib
2460,L412F,D,Resistance,Basal Cell Carcinoma,Vismodegib
2461,L412F,D,Resistance,Basal Cell Carcinoma,Vismodegib
2462,L412F,C,Resistance,Basal Cell Carcinoma,Vismodegib
2463,W731L,D,Sensitivity/Response,Malignant Mesothelioma,Erlotinib
2464,E734Q,D,Sensitivity/Response,Malignant Mesothelioma,Erlotinib
2465,T785A,D,Sensitivity/Response,Malignant Mesothelioma,Erlotinib
2466,C797Y,D,Sensitivity/Response,Malignant Mesothelioma,Erlotinib
2467,Y801H,D,Sensitivity/Response,Malignant Mesothelioma,Erlotinib
2468,V321M,C,Resistance,Basal Cell Carcinoma,Vismodegib
2469,V321M,D,Resistance,Basal Cell Carcinoma,Vismodegib
2470,V321M,D,Resistance,Basal Cell Carcinoma,Vismodegib
2471,E709_T710>D,C,Sensitivity/Response,Lung Adenocarcinoma,Erlotinib
2472,V769A,C,Sensitivity/Response,Lung Adenocarcinoma,Erlotinib
2473,A767_V769dupASV,C,Resistance,Lung Adenocarcinoma,Erlotinib
2474,A767_V769dupASV,D,Resistance,Lung Non-small Cell Carcinoma,Erlotinib
2475,L747_S752delinsQ,C,Sensitivity/Response,Lung Adenocarcinoma,Erlotinib
2476,L861R,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
2477,N771>GY,C,Resistance,Lung Non-small Cell Carcinoma,Erlotinib
2478,P546S,D,Sensitivity/Response,Head And Neck Squamous Cell Carcinoma,Cetuximab
2479,L866M,D,Resistance,Colorectal Cancer,Cetuximab
2480,W281L,C,Resistance,Basal Cell Carcinoma,Vismodegib
2481,G497W,C,Resistance,Basal Cell Carcinoma,Vismodegib
2482,I408V,D,Resistance,Basal Cell Carcinoma,Vismodegib
2483,C469Y,D,Resistance,Basal Cell Carcinoma,Vismodegib
2484,T241M,D,Resistance,Basal Cell Carcinoma,Vismodegib
2485,A459V,D,Resistance,Basal Cell Carcinoma,Vismodegib
2486,S533N,D,Resistance,Basal Cell Carcinoma,Vismodegib
2487,W170X,C,Sensitivity/Response,Basal Cell Carcinoma,Vismodegib
2488,W712X,C,Sensitivity/Response,Basal Cell Carcinoma,Vismodegib
2489,Q787X,C,Sensitivity/Response,Basal Cell Carcinoma,Vismodegib
2490,Q17X,C,Sensitivity/Response,Basal Cell Carcinoma,Vismodegib
2491,Exon 11 Mutation,C,Resistance,Melanoma,Dasatinib
2492,H201L,C,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2493,Y232S,C,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2494,M237V,C,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2495,I242T,C,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2496,G250V,C,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2497,BCR-ABL Q252R,D,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2498,E258D,C,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2499,L273M,C,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2500,E281K,C,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2501,V289I,C,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2502,Y342H,C,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2503,D363Y,C,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2504,BCR-ABL A365V,C,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2505,BCR-ABL A366G,C,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2506,BCR-ABL V379I,C,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2507,BCR-ABL V379I,D,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2508,BCR-ABL,C,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2509,M388L,C,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2510,Y393C,C,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2511,BCR-ABL A397P,C,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2512,BCR-ABL S417Y,C,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2513,BCR-ABL S417Y,C,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2514,I418V,C,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2515,I418S,B,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2516,P441L,C,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2517,E450K,C,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2518,BCR-ABL E255K,C,Resistance,Acute Lymphoblastic Leukemia,Dasatinib
2519,E450A,C,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2520,E453V,C,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2521,E459G,C,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2522,E459G,C,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2523,M472I,C,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2524,P480L,C,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2525,G514S,C,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2526,BCR-ABL F317I,C,Resistance,Acute Lymphoblastic Leukemia,Dasatinib
2527,Q56P,C,Resistance,Melanoma,Vemurafenib
2528,E203K,C,Resistance,Melanoma,Vemurafenib
2529,R163X,C,Resistance,Melanoma,Vemurafenib
2530,Y591_V592INSVDFREYE,C,Sensitivity/Response,Acute Myeloid Leukemia,Sunitinib
2531,Y591_V592INSVDFREYE,C,Sensitivity/Response,Acute Myeloid Leukemia,Sunitinib
2532,Y591_V592INSVDFREYE,D,Sensitivity/Response,Acute Myeloid Leukemia,Sunitinib
2533,Y591_V592INSVDFREYE,D,Sensitivity/Response,Acute Myeloid Leukemia,Palbociclib
2534,E588_Y589INSKYFYVDFRE,C,Sensitivity/Response,Acute Myeloid Leukemia,Sunitinib
2535,E588_Y589INSKYFYVDFRE,C,Sensitivity/Response,Acute Myeloid Leukemia,Sunitinib
2536,E588_Y589INSKYFYVDFRE,D,Sensitivity/Response,Acute Myeloid Leukemia,Sunitinib
2537,E588_Y589INSKYFYVDFRE,D,Sensitivity/Response,Acute Myeloid Leukemia,Palbociclib
2538,V592_D593INSDFREY,C,Sensitivity/Response,Acute Myeloid Leukemia,Sunitinib
2539,V592_D593INSDFREY,C,Sensitivity/Response,Acute Myeloid Leukemia,Sunitinib
2540,V592_D593INSDFREY,D,Sensitivity/Response,Acute Myeloid Leukemia,Sunitinib
2541,V592_D593INSDFREY,D,Sensitivity/Response,Acute Myeloid Leukemia,Palbociclib
2542,E746_A750>IP,C,Sensitivity/Response,Lung Adenocarcinoma,Erlotinib
2543,RARE Exon 18-21 Mutation,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib+Gefitinib
2544,Ex19 del L858R,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib+Gefitinib
2545,K745_E749delKELRE,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib
2546,Exon 19 Deletion,C,Sensitivity/Response,Lung Adenocarcinoma,Erlotinib
2547,D2033N,C,Resistance,Lung Adenocarcinoma,Crizotinib
2548,Y956N,C,Sensitivity/Response,Lung Adenocarcinoma,Pembrolizumab
2549,Q225X,C,Sensitivity/Response,Lung Adenocarcinoma,Pembrolizumab
2550,P1460T,C,Sensitivity/Response,Lung Adenocarcinoma,Pembrolizumab
2551,Y1520X,C,Sensitivity/Response,Lung Adenocarcinoma,Pembrolizumab
2552,A59E,C,Sensitivity/Response,Lung Adenocarcinoma,Pembrolizumab
2553,C284Y,C,Sensitivity/Response,Lung Adenocarcinoma,Pembrolizumab
2554,E374K,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Pembrolizumab
2555,D1010Y,C,Sensitivity/Response,Lung Adenocarcinoma,Crizotinib
2556,G596V,C,Sensitivity/Response,Lung Adenocarcinoma,Vemurafenib
2557,D1010N,C,Sensitivity/Response,Lung Adenocarcinoma,Crizotinib
2558,D1010N,C,Sensitivity/Response,Lung Squamous Cell Carcinoma,Crizotinib
2559,L1198F,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Crizotinib
2560,N561D,D,Resistance,Melanoma,Vemurafenib
2561,D350G,D,Resistance,Melanoma,Vemurafenib
2562,Q179X,B,Resistance,Colorectal Cancer,Cetuximab
2563,EXON 14 SKIPPING MUTATION,C,Sensitivity/Response,Lung Adenocarcinoma,Crizotinib
2564,R351W,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Dasatinib
2565,G340L,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Dasatinib+Imatinib Mesylate
2566,V600_K601DELINSD,C,Sensitivity/Response,Skin Melanoma,Vemurafenib
2567,V600_K601DELINSD,C,Sensitivity/Response,Melanoma,Vemurafenib
2568,S628N,D,Sensitivity/Response,Cancer,Dasatinib+Imatinib
2569,D1010H,C,Sensitivity/Response,Lung Adenocarcinoma,Crizotinib
2570,D1010H,C,Sensitivity/Response,Lung Adenocarcinoma,Crizotinib
2571,EML4-ALK I1171S,D,Resistance,Lung Large Cell Carcinoma,Crizotinib
2572,R1192P,D,Resistance,Lung Large Cell Carcinoma,Crizotinib
2573,N771DELinsVH,C,Resistance,Lung Adenocarcinoma,Erlotinib
2574,E322K,D,Sensitivity/Response,Head And Neck Squamous Cell Carcinoma,Erlotinib
2575,DELNVTAP,D,Resistance,Pancreatic Cancer,Vemurafenib
2576,M766_A767insAI,D,Resistance,Lung Non-small Cell Carcinoma,Erlotinib
2577,Y764_V765insHH,D,Resistance,Lung Non-small Cell Carcinoma,Erlotinib
2578,D770delinsGY,C,Resistance,Lung Adenocarcinoma,Erlotinib
2579,P772_H773insYNP,C,Resistance,Lung Non-small Cell Carcinoma,Erlotinib
2580,Y508F,D,Sensitivity/Response,Chronic Myeloid Leukemia,Axitinib
2581,Y508F,D,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
2582,S1986Y,D,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
2583,S1986F,D,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
2584,Y69FS*11,D,Resistance,Esophagus Squamous Cell Carcinoma,Erlotinib
2585,G1109C,D,Resistance,Head And Neck Squamous Cell Carcinoma,Erlotinib
2586,E380Q,C,Sensitivity/Response,Breast Cancer,Palbociclib
2587,L536R,C,Sensitivity/Response,Breast Cancer,Palbociclib
2588,Y537C,C,Sensitivity/Response,Breast Cancer,Palbociclib
2589,D538G,C,Sensitivity/Response,Breast Cancer,Palbociclib
2590,S463P,C,Sensitivity/Response,Breast Cancer,Palbociclib
2591,Y537N,C,Sensitivity/Response,Breast Cancer,Palbociclib
2592,Y537N,B,Sensitivity/Response,Breast Cancer,Palbociclib
2593,Y537S,C,Sensitivity/Response,Breast Cancer,Palbociclib
2594,Y537S,B,Sensitivity/Response,Breast Cancer,Palbociclib
2595,S668FS*39,D,Resistance,Colorectal Cancer,Regorafenib
2596,L403FS*34,D,Resistance,Colorectal Cancer,Regorafenib
2597,G579W,D,Resistance,Colorectal Cancer,Regorafenib
2598,R658Q,D,Resistance,Colorectal Cancer,Regorafenib
2599,R391W,D,Resistance,Melanoma,Vemurafenib
2600,Splice Site (c.1641+2T>G),C,Resistance,Melanoma,Pembrolizumab
2601,P1175FS*5,D,Sensitivity/Response,Ovarian Clear Cell Carcinoma,Dasatinib
2602,R214H,C,Sensitivity/Response,Nasal Type Extranodal NK/T-cell Lymphoma,Crizotinib
2603,Loss-of-function,D,Sensitivity/Response,Renal Cell Carcinoma,Temsirolimus
2604,Loss-of-function,B,Resistance,Renal Cell Carcinoma,Anti-VEGF Monoclonal Antibody
2605,MUTATION,B,Resistance,Renal Cell Carcinoma,Anti-VEGF Monoclonal Antibody
2606,Mutation,D,Sensitivity/Response,Acute Myeloid Leukemia,Enasidenib
2607,AMPLIFICATION,D,Sensitivity/Response,Breast Cancer,Talazoparib
2608,Fusion,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Brigatinib
2609,T790M,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Panitumumab+Cetuximab+Brigatinib
2610,C797S,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Panitumumab+Cetuximab+Brigatinib
2611,Loss-of-function,B,Sensitivity/Response,Breast Cancer,Talazoparib
2612,Loss-of-function,B,Sensitivity/Response,Breast Cancer,Talazoparib
2613,Overexpression,B,Sensitivity/Response,Her2-receptor Positive Breast Cancer,Trastuzumab Emtansine
2614,AMPLIFICATION,B,Sensitivity/Response,Liposarcoma,Palbociclib
2615,Mutation,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Abemaciclib
2616,Fusion,B,Sensitivity/Response,Lung Adenocarcinoma,Cabozantinib
2617,Fusion,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Vandetanib
2618,Fusion,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Vandetanib
2619,Fusion,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Alectinib
2620,KIF5B-RET G810A,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Lenvatinib+Ponatinib
2621,Mutation,D,Sensitivity/Response,Thyroid Gland Carcinoma,Sapanisertib+NVP-AST487
2622,Expression,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Atezolizumab+Pembrolizumab+Nivolumab+Durvalumab+Avelumab
2623,Fusion,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Crizotinib+Alectinib
2624,Exon 19 Deletion,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib+Dacomitinib
2625,L858R,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Dacomitinib
2626,Fusion,C,Sensitivity/Response,Adrenal Carcinoma,Erdafitinib
2627,Mutation,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Pemetrexed+Trametinib+Docetaxel
2628,Mutation,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Nivolumab+Atezolizumab
2629,Mutation,E,Sensitivity/Response,Lung Non-small Cell Carcinoma,Immune Checkpoint Inhibitor
2630,Mutation,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Pembrolizumab
2631,Mutation,D,Sensitivity/Response,Colorectal Cancer,Binimetinib+Palbociclib
2632,G691R,D,Sensitivity/Response,Lung Adenocarcinoma,Infigratinib+PD173074
2633,S249C,D,Sensitivity/Response,Lung Adenocarcinoma,Infigratinib+PD173074
2634,EXPRESSION,D,Sensitivity/Response,Sarcoma,Palbociclib
2635,p16 Expression,D,Resistance,Sarcoma,Palbociclib
2636,Overexpression,D,Sensitivity/Response,Lung Small Cell Carcinoma,Olaparib+Cisplatin+Prexasertib
2637,Loss-of-function,B,Sensitivity/Response,Ovarian Cancer,Talazoparib
2638,Loss-of-function,B,Sensitivity/Response,Ovarian Cancer,Talazoparib
2639,Expression,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
2640,R248W,D,Resistance,Cancer,MDM2 Inhibitor AMGMDS3
2641,R175H,D,Resistance,Cancer,MDM2 Inhibitor AMGMDS3
2642,R273C,D,Resistance,Cancer,MDM2 Inhibitor AMGMDS3
2643,R273H,D,Resistance,Cancer,MDM2 Inhibitor AMGMDS3
2644,G245S,D,Resistance,Cancer,MDM2 Inhibitor AMGMDS3
2645,Y220C,D,Resistance,Cancer,MDM2 Inhibitor AMGMDS3
2646,M237I,D,Resistance,Glioblastoma,MDM2 Inhibitor AMGMDS3
2647,R158H,D,Resistance,Cancer,MDM2 Inhibitor AMGMDS3
2648,V157F,D,Resistance,Cancer,MDM2 Inhibitor AMGMDS3
2649,R249S,D,Resistance,Cancer,MDM2 Inhibitor AMGMDS3
2650,R280K,D,Resistance,Cancer,MDM2 Inhibitor AMGMDS3
2651,R280T,D,Resistance,Cancer,MDM2 Inhibitor AMGMDS3
2652,R158L,D,Resistance,Cancer,MDM2 Inhibitor AMGMDS3
2653,L597Q,C,Sensitivity/Response,Skin Melanoma,Trametinib
2654,Gain-of-function,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
2655,MUTATION,B,Sensitivity/Response,Uveal Melanoma,Cabozantinib
2656,Mutation,A,Sensitivity/Response,Acute Myeloid Leukemia,Enasidenib
2657,LOSS,D,Resistance,Pancreatic Cancer,Trametinib
2658,LOSS,D,Resistance,Lung Cancer,Trametinib
2659,LOSS,D,Resistance,Lung Cancer,Vemurafenib
2660,LOSS,D,Resistance,Colon Cancer,Trametinib
2661,LOSS,D,Resistance,Colon Cancer,Vemurafenib
2662,LOSS,D,Resistance,Melanoma,Trametinib
2663,LOSS,D,Resistance,Melanoma,Vemurafenib
2664,LOSS,D,Resistance,Pancreatic Cancer,Selumetinib
2665,LOSS,D,Resistance,Lung Cancer,Selumetinib
2666,Overexpression,D,Resistance,Pancreatic Cancer,Trametinib
2667,Overexpression,D,Resistance,Lung Cancer,Trametinib
2668,OVEREXPRESSION,D,Resistance,Pancreatic Cancer,Trametinib
2669,OVEREXPRESSION,D,Resistance,Pancreatic Cancer,Trametinib
2670,OVEREXPRESSION,D,Resistance,Lung Cancer,Trametinib
2671,OVEREXPRESSION,D,Resistance,Lung Cancer,Trametinib
2672,LOSS,D,Resistance,Pancreatic Cancer,Trametinib
2673,LOSS,B,Resistance,Melanoma,Dabrafenib+Vemurafenib
2674,LOSS,D,Sensitivity/Response,Lung Cancer,Trametinib
2675,F858L,D,Sensitivity/Response,Lung Cancer,Selumetinib
2676,Underexpression,B,Sensitivity/Response,Stomach Cancer,Olaparib+Paclitaxel
2677,Mutation,A,Sensitivity/Response,Acute Myeloid Leukemia,Midostaurin
2678,MUTATION,B,Sensitivity/Response,Renal Cell Carcinoma,Everolimus
2679,DELETION,D,Resistance,Medulloblastoma,Sonidegib
2680,Amplification,D,Resistance,Medulloblastoma,Sonidegib
2681,DELETION,D,Sensitivity/Response,Medulloblastoma,Sonidegib
2682,Amplification,D,Sensitivity/Response,Medulloblastoma,Arsenic Trioxide
2683,Mutation,B,Sensitivity/Response,Breast Cancer,Neratinib
2684,Mutation,B,Resistance,Renal Cell Carcinoma,Everolimus+Sunitinib
2685,Mutation,A,Resistance,Colorectal Cancer,Panitumumab+Cetuximab
2686,Mutation,A,Resistance,Colorectal Cancer,Panitumumab+Cetuximab
2687,D842V,D,Resistance,Cancer,Imatinib Mesylate
2688,V560D,D,Sensitivity/Response,Cancer,Imatinib Mesylate
2689,Overexpression,D,Sensitivity/Response,Multiple Myeloma,JQ-1
2690,Underexpression,B,Sensitivity/Response,Pancreatic Cancer,Gemcitabine
2691,Underexpression,B,Sensitivity/Response,Pancreatic Cancer,Gemcitabine
2692,AMPLIFICATION,C,Sensitivity/Response,Liposarcoma,HDM2 Inhibitor MK-8242
2693,Underexpression,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gemcitabine
2694,F354L,B,Sensitivity/Response,Breast Cancer,Everolimus+Exemestane
2695,MUTATION,D,Sensitivity/Response,Acute Promyelocytic Leukemia,Nilotinib
2696,Mutation,D,Sensitivity/Response,Acute Myeloid Leukemia,Nilotinib
2697,Mutation,B,Sensitivity/Response,Acute Myeloid Leukemia,Nilotinib
2698,Underexpression,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Paclitaxel+Vinorelbine+Gemcitabine
2699,Y646,D,Sensitivity/Response,Melanoma,Dabrafenib+JQEZ5+GSK126+UNC1999
2700,V9 EXPRESSION,E,Resistance,Prostate Cancer,Abiraterone Acetate
2701,V774_C775insHV,D,Resistance,Cancer,Erlotinib
2702,EXPRESSION,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Atezolizumab
2703,Expression,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Pembrolizumab
2704,UNDEREXPRESSION,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Atezolizumab
2705,S1088F,C,Sensitivity/Response,Prostate Cancer,Cisplatin
2706,Loss-of-function,B,Sensitivity/Response,Her2-receptor Negative Breast Cancer,Olaparib
2707,Loss-of-function,B,Sensitivity/Response,Her2-receptor Negative Breast Cancer,Olaparib
2708,V777L,C,Resistance,Her2-receptor Positive Breast Cancer,Trastuzumab Emtansine+Trastuzumab
2709,D761N,D,Sensitivity/Response,Cancer,Multikinase Inhibitor AEE788
2710,S784F,D,Sensitivity/Response,Cancer,Multikinase Inhibitor AEE788
2711,G810S,D,Sensitivity/Response,Cancer,Multikinase Inhibitor AEE788
2712,Overexpression,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib
2713,OVEREXPRESSION,D,Sensitivity/Response,Her2-receptor Positive Breast Cancer,"Dovitinib+FGF/VEGF Receptor Tyrosine Kinase Inhibitor, PD173074"
2714,L1237F,C,Sensitivity/Response,Ureter Small Cell Carcinoma,Checkpoint Kinase Inhibitor AZD7762+Irinotecan
2715,Mutation,B,Sensitivity/Response,Her2-receptor Negative Breast Cancer,Olaparib
2716,Mutation,B,Sensitivity/Response,Breast Cancer,Olaparib
2717,Underexpression,D,Sensitivity/Response,Osteosarcoma,VE-821+AZ20
2718,Loss-of-function,B,Sensitivity/Response,Renal Cell Carcinoma,MTOR Inhibitor
2719,LOSS-OF-FUNCTION,B,Sensitivity/Response,Renal Cell Carcinoma,MTOR Inhibitor
2720,Gain-of-Function,B,Sensitivity/Response,Renal Cell Carcinoma,MTOR Inhibitor
2721,ATP1B1-NRG1,C,Sensitivity/Response,Cholangiocarcinoma,Afatinib
2722,SDC4-NRG1,C,Sensitivity/Response,Lung Adenocarcinoma,Afatinib
2723,A829P,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Ponatinib
2724,E384*,C,Sensitivity/Response,Cholangiocarcinoma,Erlotinib
2725,EXPRESSION,D,Sensitivity/Response,Lung Small Cell Carcinoma,Temozolomide+Talazoparib
2726,EXPRESSION,D,Sensitivity/Response,Ewing Sarcoma,Temozolomide+Niraparib
2727,V600E,C,Sensitivity/Response,Cholangiocarcinoma,Trametinib+Dabrafenib
2728,V600E,C,Sensitivity/Response,Intrahepatic Cholangiocarcinoma,Dabrafenib+Trametinib
2729,V600E,C,Sensitivity/Response,Intrahepatic Cholangiocarcinoma,Dabrafenib+Trametinib
2730,V600,B,Sensitivity/Response,Cholangiocarcinoma,Vemurafenib
2731,V600E,C,Sensitivity/Response,Cholangiocarcinoma,Panitumumab+Vemurafenib+Irinotecan
2732,Amplification,B,Resistance,Melanoma,Nilotinib
2733,Fusion,B,Sensitivity/Response,Cholangiocarcinoma,Infigratinib
2734,EGFR-RAD51,C,Sensitivity/Response,Lung Adenocarcinoma,Erlotinib
2735,OVEREXPRESSION,C,Sensitivity/Response,Breast Angiosarcoma,Sunitinib
2736,AMPLIFICATION,C,Sensitivity/Response,Angiosarcoma,Pazopanib
2737,Mutation,B,Sensitivity/Response,Cholangiocarcinoma,Infigratinib
2738,Mutation,B,Sensitivity/Response,Pancreatic Cancer,Olaparib
2739,Mutation,B,Sensitivity/Response,Pancreatic Cancer,Olaparib
2740,Mutation,B,Sensitivity/Response,Pancreatic Cancer,Cisplatin+Oxaliplatin
2741,Mutation,B,Sensitivity/Response,Pancreatic Cancer,Platinum Compound
2742,EXPRESSION,B,Sensitivity/Response,Head And Neck Cancer,Pembrolizumab
2743,Expression,B,Sensitivity/Response,Lung Small Cell Carcinoma,Rovalpituzumab Tesirine
2744,FUS-DDIT3,D,Sensitivity/Response,Myxoid Liposarcoma,NVP-AEW541
2745,L1678P,C,Sensitivity/Response,Adult T-cell Leukemia,Nirogacestat
2746,L858R,D,Sensitivity/Response,Cancer,Erlotinib
2747,Mutation,B,Sensitivity/Response,Peritoneal Mesothelioma,Cytoreductive Surgery+Hyperthermic Intraperitoneal Chemotherapy
2748,Amplification,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib+Gefitinib
2749,Amplification,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib+Erlotinib
2750,KMT2E-ASNS,D,Resistance,T-cell Lymphoblastic Leukemia/lymphoma,Asparaginase
2751,G12C,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,ARS-1620
2752,INACTIVATING MUTATION,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Tozasertib
2753,ALTERNATIVE TRANSCRIPT (ATI),D,Sensitivity/Response,Malignant Mesothelioma,Olaparib+Apitolisib
2754,LOSS,D,Sensitivity/Response,Renal Carcinoma,Olaparib
2755,Mutation,B,Sensitivity/Response,Pancreatic Cancer,Gemcitabine+Veliparib+Cisplatin
2756,Mutation,B,Sensitivity/Response,Pancreatic Cancer,Veliparib+Gemcitabine+Cisplatin
2757,Mutation,C,Sensitivity/Response,Pancreatic Cancer,Iniparib
2758,A763_Y764insFQEA,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib
2759,D770delinsGY,C,Resistance,Lung Non-small Cell Carcinoma,Erlotinib
2760,V769_770insASV,C,Resistance,Lung Non-small Cell Carcinoma,Erlotinib
2761,L747_P753delinsS,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib+Afatinib
2762,E746_A750del,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib
2763,E746_A750del,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Afatinib
2764,A767_V769dupASV,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib
2765,A763_Y764insFQEA,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib+Afatinib
2766,STRN-ALK,C,Sensitivity/Response,Colon Adenocarcinoma,Ceritinib
2767,LOSS-OF-FUNCTION,D,Sensitivity/Response,Colorectal Cancer,Olaparib
2768,Fusion,C,Sensitivity/Response,Thyroid Gland Anaplastic Carcinoma,Crizotinib
2769,V600E,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Vemurafenib
2770,V600E,B,Sensitivity/Response,Ovarian Cancer,Vemurafenib
2771,V600E,C,Sensitivity/Response,Colorectal Cancer,Vemurafenib
2772,V600E,C,Sensitivity/Response,Thyroid Gland Anaplastic Carcinoma,Vemurafenib+Pertuzumab
2773,V600E,C,Sensitivity/Response,Laryngeal Squamous Cell Carcinoma,Vemurafenib
2774,CUX1-BRAF,C,Sensitivity/Response,Pancreatic Cancer,Vemurafenib
2775,MUTATION,B,Sensitivity/Response,Cancer,Vismodegib
2776,Mutation,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Pertuzumab+Trastuzumab
2777,Amplification,B,Sensitivity/Response,Colorectal Cancer,Pertuzumab+Trastuzumab
2778,Amplification,B,Sensitivity/Response,Bladder Carcinoma,Pertuzumab+Trastuzumab
2779,Amplification,B,Sensitivity/Response,Biliary Tract Cancer,Trastuzumab+Pertuzumab
2780,Amplification,B,Sensitivity/Response,Salivary Gland Carcinoma,Trastuzumab+Pertuzumab
2781,Amplification,B,Sensitivity/Response,Pancreatic Cancer,Trastuzumab+Pertuzumab
2782,LOSS,D,Sensitivity/Response,Sarcoma,Chloroquine+Pegargiminase
2783,LOSS,D,Resistance,Ovarian Cancer,Platinum Compound
2784,Mutation,C,Sensitivity/Response,Papillary Renal Cell Carcinoma,Everolimus
2785,Loss,D,Sensitivity/Response,Renal Carcinoma,Sirolimus
2786,LOSS,D,Sensitivity/Response,Kabuki Syndrome,HDAC Inhibitor AR-42
2787,LOSS-OF-FUNCTION,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Trametinib
2788,Loss-of-function,D,Sensitivity/Response,Lung Adenocarcinoma,Olaparib
2789,Mutation,B,Sensitivity/Response,Renal Cell Carcinoma,Sunitinib+Everolimus
2790,MUTATION,B,Sensitivity/Response,Renal Cell Carcinoma,Sunitinib+Everolimus
2791,ISOFORM EXPRESSION,D,Sensitivity/Response,Malignant Pleural Mesothelioma,Apitolisib+Olaparib
2792,Overexpression,D,Sensitivity/Response,Melanoma,Sertraline
2793,AMPLIFICATION,D,Sensitivity/Response,Breast Cancer,GF109203X+Go6983
2794,D594G,D,Sensitivity/Response,Skin Melanoma,Sorafenib
2795,D594G,D,Resistance,Skin Melanoma,U0126
2796,G469E,D,Sensitivity/Response,Skin Melanoma,Sorafenib
2797,G469E,D,Resistance,Skin Melanoma,U0126
2798,L747_P753delinsS,C,Sensitivity/Response,Pancreatic Adenocarcinoma,Erlotinib
2799,Amplification,D,Sensitivity/Response,Neuroblastoma,JQ1
2800,Amplification,D,Sensitivity/Response,Neuroblastoma,Birabresib
2801,Amplification,D,Sensitivity/Response,Neuroblastoma,JQ1+Panobinostat
2802,Amplification,D,Sensitivity/Response,Neuroblastoma,JQEZ5+GSK126
2803,A702S,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
2804,E709K and G719A,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib+Erlotinib
2805,E709Q,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
2806,Exon 18 deletion,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib+Erlotinib
2807,E709A and G719C,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib
2808,G719S,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib
2809,I744_K745insKIPVAI,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib
2810,Fusion,C,Sensitivity/Response,Vagina Sarcoma,Crizotinib
2811,Fusion,C,Sensitivity/Response,Epithelioid Inflammatory Myofibroblastic Sarcoma,Crizotinib
2812,V600,A,Sensitivity/Response,Melanoma,Vemurafenib+Cobimetinib
2813,V600E,B,Sensitivity/Response,Thyroid Gland Anaplastic Carcinoma,Vemurafenib
2814,V600,B,Sensitivity/Response,Colorectal Cancer,Encorafenib+Cetuximab
2815,V600,B,Sensitivity/Response,Colorectal Cancer,Encorafenib+Cetuximab+Alpelisib
2816,T41A,C,Sensitivity/Response,Desmoid Tumor,Celecoxib
2817,T41A,B,Sensitivity/Response,Desmoid Tumor,Meloxicam
2818,Fusion,C,Sensitivity/Response,Pancreatic Cancer,Larotrectinib
2819,Fusion,C,Sensitivity/Response,Cholangiocarcinoma,Larotrectinib
2820,Loss-of-function,C,Sensitivity/Response,Renal Cell Carcinoma,MTOR Inhibitor
2821,Mutation,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Trametinib
2822,D1028N,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Crizotinib
2823,Loss-of-function,B,Sensitivity/Response,Pancreatic Cancer,Olaparib
2824,Loss-of-function,B,Sensitivity/Response,Pancreatic Cancer,Olaparib
2825,T41A,B,Sensitivity/Response,Hepatoblastoma,
2826,S37C,E,Sensitivity/Response,Hepatoblastoma,
2827,G328V,D,Sensitivity/Response,"Diffuse Midline Glioma, H3 K27M-mutant",ALK2 Inhibitor LDN-193189
2828,Fusion,C,Sensitivity/Response,Mucinous Adenocarcinoma,Anti-HER3 Monoclonal Antibody GSK2849330
2829,MUTATION,C,Resistance,Breast Cancer,Ribociclib+Palbociclib
2830,STRN-NTRK2,C,Sensitivity/Response,Sarcoma,Larotrectinib
2831,ETV6-NTRK3,A,Sensitivity/Response,Congenital Fibrosarcoma,Larotrectinib
2832,LMNA-NTRK1,C,Sensitivity/Response,Sarcoma,Larotrectinib
2833,TPM3-NTRK1,C,Sensitivity/Response,Sarcoma,Larotrectinib
2834,PDE4DIP-NTRK1,C,Sensitivity/Response,Sarcoma,Larotrectinib
2835,SQSTM1-NTRK1,C,Sensitivity/Response,Congenital Fibrosarcoma,Larotrectinib
2836,V600E,B,Sensitivity/Response,Colorectal Cancer,Trametinib+Panitumumab+Dabrafenib
2837,Overexpression,C,Sensitivity/Response,Salivary Gland Cancer,Paclitaxel+Trastuzumab
2838,Overexpression,C,Sensitivity/Response,Salivary Gland Cancer,Trastuzumab+Zoledronic Acid+Capecitabine
2839,Y220C,C,Sensitivity/Response,Breast Cancer,Bortezomib
2840,L869R,C,Sensitivity/Response,Breast Cancer,Neratinib
2841,T798I,C,Resistance,Breast Cancer,Neratinib
2842,A750T,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib+Gefitinib
2843,V600E,B,Sensitivity/Response,Melanoma,Trametinib+Dabrafenib
2844,V600K,B,Sensitivity/Response,Melanoma,Trametinib+Dabrafenib
2845,V600,B,Sensitivity/Response,Melanoma,Dabrafenib+Trametinib
2846,L858R,B,Sensitivity/Response,Lung Adenocarcinoma,Gefitinib
2847,Exon 19 Deletion,B,Sensitivity/Response,Lung Adenocarcinoma,Gefitinib
2848,Rare Mutation,C,Sensitivity/Response,Lung Adenocarcinoma,Gefitinib
2849,BCR-ABL T315A,D,Resistance,Chronic Myeloid Leukemia,Dasatinib
2850,BCR-ABL T315I,D,Resistance,Chronic Myeloid Leukemia,Dasatinib+Imatinib Mesylate
2851,BCR-ABL E255K,D,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate+Dasatinib
2852,BCR-ABL E255K,D,Resistance,Chronic Myeloid Leukemia,Dasatinib+Imatinib Mesylate+Nilotinib
2853,BCR-ABL T315I,D,Resistance,Chronic Myeloid Leukemia,Nilotinib
2854,BCR-ABL T315I,D,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate+Nilotinib
2855,BCR-ABL T315I,B,Sensitivity/Response,Chronic Myeloid Leukemia,Omacetaxine Mepesuccinate
2856,BCR-ABL Y253H,C,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate+Nilotinib
2857,H1047R,D,Resistance,Breast Cancer,Lapatinib
2858,H1047R,D,Resistance,Breast Cancer,Trastuzumab
2859,H1047R,D,Resistance,Her2-receptor Positive Breast Cancer,Lapatinib+Trastuzumab
2860,H1047R,D,Sensitivity/Response,Breast Cancer,Lapatinib+Dactolisib
2861,E545K,D,Resistance,Her2-receptor Positive Breast Cancer,Lapatinib
2862,BCR-ABL F317V,D,Resistance,Chronic Myeloid Leukemia,Dasatinib
2863,E545K,D,Resistance,Her2-receptor Positive Breast Cancer,Trastuzumab
2864,BCR-ABL L248R,D,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate+Dasatinib
2865,E545K,D,Resistance,Her2-receptor Positive Breast Cancer,Trastuzumab+Lapatinib
2866,BCR-ABL E255K,D,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate+Dasatinib
2867,BCR-ABL F317L,D,Resistance,Chronic Myeloid Leukemia,Dasatinib
2868,BCR-ABL V299L,D,Resistance,Chronic Myeloid Leukemia,Dasatinib
2869,BCR-ABL F317I,D,Resistance,Chronic Myeloid Leukemia,Dasatinib
2870,BCR-ABL F317S,D,Resistance,Chronic Myeloid Leukemia,Dasatinib
2871,BCR-ABL Q252H,D,Resistance,Chronic Myeloid Leukemia,Dasatinib
2872,BCR-ABL T315I,D,Sensitivity/Response,Chronic Myeloid Leukemia,Omacetaxine Mepesuccinate
2873,BCR-ABL E255K,C,Resistance,Chronic Myeloid Leukemia,Nilotinib+Imatinib Mesylate
2874,BCR-ABL F359C,C,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate+Nilotinib
2875,BCR-ABL T315I,D,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate+Dasatinib
2876,BCR-ABL T315I,D,Resistance,Chronic Myeloid Leukemia,Dasatinib+Nilotinib
2877,BCR-ABL L248V,D,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate+Nilotinib
2878,BCR-ABL Y253H,D,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate+Nilotinib
2879,BCR-ABL F311L,D,Resistance,Chronic Myeloid Leukemia,Nilotinib+Imatinib Mesylate
2880,BCR-ABL F359C,D,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate+Nilotinib
2881,BCR-ABL H396P,D,Resistance,Chronic Myeloid Leukemia,Nilotinib+Imatinib Mesylate
2882,BCR-ABL V299L,D,Resistance,Chronic Myeloid Leukemia,Dasatinib+Imatinib Mesylate
2883,BCR-ABL M244V,D,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate
2884,BCR-ABL L248R,D,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate
2885,BCR-ABL G250E,D,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate
2886,BCR-ABL Q252H,D,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate
2887,BCR-ABL D276G,D,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate
2888,BCR-ABL V299L,D,Resistance,Chronic Myeloid Leukemia,Dasatinib
2889,BCR-ABL F311I,D,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate
2890,BCR-ABL F311V,D,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate
2891,BCR-ABL F317C,D,Resistance,Chronic Myeloid Leukemia,Dasatinib
2892,BCR-ABL F317I,D,Resistance,Chronic Myeloid Leukemia,Dasatinib
2893,BCR-ABL F317L,D,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate
2894,BCR-ABL F317V,D,Resistance,Chronic Myeloid Leukemia,Dasatinib
2895,BCR-ABL M351T,D,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate
2896,BCR-ABL E355G,D,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate
2897,BCR-ABL F359V,D,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate
2898,BCR-ABL V379I,D,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate
2899,BCR-ABL H396R,D,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate
2900,Q79K,C,Resistance,Melanoma,Dabrafenib
2901,OVEREXPRESSION,D,Resistance,Melanoma,Vemurafenib
2902,V600E/K and Amplification,B,Resistance,Melanoma,Dabrafenib+Vemurafenib
2903,Mutation,B,Resistance,Melanoma,Dabrafenib+Vemurafenib
2904,Mutation,B,Resistance,Melanoma,Vemurafenib+Dabrafenib
2905,OVEREXPRESSION,D,Resistance,Melanoma,Vemurafenib
2906,BCR-ABL G250E,D,Resistance,Chronic Myeloid Leukemia,Nilotinib
2907,R172I,C,Resistance,Melanoma,Vemurafenib
2908,BCR-ABL F317L,D,Resistance,Chronic Myeloid Leukemia,Dasatinib
2909,Loss,D,Resistance,Melanoma,Vemurafenib
2910,WILD TYPE,D,Sensitivity/Response,Melanoma,Vemurafenib
2911,Fusion,C,Sensitivity/Response,Pancreatic Adenocarcinoma,Afatinib
2912,BCR-ABL Q252H,D,Resistance,Chronic Myeloid Leukemia,Dasatinib
2913,Amplification,D,Resistance,Melanoma,Vemurafenib
2914,BCR-ABL L384M,D,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate
2915,BCR-ABL E255V,D,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate
2916,BCR-ABL F359C,D,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate
2917,BCR-ABL Y253H,D,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate
2918,BCR-ABL L248V,D,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate
2919,BCR-ABL L248V,D,Resistance,Chronic Myeloid Leukemia,Dasatinib
2920,BCR-ABL E255K,D,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate
2921,BCR-ABL E255K,D,Resistance,Chronic Myeloid Leukemia,Dasatinib
2922,BCR-ABL T315I,D,Resistance,Chronic Myeloid Leukemia,Dasatinib
2923,BCR-ABL T315I,D,Resistance,Chronic Myeloid Leukemia,Nilotinib+Imatinib Mesylate+Dasatinib
2924,G12/G13,B,Resistance,Colorectal Cancer,Cetuximab
2925,Mutation,B,Resistance,Colorectal Cancer,Cetuximab
2926,Mutation,B,Resistance,Colorectal Cancer,Oxaliplatin
2927,Mutation,B,Resistance,Colorectal Cancer,Irinotecan
2928,Mutation,B,Resistance,Colorectal Cancer,Bevacizumab
2929,Mutation,B,Resistance,Colorectal Cancer,Cetuximab
2930,BCR-ABL F317L,B,Resistance,Chronic Myeloid Leukemia,Dasatinib
2931,G13V,C,Resistance,Colorectal Cancer,Panitumumab+Cetuximab
2932,G12S,C,Resistance,Colorectal Cancer,Panitumumab+Cetuximab
2933,Loss,B,Resistance,Colorectal Cancer,Cetuximab+Panitumumab
2934,G12D,C,Resistance,Colorectal Cancer,Panitumumab+Cetuximab
2935,Amplification,D,Resistance,Melanoma,Vemurafenib
2936,T790M,D,Resistance,Lung Non-small Cell Carcinoma,Naquotinib+Mitogen-Activated Protein Kinase Kinase Inhibitor+Osimertinib
2937,G12A,C,Resistance,Colorectal Cancer,Panitumumab+Cetuximab
2938,G13D,C,Resistance,Colorectal Cancer,Cetuximab+Panitumumab
2939,G12V,C,Resistance,Colorectal Cancer,Panitumumab+Cetuximab
2940,Mutation,B,Sensitivity/Response,Ovarian Serous Carcinoma,Olaparib
2941,Mutation,B,Sensitivity/Response,Ovarian Serous Carcinoma,Olaparib
2942,Y35N,D,Resistance,Kidney Cancer,Sirolimus
2943,Mutation,B,Sensitivity/Response,Ovarian Cancer,Rucaparib
2944,Mutation,B,Sensitivity/Response,Ovarian Cancer,Rucaparib
2945,Mutation,B,Resistance,Colorectal Cancer,Panitumumab+Cetuximab
2946,G12/G13,B,Resistance,Colorectal Cancer,Panitumumab+Cetuximab
2947,UNDEREXPRESSION,C,Sensitivity/Response,Cancer,Tazemetostat
2948,UNDEREXPRESSION,C,Sensitivity/Response,Cancer,Tazemetostat
2949,Mutation,B,Sensitivity/Response,Colorectal Cancer,Aspirin
2950,R351W,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Imatinib
2951,Exon 11 Mutation,B,Sensitivity/Response,Gastrointestinal Stromal Tumor,Regorafenib
2952,EWSR1-NR4A3,B,Sensitivity/Response,Extraskeletal Myxoid Chondrosarcoma,Sunitinib
2953,UNDEREXPRESSION,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
2954,T618I,D,Sensitivity/Response,Chronic Neutrophilic Leukemia,Ruxolitinib
2955,T618I,C,Sensitivity/Response,Chronic Neutrophilic Leukemia,Ruxolitinib
2956,56_61QKQKVG>R,D,Resistance,Langerhans-cell Histiocytosis,Trametinib
2957,C121S and G128D,D,Resistance,Langerhans-cell Histiocytosis,Trametinib
2958,NTRK1-TRIM63,E,Sensitivity/Response,Melanoma,Larotrectinib
2959,NTRK1-DDR2,E,Sensitivity/Response,Melanoma,Larotrectinib
2960,NTRK1-GON4L,E,Sensitivity/Response,Melanoma,Larotrectinib
2961,ETV6-NTRK3,C,Sensitivity/Response,Hematologic Cancer,Larotrectinib
2962,ETV6-NTRK2,C,Sensitivity/Response,Acute Myeloid Leukemia,Larotrectinib
2963,AMPLIFICATION,D,Resistance,Lung Non-small Cell Carcinoma,Gefitinib
2964,AMPLIFICATION,D,Sensitivity/Response,Stomach Cancer,Dasatinib
2965,LOSS-OF-FUNCTION,D,Sensitivity/Response,Ovarian Cancer,Atezolizumab+Pembrolizumab+Nivolumab
2966,intron 10 rearrangement,B,Resistance,Melanoma,Vemurafenib+Dabrafenib
2967,intron 9 rearrangement,B,Resistance,Melanoma,Vemurafenib+Dabrafenib
2968,D594K,B,Resistance,Colorectal Cancer,Irinotecan
2969,D594K,B,Resistance,Colorectal Cancer,Oxaliplatin
2970,S249C,B,Sensitivity/Response,Transitional Cell Carcinoma,Infigratinib
2971,V443L,C,Resistance,Transitional Cell Carcinoma,Infigratinib
2972,V443M,C,Resistance,Transitional Cell Carcinoma,Infigratinib
2973,V496V,C,Resistance,Transitional Cell Carcinoma,Infigratinib
2974,V555M,D,Resistance,Myeloid Neoplasm,FGFR Inhibitor AZD4547+AZ12908010+PD173074
2975,FGFR3-TACC3,C,Sensitivity/Response,Transitional Cell Carcinoma,Infigratinib
2976,R248C,B,Sensitivity/Response,Transitional Cell Carcinoma,Infigratinib
2977,Y373C,C,Sensitivity/Response,Transitional Cell Carcinoma,Infigratinib
2978,Y375C,C,Sensitivity/Response,Transitional Cell Carcinoma,Infigratinib
2979,G380R,C,Sensitivity/Response,Transitional Cell Carcinoma,Infigratinib
2980,G370C,B,Sensitivity/Response,Transitional Cell Carcinoma,Infigratinib
2981,F386L,C,Sensitivity/Response,Transitional Cell Carcinoma,Infigratinib
2982,N78S (c.233A>G),C,Sensitivity/Response,Von Hippel-Lindau Disease,Sunitinib
2983,Underexpression,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Platinum Compound
2984,Underexpression,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Cisplatin+Gemcitabine
2985,Underexpression,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gemcitabine+Cisplatin
2986,Underexpression,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Cisplatin
2987,Underexpression,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gemcitabine+Platinum Compound
2988,OVEREXPRESSION,B,Resistance,Lung Non-small Cell Carcinoma,Gemcitabine+Nedaplatin
2989,Underexpression,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gemcitabine+Cisplatin
2990,UNDEREXPRESSION,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gemcitabine
2991,R132,D,Sensitivity/Response,Intrahepatic Cholangiocarcinoma,Dasatinib
2992,Mutation,B,Resistance,Lung Adenocarcinoma,Nivolumab+Pembrolizumab+Atezolizumab
2993,E102_I103delEI,C,Sensitivity/Response,Langerhans-cell Histiocytosis,Trametinib
2994,LOSS-OF-FUNCTION,B,Resistance,Colorectal Cancer,Lysine
2995,Mutation,B,Sensitivity/Response,Endometrial Cancer,Fulvestrant+Dovitinib
2996,Mutation,B,Resistance,Colorectal Cancer,Cetuximab
2997,Mutation,D,Resistance,Lung Non-small Cell Carcinoma,Afatinib+Gefitinib
2998,ETV6-NTRK3,C,Sensitivity/Response,Congenital Fibrosarcoma,Larotrectinib
2999,ETV6-NTRK3,C,Sensitivity/Response,Breast Secretory Carcinoma,Larotrectinib
3000,LOSS-OF-FUNCTION,B,Resistance,Breast Cancer,Letrozole+Anastrozole+Exemestane
3001,Fusion,B,Sensitivity/Response,Solid Tumor,Larotrectinib
3002,Fusion,A,Sensitivity/Response,Solid Tumor,Larotrectinib
3003,Fusion,B,Sensitivity/Response,Sarcoma,Larotrectinib
3004,AMPLIFICATION,D,Sensitivity/Response,Melanoma,Binimetinib
3005,Amplification,B,Sensitivity/Response,Gastric Adenocarcinoma,Cetuximab
3006,Amplification,D,Sensitivity/Response,Esophageal Carcinoma,Ibrutinib
3007,Amplification,D,Sensitivity/Response,Esophageal Cancer,Ibrutinib
3008,ETV6-NTRK3,D,Sensitivity/Response,B-lymphoblastic Leukemia/lymphoma,Larotrectinib
3009,LOSS-OF-FUNCTION,D,Sensitivity/Response,Triple-receptor Negative Breast Cancer,Sunitinib+Crizotinib
3010,V600,B,Sensitivity/Response,Melanoma,Dabrafenib+Trametinib
3011,V600E,B,Sensitivity/Response,Melanoma,Dabrafenib+Trametinib
3012,V600K,B,Sensitivity/Response,Melanoma,Dabrafenib+Trametinib
3013,V600E,B,Sensitivity/Response,Melanoma,Trametinib+Dabrafenib
3014,V600K,B,Sensitivity/Response,Melanoma,Trametinib+Dabrafenib
3015,KIF5B-RET,C,Sensitivity/Response,Lung Cancer,Selpercatinib
3016,Fusion,D,Sensitivity/Response,Cancer,Selpercatinib
3017,M918T,C,Sensitivity/Response,Thyroid Gland Medullary Carcinoma,Selpercatinib
3018,V804M,C,Sensitivity/Response,Thyroid Gland Medullary Carcinoma,Selpercatinib
3019,Y646F,D,Sensitivity/Response,Skin Melanoma,JQEZ5
3020,OVEREXPRESSION,B,Sensitivity/Response,Salivary Gland Cancer,Leuprolide+Bicalutamide
3021,V7 EXPRESSION,C,Resistance,Salivary Gland Cancer,Abiraterone Acetate
3022,D816V,E,Resistance,Gastrointestinal Stromal Tumor,Sunitinib
3023,D816H,D,Resistance,Acute Myeloid Leukemia,Imatinib Mesylate
3024,N822K,D,Sensitivity/Response,Acute Myeloid Leukemia,Imatinib Mesylate
3025,Promoter Mutation,B,Resistance,Thyroid Gland Carcinoma,Iodine I-131
3026,V600K,B,Sensitivity/Response,Melanoma,Trametinib+Dabrafenib
3027,V600,B,Sensitivity/Response,Melanoma,Vemurafenib+Cobimetinib
3028,ETV6-ABL1,C,Sensitivity/Response,B-lymphoblastic Leukemia/lymphoma,Dasatinib
3029,BCR-ABL F359V,C,Resistance,Chronic Myeloid Leukemia,Nilotinib+Imatinib Mesylate
3030,BCR-ABL E255V,C,Resistance,Chronic Myeloid Leukemia,Nilotinib+Imatinib Mesylate
3031,Overexpression,D,Sensitivity/Response,Ovarian Cancer,Ganitumab
3032,V600E,B,Sensitivity/Response,Thyroid Gland Anaplastic Carcinoma,Trametinib+Dabrafenib
3033,EBF1-PDGFRB,C,Sensitivity/Response,Childhood B-cell Acute Lymphoblastic Leukemia,Imatinib
3034,C475V,C,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate
3035,BCR-ABL F317L,C,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate
3036,BCR-ABL N336S,C,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate
3037,BCR-ABL E453A,C,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate
3038,BCR-ABL L387F,C,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate
3039,BCR-ABL V299L,B,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate
3040,BCR-ABL Q300R,C,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate
3041,BCR-ABL F359I,C,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate
3042,BCR-ABL F359C,C,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate
3043,BCR-ABL E255V,C,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate
3044,BCR-ABL F486S,C,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate
3045,BCR-ABL H396R,C,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate
3046,BCR-ABL M351T,C,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate
3047,BCR-ABL T315I,C,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate
3048,BCR-ABL E255K,C,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate
3049,BCR-ABL Y253H,C,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate
3050,BCR-ABL G250E,C,Resistance,Chronic Myeloid Leukemia,Imatinib
3051,BCR-ABL M244V,C,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate
3052,BCR-ABL F359V,C,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate
3053,AGGF1-PDGFRB C843G,D,Sensitivity/Response,Childhood B-cell Acute Lymphoblastic Leukemia,CHZ868
3054,Overexpression,B,Sensitivity/Response,Pancreatic Adenocarcinoma,Ganitumab+Gemcitabine
3055,Overexpression,D,Sensitivity/Response,Pancreatic Cancer,Tarextumab
3056,Overexpression,D,Sensitivity/Response,Rectum Cancer,Tarextumab
3057,GOLGA5-JAK2,C,Sensitivity/Response,"B-lymphoblastic Leukemia/lymphoma, BCR-ABL1–like",Ruxolitinib
3058,PAX3-FOXO1,D,Sensitivity/Response,Alveolar Rhabdomyosarcoma,BET Inhibitor
3059,Overexpression,D,Sensitivity/Response,Neuroblastoma,Dinaciclib
3060,Overexpression,B,Sensitivity/Response,Glioblastoma,Bevacizumab
3061,Overexpression,B,Sensitivity/Response,Breast Cancer,Lapatinib
3062,Overexpression,B,Sensitivity/Response,Breast Cancer,Lapatinib
3063,OVEREXPRESSION,D,Sensitivity/Response,Malignant Peripheral Nerve Sheath Tumor,Olaparib
3064,BRD4-NUTM1,C,Sensitivity/Response,NUT Midline Carcinoma,Birabresib
3065,FIP1L1-PDGFRA T674I,C,Resistance,"Myeloid And Lymphoid Neoplasms With Eosinophilia And Abnormalities Of PDGFRA, PDGFRB, And FGFR1",Imatinib
3066,F694L,C,Sensitivity/Response,Childhood B-cell Acute Lymphoblastic Leukemia,Ruxolitinib
3067,Mutation,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib
3068,EBF1-PDGFRB,C,Sensitivity/Response,Childhood B-cell Acute Lymphoblastic Leukemia,Imatinib
3069,BCR-ABL F317L,C,Reduced Sensitivity,Chronic Myeloid Leukemia,Dasatinib
3070,BCR-ABL E255K,C,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate
3071,BCR-ABL V379I,C,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate
3072,BCR-ABL A397P,C,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate
3073,BCR-ABL F359C,C,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate
3074,BCR-ABL E355G,C,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate
3075,BCR-ABL M351T,C,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate
3076,BCR-ABL T315I,C,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate
3077,BCR-ABL E255K,C,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate
3078,BCR-ABL Y253H,B,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate
3079,BCR-ABL G250E,B,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate
3080,BCR-ABL M244V,C,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate
3081,BCR-ABL F359V,C,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate
3082,BCR-ABL L248V,C,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate
3083,BCR-ABL F317L,C,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate
3084,BCR-ABL E459K,C,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate
3085,Wildtype,B,Sensitivity/Response,Colorectal Cancer,Oxaliplatin+Fluorouracil+Panitumumab+Leucovorin
3086,Fusion,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Brigatinib
3087,Expression,B,Sensitivity/Response,Renal Cell Carcinoma,Abexinostat+Pazopanib
3088,ITD,B,Sensitivity/Response,Acute Myeloid Leukemia,Midostaurin
3089,Overexpression,B,Sensitivity/Response,Gastroesophageal Junction Adenocarcinoma,Trastuzumab
3090,Overexpression,B,Sensitivity/Response,Stomach Cancer,Trastuzumab
3091,Fusion,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Selpercatinib
3092,KIF5B-RET,B,Sensitivity/Response,Lung Cancer,Selpercatinib
3093,V804M,C,Sensitivity/Response,Thyroid Gland Medullary Carcinoma,Selpercatinib
3094,Fusion,B,Sensitivity/Response,Thyroid Gland Papillary Carcinoma,Selpercatinib
3095,Mutation,B,Sensitivity/Response,Thyroid Gland Medullary Carcinoma,Selpercatinib
3096,AMPLIFICATION,D,Sensitivity/Response,Colorectal Cancer,Dual IGF-1R/InsR Inhibitor BMS-754807
3097,G13D,D,Resistance,Colorectal Cancer,Dual IGF-1R/InsR Inhibitor BMS-754807
3098,V600E,D,Resistance,Colorectal Cancer,Dual IGF-1R/InsR Inhibitor BMS-754807
3099,Overexpression,B,Sensitivity/Response,Salivary Gland Cancer,Trastuzumab+Docetaxel
3100,I462K,B,Resistance,Colorectal Cancer,Cetuximab+Panitumumab
3101,I462R,B,Resistance,Colorectal Cancer,Cetuximab+Panitumumab
3102,S464L,B,Resistance,Colorectal Cancer,Panitumumab+Cetuximab
3103,S464T,B,Resistance,Colorectal Cancer,Panitumumab+Cetuximab
3104,G465R,B,Resistance,Colorectal Cancer,Panitumumab+Cetuximab
3105,G465E,B,Resistance,Colorectal Cancer,Cetuximab+Panitumumab
3106,G465V,B,Resistance,Colorectal Cancer,Cetuximab+Panitumumab
3107,K467N,B,Resistance,Colorectal Cancer,Cetuximab+Panitumumab
3108,K467T,B,Resistance,Colorectal Cancer,Cetuximab+Panitumumab
3109,K489Q,B,Resistance,Colorectal Cancer,Panitumumab+Cetuximab
3110,K489E,B,Resistance,Colorectal Cancer,Panitumumab+Cetuximab
3111,I491K,B,Resistance,Colorectal Cancer,Cetuximab+Panitumumab
3112,I491R,B,Resistance,Colorectal Cancer,Panitumumab+Cetuximab
3113,S492R,B,Resistance,Colorectal Cancer,Cetuximab+Panitumumab
3114,S492C,B,Resistance,Colorectal Cancer,Panitumumab+Cetuximab
3115,V441G,B,Resistance,Colorectal Cancer,Panitumumab+Cetuximab
3116,V441D,B,Resistance,Colorectal Cancer,Cetuximab+Panitumumab
3117,V441F,E,Resistance,Colorectal Cancer,Panitumumab+Cetuximab
3118,S442R,B,Resistance,Colorectal Cancer,Cetuximab+Panitumumab
3119,S442I,B,Resistance,Colorectal Cancer,Cetuximab+Panitumumab
3120,F404I,B,Resistance,Colorectal Cancer,Panitumumab+Cetuximab
3121,F404V,B,Resistance,Colorectal Cancer,Panitumumab+Cetuximab
3122,T415M,B,Resistance,Colorectal Cancer,Cetuximab+Panitumumab
3123,Amplification,C,Sensitivity/Response,Colorectal Cancer,Sorafenib
3124,Amplification,B,Resistance,Colorectal Cancer,Panitumumab+Cetuximab
3125,EBF1-PDGFRB,C,Sensitivity/Response,B-cell Adult Acute Lymphocytic Leukemia,Imatinib
3126,EBF1-PDGFRB,C,Sensitivity/Response,Childhood B-cell Acute Lymphoblastic Leukemia,Dasatinib+Imatinib
3127,ATF7IP-PDGFRB,C,Sensitivity/Response,Childhood B-cell Acute Lymphoblastic Leukemia,Dasatinib
3128,Overexpression,D,Sensitivity/Response,Alveolar Rhabdomyosarcoma,Crizotinib
3129,OVEREXPRESSION,D,Sensitivity/Response,Alveolar Rhabdomyosarcoma,Ponatinib
3130,OVEREXPRESSION,D,Resistance,Alveolar Rhabdomyosarcoma,Palbociclib+Ribociclib
3131,AMPLIFICATION,C,Sensitivity/Response,Angiosarcoma,Pazopanib
3132,Fusion,D,Sensitivity/Response,Anaplastic Large Cell Lymphoma,Crizotinib
3133,MUTATION,B,Sensitivity/Response,Melanoma,Nilotinib
3134,LOSS,D,Sensitivity/Response,Ovarian Small Cell Carcinoma,Ribociclib+Abemaciclib+Palbociclib
3135,LOSS,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Palbociclib+Abemaciclib
3136,R248Q,D,Resistance,Ovarian Cancer,Paclitaxel+Doxorubicin+Etoposide
3137,A146T,D,Resistance,Colorectal Cancer,Cetuximab
3138,Q61P,D,Resistance,Colorectal Cancer,Irinotecan+Cetuximab
3139,G12S,D,Resistance,Lung Non-small Cell Carcinoma,MUC1-targeted Peptide GO-203-2C
3140,Activating Mutation,B,Sensitivity/Response,Pancreatic Cancer,Salirasib
3141,G12D,D,Sensitivity/Response,Pancreatic Cancer,Phosphatidylinositide 3-Kinase Inhibitor
3142,Activating Mutation,D,Sensitivity/Response,Pancreatic Cancer,Inhibitor
3143,G12,D,Resistance,Pancreatic Cancer,Mitogen-Activated Protein Kinase Kinase Inhibitor
3144,Activating Mutation,D,Sensitivity/Response,Pancreatic Cancer,Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor+Mitogen-Activated Protein Kinase Kinase Inhibitor
3145,Mutation,B,Sensitivity/Response,Head And Neck Squamous Cell Carcinoma,Sulindac+Celecoxib+Aspirin
3146,Amplification,B,Sensitivity/Response,Head And Neck Squamous Cell Carcinoma,Sulindac+Ibuprofen+Aspirin
3147,Mutation,B,Sensitivity/Response,Colorectal Cancer,Aspirin
3148,M541L,E,Sensitivity/Response,Colon Signet Ring Adenocarcinoma,Imatinib
3149,ATF7IP-PDGFRB,D,Sensitivity/Response,Childhood B-cell Acute Lymphoblastic Leukemia,Nilotinib+Imatinib+Rebastinib+Dasatinib+Bafetinib+Ponatinib
3150,KIAA1549-BRAF,D,Sensitivity/Response,Childhood Low-grade Glioma,Everolimus+Trametinib
3151,FAM131B-BRAF,D,Sensitivity/Response,Childhood Low-grade Glioma,Everolimus+Trametinib
3152,KIAA1549-BRAF,D,Sensitivity/Response,Childhood Low-grade Glioma,Everolimus+Trametinib
3153,Activating Mutation,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Afatinib
3154,A775_G776insYVMA,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Afatinib
3155,KIAA1549-BRAF,D,Adverse Response,Childhood Low-grade Glioma,Vemurafenib+PLX4720
3156,Overexpression,D,Sensitivity/Response,Childhood B-cell Acute Lymphoblastic Leukemia,Inhibitor
3157,NUP214-ABL1,C,Sensitivity/Response,"B-lymphoblastic Leukemia/lymphoma, BCR-ABL1–like",Vincristine+Dasatinib+Dexamethasone
3158,F232C,D,Sensitivity/Response,B-lymphoblastic Leukemia/lymphoma,JAK Inhibitor I
3159,Overexpression,B,Sensitivity/Response,Stomach Cancer,Bevacizumab
3160,Overexpression,B,Resistance,Ovarian Cancer,Bevacizumab+Erlotinib
3161,SNX2-ABL1,C,Resistance,B-lymphoblastic Leukemia/lymphoma,Dasatinib
3162,Overexpression,D,Sensitivity/Response,"Diffuse Midline Glioma, H3 K27M-mutant",Adavosertib
3163,Overexpression,D,Sensitivity/Response,"Diffuse Midline Glioma, H3 K27M-mutant",Adavosertib
3164,G284R,C,Sensitivity/Response,Breast Cancer,Lapatinib+Trastuzumab
3165,BCR-ABL E255V,C,Resistance,Chronic Myeloid Leukemia,Imatinib Mesylate
3166,Amplification,C,Sensitivity/Response,Breast Cancer,Pazopanib
3167,Mutation,B,Sensitivity/Response,Clear Cell Renal Cell Carcinoma,Anti-PD-L1 Monoclonal Antibody+CTLA-4 Inhibitor
3168,RCSD1-ABL1,C,Sensitivity/Response,"B-lymphoblastic Leukemia/lymphoma, BCR-ABL1–like",Imatinib
3169,RCSD1-ABL1,D,Sensitivity/Response,"B-lymphoblastic Leukemia/lymphoma, BCR-ABL1–like",Dasatinib
3170,Fusion,C,Sensitivity/Response,"B-lymphoblastic Leukemia/lymphoma, BCR-ABL1–like",Imatinib
3171,Fusion,D,Sensitivity/Response,"B-lymphoblastic Leukemia/lymphoma, BCR-ABL1–like",Dasatinib
3172,D579del,C,Sensitivity/Response,Sinonasal Undifferentiated Carcinoma,Imatinib Mesylate
3173,SNX2-ABL1,C,Reduced Sensitivity,B-lymphoblastic Leukemia/lymphoma,Imatinib
3174,SSBP2-JAK2,C,Sensitivity/Response,"B-lymphoblastic Leukemia/lymphoma, BCR-ABL1–like",Ruxolitinib
3175,V600E,B,Sensitivity/Response,Colorectal Cancer,Encorafenib+Cetuximab+Binimetinib
3176,Fusion,A,Sensitivity/Response,Transitional Cell Carcinoma,Erdafitinib
3177,Fusion,A,Sensitivity/Response,Transitional Cell Carcinoma,Erdafitinib
3178,Mutation,A,Sensitivity/Response,Transitional Cell Carcinoma,Erdafitinib
3179,V600E,B,Sensitivity/Response,Biliary Tract Cancer,Dabrafenib+Trametinib
3180,Loss,C,Sensitivity/Response,Neurofibroma,Trametinib
3181,Mutation,B,Sensitivity/Response,Plexiform Neurofibroma,Selumetinib
3182,G595R,B,Resistance,Solid Tumor,Larotrectinib
3183,G623R,C,Resistance,Solid Tumor,Larotrectinib
3184,G595R,C,Sensitivity/Response,Solid Tumor,Selitrectinib
3185,G623R,C,Sensitivity/Response,Solid Tumor,Selitrectinib
3186,EXON 14 SKIPPING MUTATION,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Tepotinib
3187,Exon 20 Insertion,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,TAK-788
3188,Mutation,A,Sensitivity/Response,Ovarian Cancer,Olaparib
3189,Mutation,A,Sensitivity/Response,Ovarian Cancer,Olaparib
3190,Mutation,A,Sensitivity/Response,Ovarian Cancer,Olaparib
3191,Mutation,A,Sensitivity/Response,Ovarian Cancer,Olaparib
3192,Mutation,A,Sensitivity/Response,Acute Myeloid Leukemia,Ivosidenib
3193,Mutation,A,Sensitivity/Response,Acute Myeloid Leukemia,Enasidenib
3194,Loss-of-function,A,Sensitivity/Response,Tuberous Sclerosis,Everolimus
3195,LOSS-OF-FUNCTION,A,Sensitivity/Response,Tuberous Sclerosis,Everolimus
3196,Fusion,A,Sensitivity/Response,Lung Non-small Cell Carcinoma,Crizotinib
3197,Mutation,B,Sensitivity/Response,Acute Myeloid Leukemia,Gilteritinib
3198,Fusion,A,Sensitivity/Response,Lung Non-small Cell Carcinoma,Alectinib
3199,Fusion,A,Sensitivity/Response,Lung Non-small Cell Carcinoma,Ceritinib
3200,Fusion,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Lorlatinib
3201,V600,A,Sensitivity/Response,Melanoma,Encorafenib+Binimetinib
3202,V555_V559DEL,C,Resistance,Gastrointestinal Stromal Tumor,Sunitinib
3203,FOXP1-ABL1,C,Sensitivity/Response,B-lymphoblastic Leukemia/lymphoma,Dasatinib
3204,MUTATION,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,SU11274
3205,Q294E,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,SU11274
3206,S80N and H94Y,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,SU11274
3207,V391I,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,SU11274
3208,W802*,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,SU11274
3209,LOSS-OF-FUNCTION,B,Sensitivity/Response,Renal Cell Carcinoma,Ipilimumab
3210,Amplification,B,Sensitivity/Response,Colorectal Cancer,Pertuzumab+Trastuzumab
3211,Promoter Methylation,A,Sensitivity/Response,Glioblastoma,Temozolomide+Lomustine
3212,DEK-AFF2,C,Sensitivity/Response,Head And Neck Cancer,Pembrolizumab
3213,R248C,A,Sensitivity/Response,Transitional Cell Carcinoma,Erdafitinib
3214,S249C,A,Sensitivity/Response,Transitional Cell Carcinoma,Erdafitinib
3215,G370C,A,Sensitivity/Response,Transitional Cell Carcinoma,Erdafitinib
3216,Y373C,A,Sensitivity/Response,Transitional Cell Carcinoma,Erdafitinib
3217,KIF5B-MET,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Crizotinib
3218,G12R,C,Sensitivity/Response,Histiocytosis-Lymphadenopathy Plus Syndrome,Cobimetinib
3219,KIAA1549-BRAF,C,Sensitivity/Response,Spindle Cell Sarcoma,Sorafenib+Bevacizumab+Temsirolimus
3220,Mutation,A,Sensitivity/Response,Breast Cancer,Fulvestrant+Alpelisib
3221,EGFR-RAD51,C,Sensitivity/Response,Lung Adenocarcinoma,Icotinib
3222,E542K,A,Sensitivity/Response,Breast Cancer,Fulvestrant+Alpelisib
3223,E545X,A,Sensitivity/Response,Breast Cancer,Alpelisib+Fulvestrant
3224,Mutation,A,Sensitivity/Response,Breast Cancer,Fulvestrant+Alpelisib
3225,H1047X,A,Sensitivity/Response,Breast Cancer,Fulvestrant+Alpelisib
3226,Fusion,C,Sensitivity/Response,Cholangiocarcinoma,Futibatinib
3227,T1977K,D,Sensitivity/Response,Solid Tumor,Sirolimus
3228,C1483F,D,Sensitivity/Response,Solid Tumor,Sirolimus
3229,F1888L,D,Sensitivity/Response,Solid Tumor,Sirolimus
3230,S2215F,D,Sensitivity/Response,Solid Tumor,Sirolimus
3231,L2230V,D,Sensitivity/Response,Solid Tumor,Sirolimus
3232,LOSS-OF-FUNCTION,D,Sensitivity/Response,Liver Cancer,Sorafenib
3233,Fusion,B,Sensitivity/Response,Cholangiocarcinoma,Derazantinib
3234,OVEREXPRESSION,D,Sensitivity/Response,Colorectal Cancer,Carfilzomib
3235,ｍRNA expression low,B,Sensitivity/Response,Breast Cancer,Fulvestrant+Palbociclib
3236,Q61H,B,Sensitivity/Response,Melanoma,Ipilimumab
3237,V600,B,Sensitivity/Response,Colorectal Cancer,Irinotecan+Vemurafenib+Cetuximab
3238,D820E,C,Sensitivity/Response,Thymic Carcinoma,Sorafenib
3239,V559G,C,Sensitivity/Response,Thymic Carcinoma,Imatinib Mesylate
3240,Y553N,C,Sensitivity/Response,Thymic Carcinoma,Imatinib Mesylate
3241,V560DEL,C,Sensitivity/Response,Thymic Carcinoma,Imatinib Mesylate
3242,P577_D579DEL,C,Sensitivity/Response,Thymic Carcinoma,Sorafenib
3243,Mutation,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Dacomitinib
3244,DELETION,B,Sensitivity/Response,Childhood B-cell Acute Lymphoblastic Leukemia,Cytarabine+Methotrexate+Daunorubicin+Imatinib+Fludarabine
3245,R832L,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib
3246,R832L,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
3247,ITD,D,Sensitivity/Response,Acute Myeloid Leukemia,Ponatinib
3248,ITD,D,Sensitivity/Response,Leukemia,Sorafenib
3249,ITD,D,Sensitivity/Response,Leukemia,Sunitinib
3250,FIP1L1-PDGFRA,D,Sensitivity/Response,Acute Myeloid Leukemia,Sorafenib
3251,FIP1L1-PDGFRA,D,Sensitivity/Response,Acute Myeloid Leukemia,Sunitinib+Sorafenib
3252,N822K,D,Sensitivity/Response,Acute Myeloid Leukemia,Ponatinib
3253,FGFR1OP2-FGFR1,D,Sensitivity/Response,Acute Myeloid Leukemia,Ponatinib
3254,FIP1L1-PDGFRA,D,Sensitivity/Response,Acute Myeloid Leukemia,Ponatinib
3255,ITD,D,Sensitivity/Response,Leukemia,Sunitinib+Sorafenib
3256,Loss-of-function,A,Sensitivity/Response,Pancreatic Adenocarcinoma,Olaparib
3257,Loss-of-function,A,Sensitivity/Response,Pancreatic Adenocarcinoma,Olaparib
3258,Overexpression,B,Sensitivity/Response,Endometrial Serous Adenocarcinoma,Paclitaxel+Carboplatin+Trastuzumab
3259,G12C,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Sotorasib
3260,M766Q,C,Resistance,Lung Non-small Cell Carcinoma,Osimertinib
3261,M766Q,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Neratinib
3262,M766Q,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Poziotinib
3263,A502_Y503insAY,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Sunitinib
3264,V560G,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Ponatinib+Regorafenib+Imatinib
3265,V560G,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Regorafenib+Imatinib+Ponatinib
3266,V560G,E,Sensitivity/Response,Gastrointestinal Stromal Tumor,Sunitinib
3267,K642E,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Sunitinib+Ponatinib
3268,KIAA1549-BRAF,D,Resistance,Childhood Pilocytic Astrocytoma,Vemurafenib+Sorafenib
3269,N822K,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Ponatinib
3270,D816H,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Ponatinib
3271,D816G,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Ponatinib
3272,D820A,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Ponatinib
3273,D820G,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,Ponatinib
3274,N822K,D,Resistance,Gastrointestinal Stromal Tumor,Sunitinib+Imatinib
3275,A829P,D,Resistance,Gastrointestinal Stromal Tumor,Sunitinib+Imatinib
3276,T670I,D,Resistance,Gastrointestinal Stromal Tumor,Imatinib
3277,ETV6-NTRK3,C,Sensitivity/Response,Congenital Fibrosarcoma,Larotrectinib
3278,TPM3-NTRK1,C,Sensitivity/Response,Spindle Cell Sarcoma,Larotrectinib
3279,PDE4DIP-NTRK1,C,Sensitivity/Response,Sarcoma,Larotrectinib
3280,Mutation,A,Sensitivity/Response,Transitional Cell Carcinoma,Erdafitinib
3281,Fusion,A,Sensitivity/Response,Transitional Cell Carcinoma,Erdafitinib
3282,Fusion,A,Sensitivity/Response,Transitional Cell Carcinoma,Erdafitinib
3283,MUTATION,B,Sensitivity/Response,Lung Squamous Cell Carcinoma,Sapanisertib
3284,Overexpression,B,Sensitivity/Response,Breast Cancer,Patritumab Deruxtecan
3285,EML6::ALK e1-e20 and FBXO11::ALK e1-e20,C,Sensitivity/Response,Lung Adenocarcinoma,Crizotinib
3286,R273H,D,Resistance,Osteosarcoma,Methotrexate+Doxorubicin
3287,Mutation,C,Sensitivity/Response,Pancreatic Cancer,Rucaparib
3288,LOSS-OF-FUNCTION,D,Sensitivity/Response,Cancer,Phosphatidylinositide 3-Kinase Inhibitor
3289,MUTATION,B,Sensitivity/Response,Lung Squamous Cell Carcinoma,Sapanisertib
3290,Mutation,B,Sensitivity/Response,Cholangiocarcinoma,Ivosidenib
3291,R132,B,Sensitivity/Response,Glioma,Mutant IDH1 Inhibitor DS-1001
3292,Mutation,B,Sensitivity/Response,Melanoma,Belvarafenib
3293,V600E,B,Sensitivity/Response,Cholangiocarcinoma,Dabrafenib+Trametinib
3294,V600E,B,Sensitivity/Response,Ovarian Cancer,Dabrafenib+Trametinib
3295,G12C,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Sotorasib
3296,ATM,B,Sensitivity/Response,Prostate Cancer,Olaparib
3297,Mutation,B,Sensitivity/Response,Prostate Cancer,Olaparib
3298,Mutation,B,Sensitivity/Response,Prostate Cancer,Olaparib
3299,Mutation,B,Sensitivity/Response,Breast Cancer,Rucaparib
3300,LOSS,B,Sensitivity/Response,Solid Tumor,Elimusertib
3301,D816V,C,Resistance,Cancer,Dasatinib+Imatinib
3302,NRG1 FUSIONS,C,Sensitivity/Response,Pancreatic Cancer,Afatinib
3303,E545,A,Sensitivity/Response,Breast Cancer,Alpelisib+Fulvestrant
3304,MUTATION,C,Sensitivity/Response,Colorectal Cancer,Pembrolizumab
3305,Mutation,B,Sensitivity/Response,Prostate Cancer,Olaparib
3306,Mutation,B,Sensitivity/Response,Prostate Cancer,Olaparib
3307,Mutation,B,Sensitivity/Response,Prostate Cancer,Olaparib
3308,Mutation,B,Sensitivity/Response,Prostate Cancer,Olaparib
3309,D842V,B,Sensitivity/Response,Gastrointestinal Stromal Tumor,Avapritinib
3310,CCDC6-RET,C,Sensitivity/Response,Colorectal Cancer,Agerafenib
3311,CAD-ALK,C,Sensitivity/Response,Colorectal Cancer,Entrectinib
3312,GOPC-ROS1,D,Sensitivity/Response,Glioblastoma,Lorlatinib
3313,V600E,B,Sensitivity/Response,Childhood Pilocytic Astrocytoma,Selumetinib
3314,KIAA1549-BRAF,B,Sensitivity/Response,Childhood Pilocytic Astrocytoma,Selumetinib
3315,Mutation,B,Sensitivity/Response,Childhood Low-grade Glioma,Selumetinib
3316,Amplification,B,Sensitivity/Response,Breast Cancer,Lucitanib
3317,SLC3A2-NRG1,C,Sensitivity/Response,Mucinous Adenocarcinoma,Afatinib
3318,CD74-NRG1,C,Sensitivity/Response,Mucinous Adenocarcinoma,Afatinib
3319,SLC3A2-NRG1,C,Sensitivity/Response,Lung Adenocarcinoma,Afatinib
3320,ATP1B1-NRG1,C,Sensitivity/Response,Pancreatic Ductal Adenocarcinoma,Afatinib
3321,APP-NRG1,C,Sensitivity/Response,Pancreatic Ductal Adenocarcinoma,Afatinib
3322,CD74-NRG1,C,Sensitivity/Response,Mucinous Adenocarcinoma,Afatinib
3323,SLC3A2-NRG1,C,Sensitivity/Response,Mucinous Adenocarcinoma,Erlotinib+Lumretuzumab
3324,ETV6-NTRK3,A,Sensitivity/Response,Solid Tumor,Larotrectinib
3325,R1004G,C,Sensitivity/Response,Head And Neck Cancer,Crizotinib
3326,Amplification,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Crizotinib
3327,Exon 14 Mutation,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Crizotinib
3328,N549H,D,Sensitivity/Response,Chronic Myeloid Leukemia,Bosutinib
3329,N549H,D,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
3330,V561M,D,Resistance,Chronic Myeloid Leukemia,Bosutinib
3331,V561M,D,Resistance,Chronic Myeloid Leukemia,Dasatinib
3332,D842V,D,Sensitivity/Response,Chronic Myeloid Leukemia,Bosutinib
3333,KIF5B-RET V804L,D,Resistance,Chronic Myeloid Leukemia,Dasatinib
3334,V804M,D,Resistance,Chronic Myeloid Leukemia,Dasatinib
3335,R849W,D,Resistance,Chronic Myeloid Leukemia,Bosutinib
3336,Overexpression,D,Sensitivity/Response,Hepatocellular Carcinoma,FGFR4 Inhibitor H3B-6527
3337,Overexpression,D,Resistance,Hepatocellular Carcinoma,Sorafenib
3338,OVEREXPRESSION,D,Resistance,Lung Adenocarcinoma,Erlotinib
3339,OVEREXPRESSION,D,Sensitivity/Response,Lung Adenocarcinoma,FGFR Inhibitor AZD4547+Erlotinib
3340,ITD N676K,C,Resistance,Acute Myeloid Leukemia,Midostaurin
3341,Fusion,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Alectinib
3342,Fusion,C,Sensitivity/Response,Pancreatic Adenocarcinoma,Erlotinib+Pertuzumab
3343,Fusion,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Ceritinib
3344,LOSS-OF-FUNCTION,B,Sensitivity/Response,Renal Cell Carcinoma,Pembrolizumab+Nivolumab
3345,LOSS-OF-FUNCTION,B,Sensitivity/Response,Renal Cell Carcinoma,Atezolizumab+Durvalumab
3346,CD74-ROS1 G2032R,D,Sensitivity/Response,Lung Adenocarcinoma,DS-6501b
3347,AMPLIFICATION,C,Sensitivity/Response,Ewing Sarcoma,Pazopanib
3348,Mutation,B,Sensitivity/Response,Solid Tumor,Vorinostat+Pazopanib
3349,Fusion,C,Sensitivity/Response,Anaplastic Large Cell Lymphoma,Ceritinib
3350,Fusion,C,Sensitivity/Response,Inflammatory Myofibroblastic Tumor,Ceritinib
3351,G466V,D,Sensitivity/Response,Colorectal Cancer,Panitumumab+Irinotecan
3352,L525R,D,Resistance,Solid Tumor,Cetuximab
3353,N486_P490del,D,Sensitivity/Response,Solid Tumor,Mitogen-Activated Protein Kinase Kinase Inhibitor
3354,Mutation,B,Sensitivity/Response,Urinary Bladder Cancer,Cisplatin+Gemcitabine
3355,G12C,D,Sensitivity/Response,Solid Tumor,KRAS G12C Inhibitor MRTX849
3356,D594E,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Trametinib+Dabrafenib
3357,Class 3 Mutations,B,Sensitivity/Response,Colorectal Cancer,Cetuximab+Panitumumab
3358,V211D,C,Resistance,Colorectal Cancer,Binimetinib+Panitumumab
3359,V211D,D,Sensitivity/Response,Colorectal Cancer,MAP855
3360,Fusion,D,Sensitivity/Response,Acute Biphenotypic Leukemia,EPZ004777
3361,V600E,B,Sensitivity/Response,Langerhans Cell Sarcoma,Vemurafenib
3362,LOSS-OF-FUNCTION,B,Sensitivity/Response,Renal Cell Carcinoma,Nivolumab
3363,Exon 19 Deletion,B,Resistance,Lung Non-small Cell Carcinoma,Pembrolizumab+Nivolumab
3364,Exon 19 Deletion,B,Resistance,Lung Non-small Cell Carcinoma,Durvalumab+Atezolizumab+Avelumab
3365,gBRCAm,B,Sensitivity/Response,Her2-receptor Negative Breast Cancer,Olaparib
3366,Fusion,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Lorlatinib
3367,EML4-ALK G1202R and L1196M,C,Resistance,Lung Non-small Cell Carcinoma,Lorlatinib
3368,EML4-ALK G1202R and L1196M,D,Resistance,Cancer,Lorlatinib+Ceritinib+Brigatinib+Alectinib+Crizotinib
3369,ALK Fusion G1202R,D,Sensitivity/Response,Cancer,Lorlatinib
3370,EML4-ALK L1196M and L1198F,D,Sensitivity/Response,Cancer,Crizotinib
3371,EML4-ALK G1202R and L1198F,D,Resistance,Cancer,Lorlatinib+Brigatinib+Ceritinib+Alectinib
3372,FRAMESHIFT MUTATION,C,Sensitivity/Response,Uveal Melanoma,PD1 Inhibitor
3373,EML4-ALK L1196M,D,Sensitivity/Response,Cancer,Brigatinib+Alectinib+Lorlatinib+Ceritinib
3374,EML4-ALK L1196M,D,Resistance,Cancer,Crizotinib
3375,EML4-ALK G1202del,C,Resistance,Lung Non-small Cell Carcinoma,Ceritinib
3376,low expression,B,Sensitivity/Response,Glioblastoma,Akt/ERK Inhibitor ONC201
3377,K28M,B,Sensitivity/Response,Glioma,Akt/ERK Inhibitor ONC201
3378,K27M,B,Sensitivity/Response,Glioma,Akt/ERK Inhibitor ONC201
3379,EML4-ALK L1198F,D,Sensitivity/Response,Cancer,Crizotinib
3380,G697R,D,Resistance,Acute Myeloid Leukemia,Midostaurin+SU5614+K 252a
3381,EML4::ALK C1156Y-L1198F,D,Sensitivity/Response,Cancer,Crizotinib
3382,Exon 20 Insertion,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Osimertinib
3383,V600E,B,Sensitivity/Response,Colorectal Cancer,Cetuximab+Binimetinib+Encorafenib
3384,EML4-ALK C1156Y,D,Resistance,Cancer,Crizotinib
3385,V600R,B,Sensitivity/Response,Melanoma,BRAF Inhibitor
3386,V600D,C,Sensitivity/Response,Melanoma,BRAF Inhibitor
3387,L597,C,Sensitivity/Response,Melanoma,BRAF Inhibitor
3388,V600R,B,Sensitivity/Response,Melanoma,BRAF Inhibitor+Mitogen-Activated Protein Kinase Kinase Inhibitor
3389,V600D,C,Sensitivity/Response,Melanoma,BRAF Inhibitor+Mitogen-Activated Protein Kinase Kinase Inhibitor
3390,V600_K601>E,C,Sensitivity/Response,Melanoma,BRAF Inhibitor+Mitogen-Activated Protein Kinase Kinase Inhibitor
3391,V600M,B,Sensitivity/Response,Melanoma,BRAF Inhibitor+Mitogen-Activated Protein Kinase Kinase Inhibitor
3392,L597,B,Sensitivity/Response,Melanoma,BRAF Inhibitor+Mitogen-Activated Protein Kinase Kinase Inhibitor
3393,V601E,B,Sensitivity/Response,Melanoma,BRAF Inhibitor+Mitogen-Activated Protein Kinase Kinase Inhibitor
3394,G469,B,Sensitivity/Response,Melanoma,Mitogen-Activated Protein Kinase Kinase Inhibitor+BRAF Inhibitor
3395,Overexpression,B,Sensitivity/Response,Hepatocellular Carcinoma,Fisogatinib
3396,Amplification,C,Sensitivity/Response,Cholangiocarcinoma,Trastuzumab+Pertuzumab
3397,Amplification,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Crizotinib
3398,EXON 14 SKIPPING MUTATION,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Crizotinib
3399,R683G,D,Sensitivity/Response,Childhood B-cell Acute Lymphoblastic Leukemia,Sirolimus
3400,EXON 14 SKIPPING MUTATION,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Crizotinib
3401,EXON 14 SKIPPING MUTATION,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Crizotinib
3402,Alternative Transcript (ATI),D,Sensitivity/Response,Cancer,Crizotinib
3403,Amplification,B,Sensitivity/Response,Stomach Cancer,Trastuzumab Deruxtecan
3404,Amplification,B,Sensitivity/Response,Breast Cancer,Trastuzumab Deruxtecan
3405,Fusion,C,Sensitivity/Response,Pancreatic Cancer,Larotrectinib
3406,Mutation,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Gefitinib+Pemetrexed
3407,Expression,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Afatinib
3408,Expression,C,Resistance,Lung Non-small Cell Carcinoma,Gefitinib+Erlotinib
3409,SNX2-ABL1,D,Resistance,B-lymphoblastic Leukemia/lymphoma,Dasatinib+Imatinib
3410,D594H,D,Sensitivity/Response,Cancer,Enfortumab Vedotin
3411,V60E,C,Resistance,Melanoma,Vemurafenib+Dabrafenib
3412,G128V,C,Resistance,Melanoma,Vemurafenib+Dabrafenib
3413,V154I,C,Resistance,Melanoma,Dabrafenib+Vemurafenib
3414,P124S,C,Resistance,Melanoma,Dabrafenib+Vemurafenib
3415,P124L,C,Resistance,Melanoma,Vemurafenib+Dabrafenib
3416,C125S,C,Resistance,Melanoma,Dabrafenib+Vemurafenib
3417,V35M,C,Resistance,Melanoma,Dabrafenib+Vemurafenib
3418,L46F,C,Resistance,Melanoma,Dabrafenib+Vemurafenib
3419,N126D,C,Resistance,Melanoma,Vemurafenib+Dabrafenib
3420,Amplificatioin,C,Resistance,Melanoma,Dabrafenib+Vemurafenib
3421,P29S,B,Resistance,Melanoma,Vemurafenib+Dabrafenib
3422,mutation,C,Resistance,Melanoma,Dabrafenib+Vemurafenib
3423,C125S,C,Resistance,Melanoma,Dabrafenib+Trametinib
3424,Amplification,C,Resistance,Melanoma,Dabrafenib+Trametinib
3425,Q61K,B,Resistance,Melanoma,Dabrafenib+Trametinib
3426,Loss,B,Resistance,Melanoma,Dabrafenib+Vemurafenib
3427,Exon 20 Insertion,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Trastuzumab Emtansine
3428,G2032R,B,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
3429,D2033N,C,Resistance,Lung Cancer,Crizotinib
3430,S1986F,C,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
3431,G2032R,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Repotrectinib
3432,G623E,C,Sensitivity/Response,Mammary Analogue Secretory Carcinoma,Repotrectinib
3433,S1986Y/F,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Lorlatinib
3434,R2033N,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Cabozantinib
3435,D2033N,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Cabozantinib
3436,K57N,C,Resistance,Melanoma,Selumetinib
3437,M918T,B,Sensitivity/Response,Thyroid Gland Medullary Carcinoma,Cabozantinib
3438,K3326*,C,Sensitivity/Response,Glioblastoma,Olaparib+Temozolomide
3439,Mutation,B,Sensitivity/Response,Acute Myeloid Leukemia,Gilteritinib
3440,Amplification,B,Sensitivity/Response,Stomach Cancer,Savolitinib
3441,N486_P490del,C,Sensitivity/Response,Pancreatic Cancer,Trametinib
3442,H123Q,C,Resistance,Pancreatic Cancer,Trametinib
3443,G132D,C,Resistance,Pancreatic Adenocarcinoma,Trametinib
3444,G132S,C,Resistance,Pancreatic Adenocarcinoma,Trametinib
3445,AKAP9-BRAF,C,Sensitivity/Response,Congenital Melanocytic Nevus,Trametinib
3446,D594G,D,Sensitivity/Response,Cancer,Trametinib
3447,V600E,B,Sensitivity/Response,Thyroid Gland Papillary Carcinoma,Dabrafenib
3448,V600E,B,Sensitivity/Response,Thyroid Gland Papillary Carcinoma,Trametinib+Dabrafenib
3449,NRF1-BRAF,C,Sensitivity/Response,Transitional Cell Carcinoma,Trametinib
3450,BCR-ABL T315V,D,Sensitivity/Response,Chronic Myeloid Leukemia,Axitinib
3451,BCR-ABL V299L,D,Sensitivity/Response,Chronic Myeloid Leukemia,Axitinib
3452,BCR-ABL T315A,D,Sensitivity/Response,Chronic Myeloid Leukemia,Axitinib
3453,BCR-ABL E279K,D,Sensitivity/Response,Chronic Myeloid Leukemia,Axitinib
3454,BCR-ABL F317R,D,Resistance,Chronic Myeloid Leukemia,Axitinib
3455,BCR-ABL L248R F359I,D,Resistance,Chronic Myeloid Leukemia,Axitinib
3456,BCR-ABL L248R,D,Resistance,Chronic Myeloid Leukemia,Axitinib
3457,BCR-ABL T315I,D,Resistance,Acute Lymphoblastic Leukemia,Imatinib+Dasatinib+Nilotinib
3458,BCR-ABL T315I,D,Resistance,Chronic Myeloid Leukemia,Dasatinib+Nilotinib+Imatinib
3459,BCR-ABL E255K V299L,D,Sensitivity/Response,Chronic Myeloid Leukemia,Ponatinib+Dasatinib
3460,RCSD1-ABL1,C,Sensitivity/Response,Childhood B-cell Acute Lymphoblastic Leukemia,Imatinib
3461,RCSD1-ABL1,C,Sensitivity/Response,B-lymphoblastic Leukemia/lymphoma,Imatinib
3462,Amplification,D,Sensitivity/Response,Glioblastoma,Talazoparib
3463,EXON 11-19 DELETION,C,Sensitivity/Response,Head And Neck Squamous Cell Carcinoma,Fluorouracil+Leucovorin
3464,Overexpression,C,Sensitivity/Response,Multiple Myeloma,Bortezomib
3465,Amplification,B,Sensitivity/Response,Cancer,Ribociclib
3466,Overexpression,D,Sensitivity/Response,Thyroid Gland Anaplastic Carcinoma,Ribociclib
3467,Amplification,D,Sensitivity/Response,Ovarian Cancer,Dinaciclib
3468,Overexpression,D,Resistance,Ovarian Cancer,Palbociclib
3469,MET-ATXN7L1,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Crizotinib
3470,LOSS-OF-FUNCTION,B,Adverse Response,Childhood Acute Lymphocytic Leukemia,Mercaptopurine+Thioguanine+Azathioprine
3471,EXON 14 SKIPPING MUTATION,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Capmatinib
3472,EXON 14 SKIPPING MUTATION,C,Sensitivity/Response,Histiocytic And Dendritic Cell Cancer,Crizotinib
3473,EXON 14 SKIPPING MUTATION,D,Sensitivity/Response,Cancer,Capmatinib
3474,EXPRESSION,D,Sensitivity/Response,Childhood B-cell Acute Lymphoblastic Leukemia,Dexamethasone+Ribociclib
3475,Amplification,D,Sensitivity/Response,Ovarian Cancer,Cisplatin+Dinaciclib
3476,OVEREXPRESSION,D,Sensitivity/Response,Glioblastoma Proneural Subtype,Palbociclib
3477,EXPRESSION,D,Sensitivity/Response,Childhood B-cell Acute Lymphoblastic Leukemia,Dexamethasone+Ribociclib
3478,Amplification,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Erlotinib
3479,Overexpression,D,Sensitivity/Response,Glioma,Radiation Therapy+Gefitinib
3480,Overexpression,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Pertuzumab
3481,Overexpression,D,Resistance,Colorectal Cancer,Cetuximab
3482,Overexpression,D,Sensitivity/Response,Colorectal Cancer,Lapatinib+Trastuzumab
3483,Amplification,D,Sensitivity/Response,Colorectal Cancer,Afatinib
3484,Amplification,D,Sensitivity/Response,Stomach Cancer,Afatinib
3485,Exon 18 Mutation,A,Sensitivity/Response,Gastrointestinal Stromal Tumor,Avapritinib
3486,Amplification,B,Sensitivity/Response,Transitional Cell Carcinoma,Afatinib
3487,Amplification,C,Sensitivity/Response,Adenosquamous Lung Carcinoma,Pazopanib
3488,R367Q,C,Resistance,Childhood Acute Lymphocytic Leukemia,Thioguanine+Mercaptopurine
3489,R238W,D,Resistance,Childhood Acute Lymphocytic Leukemia,Thioguanine+Mercaptopurine
3490,S445F,D,Resistance,Childhood Acute Lymphocytic Leukemia,Thioguanine+Mercaptopurine
3491,Rearrangement,D,Sensitivity/Response,Acute Biphenotypic Leukemia,
3492,BCR-ABL D363G,C,Resistance,Chronic Myeloid Leukemia,Imatinib
3493,BCR-ABL E255V,C,Resistance,Chronic Myeloid Leukemia,Imatinib
3494,BCR-ABL E98G,C,Resistance,Chronic Myeloid Leukemia,Imatinib
3495,BCR-ABL L384M,C,Resistance,Chronic Myeloid Leukemia,Imatinib
3496,BCR-ABL M244V,C,Resistance,Chronic Myeloid Leukemia,Imatinib
3497,BCR-ABL L364I,C,Resistance,Chronic Myeloid Leukemia,Imatinib
3498,BCR-ABL V186A,C,Resistance,Chronic Myeloid Leukemia,Imatinib
3499,BCR-ABL Y253H,C,Resistance,Chronic Myeloid Leukemia,Imatinib
3500,Overexpression,D,Sensitivity/Response,Colon Cancer,Rogaratinib
3501,Overexpression,D,Sensitivity/Response,Lung Cancer,Rogaratinib+Docetaxel
3502,Overexpression,D,Sensitivity/Response,Colorectal Cancer,Erdafitinib
3503,P253R,C,Sensitivity/Response,Head And Neck Squamous Cell Carcinoma,Pazopanib
3504,S249C,C,Sensitivity/Response,Transitional Cell Carcinoma,Pazopanib
3505,Amplification,C,Sensitivity/Response,Ewing Sarcoma,Pazopanib
3506,AMPLIFICATION,C,Sensitivity/Response,Ewing Sarcoma,Pazopanib
3507,BCR-ABL,D,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib+Bafetinib+Nilotinib
3508,BCR-ABL F317L,D,Resistance,Cancer,Dasatinib+Imatinib
3509,Exon 14 Mutation,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Crizotinib
3510,BCR-ABL M351T,D,Resistance,Cancer,Imatinib
3511,BCR-ABL T315A,D,Resistance,Cancer,Imatinib+Dasatinib
3512,BCR-ABL F317V,D,Resistance,Cancer,Dasatinib
3513,BCR-ABL H396P,D,Resistance,Cancer,Imatinib
3514,BCR-ABL Y253F,D,Resistance,Cancer,Imatinib
3515,BCR-ABL Q252H,D,Resistance,Cancer,Bafetinib+Imatinib
3516,BCR-ABL M244V,D,Resistance,Cancer,Bafetinib+Imatinib
3517,Overexpression,D,Resistance,Esophageal Carcinoma,Cisplatin
3518,OVEREXPRESSION,C,Sensitivity/Response,Sarcoma,Ruxolitinib
3519,BCR-ABL G250E,D,Resistance,Cancer,Imatinib+Bafetinib
3520,OVEREXPRESSION,B,Sensitivity/Response,Neuroendocrine Tumor,Pazopanib
3521,Amplification,B,Sensitivity/Response,Salivary Gland Cancer,Trastuzumab Emtansine
3522,G719X,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Osimertinib
3523,L861Q,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Osimertinib
3524,S768I,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Osimertinib
3525,Y1021H,C,Sensitivity/Response,Lung Adenocarcinoma,Crizotinib
3526,G469E,C,Sensitivity/Response,Breast Ductal Carcinoma,Trametinib
3527,R367Q,D,Resistance,Childhood Acute Lymphocytic Leukemia,Mercaptopurine+Thioguanine
3528,EML4-ALK L1196M,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Ensartinib
3529,Expression,C,Sensitivity/Response,Glioblastoma,Crizotinib
3530,OVEREXPRESSION,D,Resistance,Breast Cancer,Olaparib
3531,OVEREXPRESSION,D,Sensitivity/Response,Sarcoma,Trabectedin+Olaparib
3532,Overexpression,D,Resistance,Lung Non-small Cell Carcinoma,Ceritinib+Crizotinib
3533,V559D,D,Sensitivity/Response,Gastrointestinal Stromal Tumor,CHMFL-KIT-031
3534,Fusion,A,Sensitivity/Response,Lung Non-small Cell Carcinoma,Alectinib
3535,Amplification,D,Sensitivity/Response,Gastric Adenocarcinoma,Cabozantinib
3536,OVEREXPRESSION,D,Resistance,Chronic Myeloid Leukemia,Nilotinib
3537,D183H,D,Resistance,Childhood B-cell Acute Lymphoblastic Leukemia,Thioguanine+Mercaptopurine
3538,T303S,D,Resistance,Childhood B-cell Acute Lymphoblastic Leukemia,Mercaptopurine+Thioguanine
3539,L191F,D,Resistance,Childhood B-cell Acute Lymphoblastic Leukemia,Thioguanine+Mercaptopurine
3540,D183E,D,Resistance,Childhood B-cell Acute Lymphoblastic Leukemia,Thioguanine+Mercaptopurine
3541,K176N,D,Resistance,Childhood B-cell Acute Lymphoblastic Leukemia,Thioguanine+Mercaptopurine
3542,G174E,D,Resistance,Childhood B-cell Acute Lymphoblastic Leukemia,Mercaptopurine+Thioguanine
3543,N144S,D,Resistance,Childhood B-cell Acute Lymphoblastic Leukemia,Mercaptopurine+Thioguanine
3544,N114D,D,Resistance,Childhood B-cell Acute Lymphoblastic Leukemia,Mercaptopurine+Thioguanine
3545,S103I,D,Resistance,Childhood B-cell Acute Lymphoblastic Leukemia,Mercaptopurine+Thioguanine
3546,S103N,D,Resistance,Childhood B-cell Acute Lymphoblastic Leukemia,Thioguanine+Mercaptopurine
3547,S103T,D,Resistance,Childhood B-cell Acute Lymphoblastic Leukemia,Mercaptopurine+Thioguanine
3548,A190V,D,Resistance,Childhood B-cell Acute Lymphoblastic Leukemia,Thioguanine+Mercaptopurine
3549,A190T,D,Resistance,Childhood B-cell Acute Lymphoblastic Leukemia,Mercaptopurine+Thioguanine
3550,N144S,D,Sensitivity/Response,Childhood B-cell Acute Lymphoblastic Leukemia,Cytarabine
3551,L191F,D,Sensitivity/Response,Childhood B-cell Acute Lymphoblastic Leukemia,Cytarabine
3552,S103T,D,Sensitivity/Response,Childhood B-cell Acute Lymphoblastic Leukemia,Mercaptopurine+Lometrexol
3553,A190T,D,Sensitivity/Response,Childhood B-cell Acute Lymphoblastic Leukemia,Lometrexol+Mercaptopurine
3554,EWSR1-ATF1,B,Sensitivity/Response,Clear Cell Sarcoma,Crizotinib
3555,Overexpression,D,Sensitivity/Response,Ovarian Clear Cell Carcinoma,Cabozantinib
3556,REARRANGEMENT,A,Sensitivity/Response,Lung Non-small Cell Carcinoma,Crizotinib
3557,Overexpression,D,Sensitivity/Response,High Grade Glioma,Dasatinib
3558,BCR-ABL S438C,C,Resistance,Chronic Myeloid Leukemia,Dasatinib
3559,Overexpression,D,Resistance,Ovarian Cancer,Cisplatin+Picoplatin
3560,Overexpression,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,FGFR Inhibitor AZD4547
3561,Amplification,D,Sensitivity/Response,Stomach Cancer,Erdafitinib
3562,Amplification,D,Sensitivity/Response,Lung Cancer,Erdafitinib
3563,Overexpression,D,Resistance,Rhabdomyosarcoma,Bazedoxifene
3564,S646F,D,Sensitivity/Response,Acute Lymphoblastic Leukemia,Ruxolitinib
3565,H1112L,D,Sensitivity/Response,Cancer,Tepotinib
3566,MUTATION,B,Sensitivity/Response,Hereditary Renal Cell Carcinoma,Metformin+Vandetanib
3567,Fusion,D,Sensitivity/Response,Cholangiocarcinoma,Derazantinib
3568,G101V,C,Resistance,Chronic Lymphocytic Leukemia,Venetoclax
3569,Mutation,B,Resistance,Glioblastoma,Temozolomide
3570,M237I,D,Resistance,Glioblastoma,Temozolomide
3571,R273H,D,Resistance,Glioblastoma,Temozolomide
3572,Overexpression,B,Sensitivity/Response,Hepatocellular Carcinoma,Sunitinib
3573,Overexpression,D,Sensitivity/Response,Rhabdomyosarcoma,Sunitinib
3574,Amplification,D,Sensitivity/Response,Lung Squamous Cell Carcinoma,Imatinib+Sunitinib
3575,BCR-PDGFRA,C,Sensitivity/Response,B-cell Acute Lymphoblastic Leukemia,Imatinib
3576,COL1A1-PDGFB,C,Sensitivity/Response,Dermatofibrosarcoma Protuberans,Sunitinib
3577,Overexpression,C,Sensitivity/Response,Dermatofibrosarcoma Protuberans,Sunitinib
3578,ETV6-NTRK3,C,Sensitivity/Response,B-lymphoblastic Leukemia/lymphoma,Larotrectinib
3579,ETV6-NTRK3,D,Sensitivity/Response,Acute Myeloid Leukemia,Entrectinib
3580,E542K,D,Resistance,Breast Cancer,PI-103
3581,E545K,D,Resistance,Breast Cancer,PI-103
3582,H1047L,D,Sensitivity/Response,Breast Cancer,PI-103
3583,H1047R,D,Sensitivity/Response,Breast Cancer,PI-103
3584,K111N,D,Sensitivity/Response,Her2-receptor Positive Breast Cancer,PI-103
3585,Loss,D,Sensitivity/Response,Her2-receptor Positive Breast Cancer,PI-103
3586,E542K,D,Sensitivity/Response,Her2-receptor Positive Breast Cancer,PI3Ka/Di
3587,E542K,D,Sensitivity/Response,Breast Cancer,PI3Ka/Di
3588,E545K,D,Sensitivity/Response,Her2-receptor Positive Breast Cancer,PI3Ka/Di
3589,E545K,D,Sensitivity/Response,Breast Cancer,PI3Ka/Di
3590,H1047L,D,Sensitivity/Response,Breast Cancer,PI3Ka/Di
3591,K111N,D,Sensitivity/Response,Her2-receptor Positive Breast Cancer,PI3Ka/Di
3592,Loss,D,Resistance,Breast Cancer,PI3Ka/Di
3593,Loss,D,Resistance,Her2-receptor Positive Breast Cancer,PI3Ka/Di
3594,C797S,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Cetuximab+Brigatinib
3595,V600E,D,Sensitivity/Response,Thyroid Gland Cancer,PLX4720+Ponatinib
3596,V600,B,Sensitivity/Response,Childhood Low-grade Glioma,Dabrafenib
3597,G328V,D,Sensitivity/Response,"Diffuse Midline Glioma, H3 K27M-mutant",MEK-1/MEKK-1 Inhibitor E6201
3598,V600E,D,Sensitivity/Response,Thyroid Gland Cancer,Ponatinib+PLX4720
3599,TPM3-NTRK1,C,Sensitivity/Response,Thyroid Gland Papillary Carcinoma,Larotrectinib
3600,Amplification,A,Sensitivity/Response,Her2-receptor Positive Breast Cancer,Neratinib+Trastuzumab
3601,Amplification,A,Sensitivity/Response,Her2-receptor Positive Breast Cancer,Neratinib+Capecitabine
3602,Amplification,A,Sensitivity/Response,Her2-receptor Positive Breast Cancer,Trastuzumab+Neratinib
3603,Amplification,B,Sensitivity/Response,Her2-receptor Positive Breast Cancer,Neratinib+Capecitabine
3604,L718V and L718Q,C,Resistance,Lung Adenocarcinoma,Osimertinib
3605,L858R,C,Sensitivity/Response,Lung Adenocarcinoma,Osimertinib
3606,L755S,C,Sensitivity/Response,Triple-receptor Negative Breast Cancer,Capecitabine+Neratinib
3607,P29S,D,Resistance,Skin Melanoma,PLX4720
3608,C797S,D,Resistance,Lung Adenocarcinoma,Osimertinib
3609,L718Q,D,Resistance,Lung Adenocarcinoma,Osimertinib
3610,L718V,D,Resistance,Lung Adenocarcinoma,Osimertinib
3611,S249C,D,Sensitivity/Response,Transitional Cell Carcinoma,Ponatinib
3612,Amplification,D,Sensitivity/Response,Stomach Cancer,Ponatinib
3613,Amplification,D,Sensitivity/Response,Stomach Cancer,Ponatinib
3614,V955I,C,Resistance,Colorectal Cancer,Cetuximab
3615,G12C,B,Sensitivity/Response,Cancer,Sotorasib
3616,L718V,D,Sensitivity/Response,Cancer,Erlotinib
3617,C797S,D,Sensitivity/Response,Cancer,Afatinib
3618,L718Q,D,Sensitivity/Response,Cancer,Afatinib
3619,Amplification,D,Sensitivity/Response,Her2-receptor Positive Breast Cancer,Neratinib
3620,Amplification,D,Sensitivity/Response,Her2-receptor Positive Breast Cancer,Neratinib
3621,L718V,D,Sensitivity/Response,Cancer,Afatinib
3622,L718Q,D,Resistance,Cancer,Erlotinib
3623,C797S,D,Sensitivity/Response,Cancer,Erlotinib
3624,R238W,D,Resistance,Acute Lymphoblastic Leukemia,Mercaptopurine+Thioguanine
3625,C797G,D,Resistance,Lung Adenocarcinoma,Osimertinib
3626,L792H,D,Resistance,Lung Adenocarcinoma,Osimertinib
3627,C797S,D,Sensitivity/Response,Lung Adenocarcinoma,Osimertinib+Erlotinib
3628,L718Q,D,Sensitivity/Response,Lung Adenocarcinoma,Osimertinib+Erlotinib
3629,Overexpression,D,Resistance,Colorectal Cancer,Oxaliplatin
3630,Expression,D,Resistance,Colon Cancer,Oxaliplatin
3631,BCR-ABL S417Y,C,Resistance,Chronic Myeloid Leukemia,Imatinib
3632,BCR-ABL E355G,C,Resistance,Chronic Myeloid Leukemia,Imatinib
3633,BCR-ABL F486S,C,Resistance,Chronic Myeloid Leukemia,Imatinib
3634,BCR-ABL E459K,C,Resistance,Chronic Myeloid Leukemia,Imatinib
3635,Double Ph,C,Resistance,Chronic Myeloid Leukemia,Imatinib
3636,P-Loop Mutation,C,Resistance,Chronic Myeloid Leukemia,Imatinib
3637,D835Y,D,Sensitivity/Response,Cancer,Gilteritinib
3638,D835Y,D,Sensitivity/Response,Acute Myeloid Leukemia,Gilteritinib
3639,OVEREXPRESSION,B,Resistance,Lung Non-small Cell Carcinoma,Cisplatin
3640,OVEREXPRESSION,D,Resistance,Lung Non-small Cell Carcinoma,Cisplatin
3641,E545K,D,Resistance,Cervical Cancer,Radiation Ionizing Radiotherapy+Cisplatin
3642,OVEREXPRESSION,D,Sensitivity/Response,Childhood B-cell Acute Lymphoblastic Leukemia,Dexamethasone+Ribociclib
3643,OVEREXPRESSION,D,Sensitivity/Response,Childhood B-cell Acute Lymphoblastic Leukemia,Dexamethasone+Ribociclib
3644,Expression,D,Sensitivity/Response,Glioblastoma,Pexidartinib
3645,Expression,D,Sensitivity/Response,Glioblastoma,Pexidartinib+Vatalanib
3646,Expression,D,Sensitivity/Response,Glioblastoma,Pexidartinib+Dovitinib
3647,Fusion,B,Sensitivity/Response,Cholangiolocellular Carcinoma,Pemigatinib
3648,G101V,B,Resistance,Chronic Lymphocytic Leukemia,Venetoclax
3649,DELETION (p.K227_T233del),C,Resistance,Acute Promyelocytic Leukemia,Tamibarotene+Tretinoin
3650,Mutation,B,Resistance,Glioblastoma,Pembrolizumab+Nivolumab
3651,PML-RARA A216V,B,Resistance,Acute Promyelocytic Leukemia,Arsenic Trioxide
3652,PML-RARA S214L,B,Resistance,Acute Promyelocytic Leukemia,Arsenic Trioxide
3653,PML-RARA A216T,B,Resistance,Acute Promyelocytic Leukemia,Arsenic Trioxide
3654,E545K,D,Sensitivity/Response,Her2-receptor Positive Breast Cancer,Trastuzumab+Dactolisib
3655,E545K,D,Sensitivity/Response,Her2-receptor Positive Breast Cancer,Dactolisib+Lapatinib+Trastuzumab
3656,H1047R,D,Sensitivity/Response,Her2-receptor Positive Breast Cancer,Trastuzumab+Dactolisib
3657,G101A,B,Resistance,Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma,Venetoclax
3658,G101V,B,Resistance,Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma,Venetoclax
3659,F104S,B,Resistance,Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma,Venetoclax
3660,F104L,B,Resistance,Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma,Venetoclax
3661,R107_R110dup,B,Resistance,Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma,Venetoclax
3662,A113G,B,Resistance,Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma,Venetoclax
3663,L119V,B,Resistance,Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma,Venetoclax
3664,VIII,D,Sensitivity/Response,Glioblastoma,Afatinib
3665,VIII,D,Sensitivity/Response,Glioblastoma,Afatinib+Pacritinib
3666,G810,C,Resistance,Lung Non-small Cell Carcinoma,Selpercatinib
3667,G810,C,Resistance,Thyroid Gland Medullary Carcinoma,Selpercatinib
3668,G598V,D,Sensitivity/Response,Glioblastoma,Afatinib+Osimertinib+Erlotinib
3669,G598V,D,Sensitivity/Response,Glioblastoma,Afatinib+Pacritinib
3670,G598V,D,Sensitivity/Response,Glioblastoma,Pacritinib+Erlotinib
3671,EBF1-PDGFRB,C,Sensitivity/Response,"B-lymphoblastic Leukemia/lymphoma, BCR-ABL1–like",Chemotherapy+Imatinib
3672,G598V,D,Sensitivity/Response,Glioblastoma,Lapatinib+Pacritinib
3673,Amplification,D,Resistance,Her2-receptor Positive Breast Cancer,Trastuzumab
3674,Amplification,D,Sensitivity/Response,Her2-receptor Positive Breast Cancer,Lapatinib
3675,Amplification,D,Sensitivity/Response,Her2-receptor Positive Breast Cancer,Dactolisib
3676,Amplification,D,Sensitivity/Response,Her2-receptor Positive Breast Cancer,Lapatinib+Trastuzumab
3677,Amplification,D,Sensitivity/Response,Her2-receptor Positive Breast Cancer,Dactolisib+Lapatinib
3678,Amplification,D,Sensitivity/Response,Her2-receptor Positive Breast Cancer,Dactolisib+Trastuzumab
3679,Amplification,D,Sensitivity/Response,Her2-receptor Positive Breast Cancer,Dactolisib+Trastuzumab+Lapatinib
3680,Loss,D,Resistance,Her2-receptor Positive Breast Cancer,Trastuzumab
3681,Loss,D,Resistance,Her2-receptor Positive Breast Cancer,Lapatinib
3682,Loss,D,Resistance,Her2-receptor Positive Breast Cancer,Dactolisib
3683,Loss,D,Sensitivity/Response,Her2-receptor Positive Breast Cancer,Lapatinib+Trastuzumab
3684,Loss,D,Sensitivity/Response,Her2-receptor Positive Breast Cancer,Trastuzumab+Dactolisib+Lapatinib
3685,R248C,B,Sensitivity/Response,Transitional Cell Carcinoma,Erdafitinib
3686,Mutation,B,Sensitivity/Response,Pancreatic Cancer,Gemcitabine
3687,Loss,D,Sensitivity/Response,Her2-receptor Positive Breast Cancer,Trastuzumab+Dactolisib
3688,G598V,D,Sensitivity/Response,Glioblastoma,Pacritinib+Osimertinib
3689,Y693,D,Resistance,Acute Myeloid Leukemia,Gilteritinib
3690,Expression,B,Sensitivity/Response,Glioblastoma,3-Dimensional Conformal Radiation Therapy+Temozolomide+Nimotuzumab
3691,PML-RARA,B,Sensitivity/Response,Acute Promyelocytic Leukemia,Gemtuzumab Ozogamicin
3692,Mutation,B,Sensitivity/Response,Colorectal Cancer,Metformin
3693,D103Y,C,Resistance,Chronic Lymphocytic Leukemia,Venetoclax
3694,G101V,C,Resistance,Chronic Lymphocytic Leukemia,Venetoclax
3695,V156D,B,Resistance,Chronic Lymphocytic Leukemia,Venetoclax
3696,R129L,C,Resistance,Chronic Lymphocytic Leukemia,Venetoclax
3697,A113G,C,Resistance,Chronic Lymphocytic Leukemia,Venetoclax
3698,R107_R110dup,B,Resistance,Chronic Lymphocytic Leukemia,Venetoclax
3699,D103V,C,Resistance,Chronic Lymphocytic Leukemia,Venetoclax
3700,D103E,C,Resistance,Chronic Lymphocytic Leukemia,Venetoclax
3701,D103Y,B,Resistance,Chronic Lymphocytic Leukemia,Venetoclax
3702,A393E,C,Sensitivity/Response,Transitional Cell Carcinoma,AZD-4547
3703,S249C,C,Sensitivity/Response,Renal Pelvis Transitional Cell Carcinoma,AZD-4547
3704,R248C,B,Sensitivity/Response,Bladder Carcinoma,Infigratinib
3705,R248C,C,Sensitivity/Response,Transitional Cell Carcinoma,Dovitinib
3706,R248C,D,Sensitivity/Response,Solid Tumor,R3Mab
3707,LOSS,D,Sensitivity/Response,Malignant Pleural Mesothelioma,EPZ011989
3708,D835,B,Sensitivity/Response,Acute Myeloid Leukemia,Gilteritinib
3709,G101V,D,Resistance,Chronic Lymphocytic Leukemia,Venetoclax
3710,D103E,D,Resistance,Chronic Lymphocytic Leukemia,Venetoclax
3711,Y842C,D,Resistance,Acute Myeloid Leukemia,FLT3/ABL/Aurora Kinase Inhibitor KW-2449
3712,Y842C,D,Resistance,Acute Myeloid Leukemia,Sorafenib
3713,Y842C,D,Resistance,Acute Myeloid Leukemia,Sunitinib
3714,Y842C,D,Sensitivity/Response,Acute Myeloid Leukemia,Lestaurtinib
3715,Y842C,D,Sensitivity/Response,Acute Myeloid Leukemia,Midostaurin
3716,F691L,D,Resistance,Acute Myeloid Leukemia,Lestaurtinib
3717,F691L,D,Resistance,Acute Myeloid Leukemia,Midostaurin
3718,D835I,D,Sensitivity/Response,Acute Myeloid Leukemia,Gilteritinib
3719,D816V,D,Resistance,Chronic Myeloid Leukemia,Imatinib
3720,D816V,D,Sensitivity/Response,Chronic Myeloid Leukemia,Dasatinib
3721,D816V,D,Sensitivity/Response,Chronic Myeloid Leukemia,Imatinib
3722,H1047R,D,Sensitivity/Response,Colorectal Cancer,Akt Inhibitor MK2206+Vemurafenib
3723,Fusion,C,Sensitivity/Response,Melanoma,Trametinib+Cobimetinib
3724,F104I,C,Resistance,Follicular Lymphoma,Venetoclax
3725,F104I,D,Resistance,Follicular Lymphoma,Venetoclax
3726,TRUNCATING MUTATIONS AND DELETERIOUS SUBSTITUTIONS,D,Resistance,Acute Lymphoblastic Leukemia,Therapeutic Glucocorticoid
3727,Oncogenic Mutations (loss of function alterations),A,Sensitivity/Response,Prostate Carcinoma,Olaparib
3728,Oncogenic Mutations (loss of function alterations),A,Sensitivity/Response,Prostate Carcinoma,Olaparib
3729,V600E,D,Sensitivity/Response,Colorectal Cancer,Irinotecan+Vemurafenib+Cetuximab
3730,V600E,D,Sensitivity/Response,Colorectal Cancer,Vemurafenib+Erlotinib
3731,BCR-ABL Y253F,C,Resistance,Chronic Myeloid Leukemia,Imatinib
3732,ITD & TKD MUTATIONS,B,Sensitivity/Response,Acute Myeloid Leukemia,Midostaurin
3733,D835H,D,Sensitivity/Response,Acute Myeloid Leukemia,Gilteritinib
3734,D835V,D,Sensitivity/Response,Acute Myeloid Leukemia,Gilteritinib
3735,IGH-CRLF2,D,Sensitivity/Response,"B-lymphoblastic Leukemia/lymphoma, BCR-ABL1–like",Ruxolitinib
3736,E545K,D,Resistance,Her2-receptor Positive Breast Cancer,Trastuzumab
3737,H1047R,D,Resistance,Her2-receptor Positive Breast Cancer,Trastuzumab
3738,C420R,D,Resistance,Her2-receptor Positive Breast Cancer,Trastuzumab
3739,K111N,D,Resistance,Her2-receptor Positive Breast Cancer,Trastuzumab
3740,F691L,D,Resistance,Acute Myeloid Leukemia,Gilteritinib
3741,MUTATION,B,Sensitivity/Response,Core Binding Factor Acute Myeloid Leukemia,Dasatinib
3742,A203T,D,Sensitivity/Response,Myelofibrosis,Entrectinib+Larotrectinib
3743,R458G,C,Sensitivity/Response,Atypical Chronic Myeloid Leukemia,Larotrectinib+Entrectinib
3744,V411L,C,Sensitivity/Response,Colorectal Cancer,
3745,S249C,D,Resistance,Transitional Cell Carcinoma,Cisplatin
3746,V600E,B,Resistance,Colorectal Cancer,Bevacizumab+Oxaliplatin+Capecitabine+Cetuximab
3747,Y842C,D,Resistance,Acute Myeloid Leukemia,Quizartinib
3748,Fusion,A,Sensitivity/Response,Lung Non-small Cell Carcinoma,Alectinib
3749,F691L,D,Sensitivity/Response,Acute Myeloid Leukemia,Pexidartinib
3750,M664I,D,Resistance,Acute Myeloid Leukemia,Pexidartinib
3751,ITD & D839G,D,Resistance,Acute Myeloid Leukemia,Pexidartinib
3752,K663Q,D,Sensitivity/Response,Acute Myeloid Leukemia,Sunitinib
3753,D839A,D,Resistance,Acute Myeloid Leukemia,Pexidartinib
3754,D839N,D,Resistance,Acute Myeloid Leukemia,Pexidartinib
3755,D839H,D,Resistance,Acute Myeloid Leukemia,Pexidartinib
3756,F691L,B,Sensitivity/Response,Acute Myeloid Leukemia,Pexidartinib
3757,Loss,B,Sensitivity/Response,Prostate Cancer,Ipatasertib
3758,R201H,C,Sensitivity/Response,Appendix Cancer,Trametinib
3759,Mutation,B,Resistance,Her2-receptor Positive Breast Cancer,Capecitabine+Lapatinib
3760,Mutation,B,Sensitivity/Response,Ovary Serous Adenocarcinoma,Binimetinib
3761,S249C,D,Sensitivity/Response,Urinary Bladder Cancer,
3762,D594N,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Trametinib+Dabrafenib
3763,EML4-ALK C1156Y,C,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
3764,G101V,D,Resistance,Chronic Lymphocytic Leukemia,Venetoclax
3765,Mutation,A,Sensitivity/Response,Prostate Cancer,Olaparib
3766,F691L,D,Resistance,Acute Myeloid Leukemia,Quizartinib
3767,F691L,D,Resistance,Acute Myeloid Leukemia,Sunitinib
3768,F691L,D,Resistance,Acute Myeloid Leukemia,Sorafenib
3769,F691L,D,Resistance,Acute Myeloid Leukemia,FLT3/ABL/Aurora Kinase Inhibitor KW-2449
3770,EXON 14 SKIPPING MUTATION,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Capmatinib
3771,EXON 14 SKIPPING MUTATION,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Tepotinib
3772,Amplification,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Capmatinib
3773,Fusion,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Selpercatinib
3774,Mutation,B,Sensitivity/Response,Thyroid Gland Medullary Carcinoma,Selpercatinib
3775,Fusion,B,Sensitivity/Response,Thyroid Gland Cancer,Selpercatinib
3776,Mutation,C,Sensitivity/Response,Acute Myeloid Leukemia,Venetoclax
3777,Mutation,C,Sensitivity/Response,Acute Myeloid Leukemia,Venetoclax
3778,N841I,D,Sensitivity/Response,Acute Myeloid Leukemia,Midostaurin
3779,EML4-ALK C1156Y,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Ensartinib
3780,EML4-ALK G1269A,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Ensartinib
3781,SQSTM1-NTRK1,C,Sensitivity/Response,Congenital Fibrosarcoma,Larotrectinib
3782,LMNA::NTRK1 e2-e10,C,Sensitivity/Response,Congenital Fibrosarcoma,Crizotinib
3783,Y373C,B,Sensitivity/Response,Transitional Cell Carcinoma,Erlotinib
3784,EML4::ALK e6-e19 G1269A and Amplification,C,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
3785,V658A,D,Resistance,Melanoma,Imatinib
3786,V658A,D,Sensitivity/Response,Melanoma,Crenolanib
3787,G12V,C,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
3788,RBPMS-MET,C,Sensitivity/Response,Congenital Fibrosarcoma,Cabozantinib
3789,ITD&F691(I/L),D,Sensitivity/Response,Acute Myeloid Leukemia,Ponatinib
3790,ITD & D835(V/Y/F/H),D,Resistance,Acute Myeloid Leukemia,Ponatinib
3791,ITD & Y842C,D,Resistance,Acute Myeloid Leukemia,Sorafenib+Ponatinib
3792,ITD & D839G,D,Sensitivity/Response,Acute Myeloid Leukemia,Quizartinib
3793,ITD & D839G,D,Resistance,Acute Myeloid Leukemia,Ponatinib+Sorafenib
3794,G697S,D,Resistance,Acute Myeloid Leukemia,Gilteritinib
3795,LMNA::NTRK1 e11-e10,C,Sensitivity/Response,Colorectal Cancer,Entrectinib
3796,LMNA::NTRK1 e2-e10,C,Sensitivity/Response,Sarcomatoid Carcinoma,TRK Inhibitor
3797,G636C,D,Sensitivity/Response,Stomach Cancer,FGFR Inhibitor ASP5878
3798,N535K,D,Sensitivity/Response,Rhabdomyosarcoma,"FGF/VEGF Receptor Tyrosine Kinase Inhibitor, PD173074"
3799,V550E,D,Sensitivity/Response,Rhabdomyosarcoma,"FGF/VEGF Receptor Tyrosine Kinase Inhibitor, PD173074"
3800,ITD and co-mutations,B,Resistance,Acute Myeloid Leukemia,Chemotherapy
3801,ITD D651G,D,Resistance,Acute Myeloid Leukemia,Sorafenib
3802,ITD  N676D,D,Resistance,Acute Myeloid Leukemia,Sorafenib
3803,ITD I687F,D,Resistance,Acute Myeloid Leukemia,Sorafenib
3804,ITD & Y842C,D,Resistance,Acute Myeloid Leukemia,Sorafenib
3805,ITD & TKD MUTATIONS,D,Resistance,Acute Myeloid Leukemia,Sorafenib
3806,Fusion,A,Sensitivity/Response,Lung Non-small Cell Carcinoma,Crizotinib
3807,ETV6-NTRK3,C,Sensitivity/Response,B-lymphoblastic Leukemia/lymphoma,Methotrexate+Larotrectinib+Etoposide
3808,G810C,C,Resistance,Cancer,Pralsetinib+Selpercatinib
3809,G810S,C,Resistance,Thyroid Gland Medullary Carcinoma,Pralsetinib+Selpercatinib
3810,Y806C,C,Resistance,Thyroid Gland Medullary Carcinoma,Pralsetinib+Selpercatinib
3811,Y806N,C,Resistance,Thyroid Gland Medullary Carcinoma,Pralsetinib+Selpercatinib
3812,V738A,D,Resistance,Cancer,Selpercatinib+Pralsetinib
3813,ITD,D,Sensitivity/Response,Acute Myeloid Leukemia,Gilteritinib
3814,ITD,D,Sensitivity/Response,Acute Myeloid Leukemia,Gilteritinib
3815,ETV6-NTRK3,D,Sensitivity/Response,B-lymphoblastic Leukemia/lymphoma,Larotrectinib
3816,Mutation,C,Sensitivity/Response,Ovary Serous Adenocarcinoma,Trametinib
3817,Q61K,C,Sensitivity/Response,Ovary Serous Adenocarcinoma,Trametinib
3818,Y842C,D,Sensitivity/Response,Acute Myeloid Leukemia,Midostaurin
3819,KIAA1549-BRAF,D,Sensitivity/Response,Childhood Pilocytic Astrocytoma,Selumetinib
3820,KIAA1549-BRAF,D,Sensitivity/Response,Childhood Pilocytic Astrocytoma,Trametinib
3821,R167Q (c.500G>A),C,Sensitivity/Response,Von Hippel-Lindau Disease,Pazopanib
3822,V600E,D,Resistance,Diffuse Large B-cell Lymphoma,Venetoclax
3823,N505I,D,Sensitivity/Response,Skin Melanoma,Sorafenib+Imatinib
3824,Overexpression,D,Resistance,Lung Adenocarcinoma,Cisplatin
3825,Overexpression,D,Sensitivity/Response,Lung Adenocarcinoma,Cisplatin+Panobinostat
3826,Loss-of-function,D,Sensitivity/Response,Prostate Cancer,Olaparib+Dasatinib
3827,Loss-of-function,D,Sensitivity/Response,Prostate Cancer,Talazoparib+Dasatinib
3828,Loss-of-function,D,Sensitivity/Response,Prostate Cancer,Dasatinib+Cisplatin
3829,Loss-of-function,D,Sensitivity/Response,Prostate Cancer,Talazoparib+Bosutinib
3830,Overexpression,D,Resistance,Ovarian Cancer,Cisplatin
3831,Mutation,B,Sensitivity/Response,Thyroid Gland Medullary Carcinoma,Cabozantinib
3832,Overexpression,D,Sensitivity/Response,Neuroblastoma,Niraparib+Talazoparib+Veliparib+Olaparib
3833,E17K,B,Sensitivity/Response,Cancer,Capivasertib
3834,Expression,B,Sensitivity/Response,Melanoma,Nivolumab+Pembrolizumab
3835,Expression,B,Sensitivity/Response,Lung Non-small Cell Carcinoma,Atezolizumab
3836,Expression,B,Sensitivity/Response,Nasopharynx Carcinoma,Nivolumab
3837,V600E,B,Sensitivity/Response,Thyroid Gland Papillary Carcinoma,Vemurafenib
3838,Mutation,B,Sensitivity/Response,Breast Cancer,Olaparib
3839,Fusion,C,Sensitivity/Response,Melanoma,Trametinib
3840,G697S,D,Reduced Sensitivity,Acute Myeloid Leukemia,Gilteritinib
3841,AMPLIFICATION,D,Sensitivity/Response,Glioblastoma,MDM2 Inhibitor KRT-232+RG7112
3842,Overexpression,D,Sensitivity/Response,Salivary Gland Adenoid Cystic Carcinoma,Gefitinib+Linsitinib+Crizotinib
3843,ITD,B,Sensitivity/Response,Acute Myeloid Leukemia,Sorafenib+Hematopoietic Cell Transplantation
3844,ITD,B,Sensitivity/Response,Acute Myeloid Leukemia,Hematopoietic Cell Transplantation+Sorafenib
3845,ITD & Y842C,D,Resistance,Acute Myeloid Leukemia,Sorafenib+Selinexor
3846,ITD & Y842C,D,Sensitivity/Response,Acute Myeloid Leukemia,FLT3 Inhibitor FF-10101 Succinate
3847,BCR-ABL G250E,D,Sensitivity/Response,Cancer,Dasatinib
3848,BCR-ABL H396P,D,Sensitivity/Response,Cancer,Dasatinib
3849,Amplification,D,Resistance,Lung Non-small Cell Carcinoma,JNJ38877605+PHA-665752
3850,G12V,D,Resistance,Head And Neck Squamous Cell Carcinoma,Alpelisib
3851,K383fs,D,Sensitivity/Response,Colon Carcinoma,7-Ethyl-10-Hydroxycamptothecin+Oxaliplatin
3852,AMPLIFICATION,D,Sensitivity/Response,Hepatocellular Carcinoma,Sorafenib
3853,Overexpression,C,Sensitivity/Response,Papillary Renal Cell Carcinoma,Sorafenib
3854,Overexpression,D,Sensitivity/Response,Neuroblastoma,Tazemetostat+GSK126
3855,Amplification,C,Resistance,Lung Non-small Cell Carcinoma,Crizotinib
3856,Overexpression,D,Sensitivity/Response,Breast Cancer,Mocetinostat
3857,G12C,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Selumetinib+ERK1/2 Inhibitor ATG-017
3858,SFPQ-ABL1,C,Sensitivity/Response,B-lymphoblastic Leukemia/lymphoma,Imatinib+Dasatinib
3859,RCSD1-ABL1,C,Sensitivity/Response,B-lymphoblastic Leukemia/lymphoma,Dasatinib
3860,RCSD1-ABL1,C,Sensitivity/Response,B-lymphoblastic Leukemia/lymphoma,Dasatinib
3861,RCSD1-ABL1,C,Reduced Sensitivity,B-lymphoblastic Leukemia/lymphoma,Dasatinib
3862,RCSD1-ABL1,C,Sensitivity/Response,B-lymphoblastic Leukemia/lymphoma,Dasatinib
3863,RCSD1-ABL1,C,Sensitivity/Response,"B-lymphoblastic Leukemia/lymphoma, BCR-ABL1–like",Tyrosine Kinase Inhibitor
3864,ETV6-ABL1,C,Sensitivity/Response,B-lymphoblastic Leukemia/lymphoma,Imatinib
3865,RANBP2-ABL1,C,Sensitivity/Response,"B-lymphoblastic Leukemia/lymphoma, BCR-ABL1–like",Dasatinib
3866,RCSD1-ABL1,C,Sensitivity/Response,B-lymphoblastic Leukemia/lymphoma,Ponatinib
3867,RCSD1-ABL1,D,Sensitivity/Response,B-lymphoblastic Leukemia/lymphoma,Ponatinib
3868,ITD,B,Sensitivity/Response,Acute Myeloid Leukemia,Pacritinib
3869,A767_V769dupASV,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Osimertinib
3870,N771_P772insL,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Osimertinib
3871,Exon 20 Insertion,B,Resistance,Lung Adenocarcinoma,Erlotinib
3872,D770_N771insG,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Osimertinib
3873,S768_D770dup,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Osimertinib
3874,A763_Y764insFQEA,C,Sensitivity/Response,Lung Non-small Cell Carcinoma,Osimertinib
3875,FGFR3-TACC3,C,Sensitivity/Response,Renal Pelvis Transitional Cell Carcinoma,FGFR Inhibitor AZD4547
3876,Overexpression,B,Sensitivity/Response,Breast Cancer,Bevacizumab
3877,Overexpression,B,Resistance,Breast Cancer,Panobinostat+Vorinostat+Trichostatin A
3878,Overexpression,D,Sensitivity/Response,Esophagus Squamous Cell Carcinoma,Adavosertib
3879,Overexpression,D,Resistance,Colorectal Cancer,Bevacizumab
3880,Deletion,D,Sensitivity/Response,Cancer,Fluorouracil+Cisplatin
3881,FGFR3-TACC3,C,Sensitivity/Response,Cervical Squamous Cell Carcinoma,FGFR Inhibitor AZD4547
3882,FGFR3-TACC3,C,Sensitivity/Response,Diffuse Astrocytoma,FGFR Inhibitor AZD4547
3883,BAG4-FGFR1,C,Sensitivity/Response,Carcinoma,FGFR Inhibitor AZD4547
3884,Loss-of-function,D,Sensitivity/Response,Neuroendocrine Tumor,JQ1
3885,Expression,D,Sensitivity/Response,B-cell Acute Lymphoblastic Leukemia,Ibrutinib
3886,Expression,D,Sensitivity/Response,B-cell Acute Lymphoblastic Leukemia,Ibrutinib
3887,overexpression of VEGF165b,D,Adverse Response,Colorectal Cancer,Bevacizumab
3888,overexpression of VEGF-Axxxa,B,Sensitivity/Response,Breast Cancer,Bevacizumab
3889,Mutation,B,Sensitivity/Response,Pancreatic Cancer,Rucaparib
3890,Mutation,C,Sensitivity/Response,Pancreatic Cancer,Rucaparib
3891,Mutation,B,Sensitivity/Response,Pancreatic Cancer,Rucaparib
3892,low ratio of VEGF165b/VEGFtotal,B,Sensitivity/Response,Colorectal Cancer,Bevacizumab
3893,Overexpression of VEGF121,B,Sensitivity/Response,Her2-receptor Negative Breast Cancer,Bevacizumab
3894,Overexpression of VEGF121 and VEGF110,B,Sensitivity/Response,Stomach Cancer,Bevacizumab
3895,Overexpression of VEGF121 and VEGF110,B,Sensitivity/Response,Breast Cancer,Bevacizumab
3896,Overexpression of VEGF121 and VEGF110,B,Sensitivity/Response,Breast Cancer,Bevacizumab
3897,Overexpression of VEGF121 and VEGF110,B,Sensitivity/Response,Breast Cancer,Bevacizumab
3898,Q575Δ,C,Sensitivity/Response,Acute Myeloid Leukemia,Gilteritinib
3899,Q575Δ,D,Sensitivity/Response,Acute Myeloid Leukemia,Tyrphostin AG 1295+Midostaurin+Sorafenib+Lestaurtinib
3900,Y572Δ,D,Sensitivity/Response,Acute Myeloid Leukemia,Quizartinib+Lestaurtinib+Crenolanib+Midostaurin+Sorafenib+Ponatinib
3901,E573Δ,D,Sensitivity/Response,Acute Myeloid Leukemia,Sorafenib+Midostaurin+Crenolanib+Ponatinib+Quizartinib+Lestaurtinib
3902,S574Δ,D,Sensitivity/Response,Acute Myeloid Leukemia,Lestaurtinib+Quizartinib+Crenolanib+Midostaurin+Ponatinib+Sorafenib
3903,Overexpression,D,Sensitivity/Response,Esophageal Cancer,CAN508+Alvocidib
3904,Overexpression,D,Sensitivity/Response,Hepatocellular Carcinoma,Dinaciclib
3905,Overexpression,D,Resistance,Lymphoma,Venetoclax+Dinaciclib
3906,EXPRESSION,D,Sensitivity/Response,Melanoma,Mirdametinib+Birabresib
3907,OVEREXPRESSION,D,Sensitivity/Response,Melanoma,
3908,OVEREXPRESSION,D,Sensitivity/Response,Childhood Medulloblastoma,JQ1
3909,OVEREXPRESSION,D,Sensitivity/Response,Esophageal Cancer,Docetaxel+Verteporfin
3910,R1032Q,D,Sensitivity/Response,Colorectal Cancer,Axitinib+Dovitinib+Lenvatinib+Cabozantinib
3911,low ratio of VEGF165b/VEGFtotal,B,Sensitivity/Response,Colorectal Cancer,Bevacizumab
3912,MEF2D-CSF1R,D,Sensitivity/Response,B-lymphoblastic Leukemia/lymphoma,Panobinostat
3913,MEF2D-CSF1R,C,Sensitivity/Response,"B-lymphoblastic Leukemia/lymphoma, BCR-ABL1–like",Imatinib
3914,Y646H,C,Sensitivity/Response,Diffuse Large B-cell Lymphoma,Tazemetostat
3915,CD4v8-v10 and CD44v3-v10,B,Resistance,Cancer,RG7356
3916,I1171T,C,Sensitivity/Response,Neuroblastoma,Ceritinib
3917,CD44v6,D,Resistance,Ovarian Cancer,Cisplatin
3918,CD44v6,D,Resistance,Stomach Cancer,Cisplatin
3919,G12C,A,Sensitivity/Response,Lung Non-small Cell Carcinoma,Sotorasib
3920,CD44v8-10,D,Reduced Sensitivity,Prostate Cancer,Docetaxel
3921,CD44v6,D,Resistance,Stomach Cancer,Cisplatin
3922,CD44v6,B,Resistance,Cervical Cancer,Cisplatin
3923,E1799K,D,Sensitivity/Response,Megalencephaly,Everolimus
3924,E1799K,D,Sensitivity/Response,Focal Cortical Dysplasia,Everolimus
3925,Overexpression of VEGF121,B,Resistance,Glioblastoma,Bevacizumab
3926,Overexpression of AR-V9,B,Resistance,Prostate Cancer,Abiraterone
3927,G469V,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Trametinib+Dabrafenib
3928,G596C,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Dabrafenib+Trametinib
3929,G469S,D,Sensitivity/Response,Lung Non-small Cell Carcinoma,Dabrafenib+Trametinib
3930,V7 EXPRESSION,B,Resistance,Prostate Cancer,Abiraterone+Enzalutamide
3931,V7 EXPRESSION,B,Sensitivity/Response,Prostate Cancer,Enzalutamide+Galeterone
3932,V7 EXPRESSION,B,Resistance,Prostate Cancer,Enzalutamide+Abiraterone
3933,V7 EXPRESSION,B,Resistance,Prostate Cancer,Enzalutamide
3934,V7 EXPRESSION,B,Resistance,Prostate Cancer,Abiraterone+Enzalutamide
3935,P447_L455del,C,Sensitivity/Response,Estrogen-receptor Positive Breast Cancer,Letrozole+Alpelisib
3936,V7 EXPRESSION,B,Resistance,Prostate Cancer,Enzalutamide+Abiraterone
3937,V567es expression,B,Resistance,Prostate Cancer,Taxane Compound
3938,E114K,D,Sensitivity/Response,Cancer,Cetuximab+Panitumumab
3939,LMNA-NTRK1,C,Sensitivity/Response,Solid Tumor,Larotrectinib
3940,TPR-NTRK1,C,Sensitivity/Response,Solid Tumor,Larotrectinib
3941,F617L,C,Resistance,Gastrointestinal Stromal Tumor,Larotrectinib
3942,G595R and G667S,C,Resistance,Solid Tumor,Larotrectinib
3943,R165Q,D,Sensitivity/Response,Colorectal Cancer,Panitumumab+Cetuximab
3944,KRAS4A,D,Resistance,Pancreatic Cancer,Rigosertib+KG5
3945,KRAS4A underexpression,D,Resistance,Pancreatic Cancer,Rigosertib+RG5
3946,TNC-L,D,Resistance,Pancreatic Cancer,Gemcitabine
3947,underexpression beta-1,B,Sensitivity/Response,Breast Cancer,Exemestane+Tamoxifen
3948,LGR5FL,D,Resistance,Colorectal Cancer,Fluorouracil
3949,EDB,B,Sensitivity/Response,Melanoma,Daromun
3950,EDB,B,Sensitivity/Response,Melanoma,Dacarbazine+L19IL2
3951,EDB,B,Sensitivity/Response,Melanoma,L19IL2
3952,Overexpression,D,Sensitivity/Response,Esophagus Adenocarcinoma,Alisertib+Cisplatin
3953,A232V,D,Sensitivity/Response,Cancer,Trastuzumab+Pertuzumab+Duligotuzumab+Lapatinib
3954,MUTATION,B,Sensitivity/Response,Bladder Urothelial Carcinoma,Tipifarnib
3955,MUTATION,B,Sensitivity/Response,Head And Neck Squamous Cell Carcinoma,Tipifarnib
3956,TOP2A/90,D,Resistance,Leukemia,Etoposide
3957,TOP2A/90,D,Resistance,Leukemia,MVT Regimen+4'-(9-acridinylamino)methanesulfon-m-anisidide+Etoposide+DVP Regmen+Pixantrone
3958,delta11q,D,Reduced Sensitivity,Breast Cancer,Cisplatin
3959,R222C,D,Sensitivity/Response,Colorectal Cancer,Cetuximab+Panitumumab
3960,S492R,D,Sensitivity/Response,Colorectal Cancer,Panitumumab
3961,P596L,D,Sensitivity/Response,Colorectal Cancer,Panitumumab+Cetuximab
3962,K708R,D,Sensitivity/Response,Colorectal Cancer,Cetuximab+Panitumumab
3963,G719S,D,Sensitivity/Response,Colorectal Cancer,Panitumumab+Cetuximab
3964,V104M,D,Sensitivity/Response,Cancer,Lapatinib+Trastuzumab+Pertuzumab+Duligotuzumab
3965,P262H,D,Sensitivity/Response,Cancer,Trastuzumab+Pertuzumab+Lapatinib+Duligotuzumab
3966,G1109C,D,Sensitivity/Response,Head And Neck Squamous Cell Carcinoma,Afatinib
3967,L861Q,D,Sensitivity/Response,Esophagus Squamous Cell Carcinoma,Afatinib
3968,G284R,D,Sensitivity/Response,Cancer,Lapatinib+Duligotuzumab+Pertuzumab+Trastuzumab
3969,v242,E,Resistance,Lung Non-small Cell Carcinoma,Durvalumab+Avelumab+Atezolizumab
3970,V777L,D,Sensitivity/Response,Cancer,Lapatinib
3971,Alternative splicing,D,Resistance,Chronic Myeloid Leukemia,Imatinib
3972,"delta-ex2, delta-ex5-6",D,Resistance,B-lymphoblastic Leukemia/lymphoma,Tisagenlecleucel
3973,DELETION POLYMORPHISM,B,Sensitivity/Response,Chronic Myeloid Leukemia,Imatinib
3974,p61BRAF(V600E),D,Resistance,Melanoma,Vemurafenib
3975,p61BRAF(V600E),C,Resistance,Melanoma,Vemurafenib
3976,,B,Sensitivity/Response,Follicular Lymphoma,Tazemetostat
3977,F691L,A,Resistance,Acute Myeloid Leukemia,Quizartinib
3978,F691L,D,Sensitivity/Response,Acute Myeloid Leukemia,Tirbanibulin
3979,Overexpression,A,Resistance,Melanoma,Multi-subtype Natural Human Leukocyte Interferon Alpha
3980,Amplification,A,Sensitivity/Response,Childhood Ependymoma,Lapatinib
3981,ITD&F691(I/L),D,Resistance,Acute Myeloid Leukemia,Quizartinib
3982,T599dup,C,Sensitivity/Response,Ganglioglioma,Trametinib+Dabrafenib
3983,ZC3HAV1-ABL2,C,Sensitivity/Response,B-lymphoblastic Leukemia/lymphoma,Imatinib
3984,EWSR1-NR4A3,B,Sensitivity/Response,Extraskeletal Myxoid Chondrosarcoma,Pazopanib
3985,V600E,A,Sensitivity/Response,Colorectal Cancer,Encorafenib+Cetuximab
3986,EXPRESSION,D,Sensitivity/Response,Ovarian Cancer,MDM2 Inhibitor KRT-232
3987,High expression,D,Sensitivity/Response,Stomach Cancer,Dasatinib
3988,Overexpression,D,Sensitivity/Response,Head And Neck Carcinoma,Dasatinib
3989,Overexpression,D,Sensitivity/Response,Esophageal Cancer,HDAC Inhibitor AR-42
3990,Overexpression,D,Sensitivity/Response,Esophageal Cancer,Trichostatin A+Vorinostat+Panobinostat
3991,V600E and Amplification,B,Sensitivity/Response,Epithelial Ovarian Cancer,Bevacizumab+Atezolizumab
